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Blood and heart-related diseases remain a significant challenge for modern-day medicine 
1. Blood cell-related diseases have also proven to be challenging to understand and treat, 
specifically diseases involving the loss of deformability (rigid) in red blood cells (RBCs) 2. Disease 
involving rigid RBCs are typically of genetic origin and thus limit treatment options and treatment 
efficacy 3. Rigid RBC disorders give rise to many medical complications, including vaso-
occlusion, pulmonary hypertension, and cardiac dysfunction 4,5. Patients inflicted with Sickle Cell 
Disease (SCD), hereditary spherocytosis, iron-deficient anemia, pyruvate kinase deficiency, 
human immunodeficiency virus (HIV), malaria, sepsis, and even natural aging all have less 
deformable (rigid) RBCs than healthy patients 3,6,7. Rigid RBCs cause major physical damage 
when traveling through the body by occluding microvasculature, depriving tissues of nutrients, 
and damaging walls of the spleen, liver, and lungs 5,8.  
The core work presented in this dissertation aims to probe how decreases in RBC 
deformability affect hemodynamics and impact functionality of other blood cells, clarifying the 
pathology of RBC-related diseases. We initially present a model of artificially rigidified human 
RBCs which offers an experimental control over extent of membrane stiffness as well as the 
fractional composition of rigid RBCs in whole blood. Here, we find that the presence of rigid 
RBCs in blood flow significantly alters the ability of immune cells to adhere to inflammation on 
the vascular wall of a microfluidic model. In some cases, the presence of highly rigid RBCs reduces 
leukocyte adhesion to the vascular wall by up to ~80%. Following this initial investigation, we 
take a pivotal focus on SCD and further quantifying the whole blood characteristics of SCD 
 xxii 
pediatric patient blood and its behavior in flow. This thesis presents multiple investigations 
highlighting the outcome of RBC rigidity in SCD. An interesting clinical case study is highlighted 
in this work as well as additional in vitro work showing how the presence of RBC rigidity alters 
immune cell adhesion functionality. An artificial model of blood infusion therapy is also developed 
to test how leukocyte adhesion to inflammation is impacted upon alteration of whole blood 
composition. This knowledge is essential in understanding why people with diseases related to 
RBC deformability are susceptible to infection and have irregular immune responses.  
In addition, we also investigate how rigid RBCs in blood flow alter the adhesion efficacy 
of vascular-targeted carriers (VTCs). The field of drug delivery has taken an interest in combating 
numerous blood and heart diseases such as atherosclerosis via the use of VTCs. Ideally, VTC 
technology increases drug delivery efficacy and simultaneously reduces cytotoxic effects, 
precisely localizing drugs only to the disease site through receptor-ligand interactions. Cellular 
interactions are not yet fully understood. The dynamics of disease-inflicted cells (rigid RBCs) are 
even less understood, thus compounding the problem of efficient VTC design under diseased blood 
conditions. We investigate various particle design parameters and assess their vascular wall 
adhesion performance in the presence of rigid RBCs. We find the vascular adhesion of stiff 
microparticles is reduced by up to ~50% in the presence of rigid RBCs. Interestingly, deformable 
hydrogel microparticles can experience an increase in vascular adhesion of up to ~ 80%. This work 




 : Introduction 
 
 
1.1. Publication Information 
 
The text in this chapter is in part from the publications listed below. Modifications have 
been made to the published documents to adapt the content to this text. This chapter provides an 
overview of blood flow dynamics and phenomena. This chapter also touches on common blood 
disorders characterized by increased red blood cell membrane stiffness and provides a more 
comprehensive overview of sickle cell disease. Additionally, this chapter provides a background 
on vascular-targeted carrier therapeutics and design considerations for optimizing performance in 
variable blood flow conditions.  
Mario Gutierrez, Margaret B. Fish, Alexander W. Golinski, and Omolola Eniola-Adefeso. 
“Presence of rigid red blood cells in blood flow interferes with the vascular wall adhesion of 
leukocytes.” Langmuir 34.6 (2018): 2363-2372. 10 
Mario Gutierrez, Mark Shamoun, Katie Giger Seu, Tyler Tanski, Theodosia A. Kalfa, and 
Omolola Eniola-Adefeso. “Characterizing bulk rigidity of rigid red blood cell populations in 
sickle-cell disease patients.” Sci Rep 11, 7909 (2021). https://doi.org/10.1038/s41598-021-86582-
8 11 
Mario Gutierrez, Lauro Sebastian Ojeda, and Omolola Eniola-Adefeso. “Vascular-targeted 
particle efficacy in the presence of rigid red blood cells: Implications for performance in diseased 
blood.” Biomicrofluidics 12.4 (2018): 042217. 12 
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1.2. Whole Blood Dynamics and Characteristics 
1.2.1. Whole Blood Physiology 
Blood is a highly concentrated, non-Newtonian suspension of RBCs, white blood cells 
(WBCs), platelets, and plasma.13 Bulk blood flow, as found in most blood vessels, is an anisotropic 
aqueous suspension, consisting of primarily RBCs in the core while the other blood cells form an 
outer ring at the wall. 14–16 Healthy RBCs are disc-shaped (6-8 µm diameter) and highly flexible, 
allowing RBCs to squeeze through capillaries.13 In healthy humans, RBCs constitute anywhere 
from 30%-45% v/v of blood, which is defined as hematocrit (Hct).13 Blood flow properties are 
influenced by multiple physical factors: cell to cell collisions, the shear rate of flow, RBC 
deformability, and vessel geometry.17 The RBC core occupies the center of flow, and the red blood 
cell-free layer (RBC-FL/CFL) develops near the walls of the vessel, which aids in pushing stiffer 
objects, e.g., WBCs and platelets, to the vessel wall to sample the endothelium for disease and 
rupture constantly.15,16,26,27,18–25 The distribution of blood components in flow, as described, is 
founded upon hydrodynamic interactions that generate varying levels of lift force.28 The lift force 
is a product of the interaction between deformable cells, e.g., RBCs, and the vessel wall in a 
process deemed wall-induced migration; this specific interaction produces the RBC-FL.28 
Naturally stiffer cells, e.g., WBCs and platelets, are less affected by the lift force and thus do not 
populate the core of flow as densely as RBCs.28 Hemodynamic, heterogeneous collisions between 
the highly deformable RBCs and stiffer WBCs and platelets also promote the distribution of the 
latter to the vascular wall.29–31 Specifically, when relatively rigid WBCs collide with deformable 
RBCs, the RBCs deform, and the stiffer cells are displaced farther towards the wall – a process 
referred to as margination. This margination phenomenon is illustrated in Figure 1.1. This 
deformability and shape-driven arrangement of cells in blood flow are essential for maintaining 
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homeostasis and for providing rapid immune responses in the body.32 Collagen-activated platelets 
and inflammatory cytokine-recruited WBCs can quickly reach any site of vascular injury due to 
their constant proximity to the vascular wall. 32 Interestingly, despite the widely known impact of 
deformability on cellular margination in blood flow, little experimental work exists explicitly 
focusing on the effects of RBC rigidity, i.e., loss of deformability, on margination.29 Work by 
Passos et al. showed that blood containing RBCs with loss of membrane deformability resulted in 
significant alterations in flow distributions and cellular flow velocity profiles in a microchannel. 
33 Mainly, a reduction in velocity bluntness was observed when stiffened RBCs were present in 
blood flow.33 Recent computational works have begun to elucidate the transport mechanisms of 
cell types with different physical properties in blood flow and have underlined the major impact 
of cell size and rigidity on blood margination.30,31,34 However, there are many challenges to 
modeling such highly complex fluid flow as human blood accurately, e.g., selecting appropriate 
boundary conditions and appropriately modeling the multiphase composition of blood.  
Figure 1.1. Illustration of Blood Flow Margination.  
The illustration shows the segregation behavior that can be observed in certain vessels. The more deformable cells, RBC 
greatly experience a lift force away from the vessel wall forming the RBC core in the center of flow. Other naturally stiffer 
cellular components localize closer to the vessel wall. 
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1.2.2. Computational Modeling of Blood Cellular Interactions 
Recent work has begun to computationally elucidate the transport mechanisms of cell types 
with different physical properties in blood flow. 30,31,34–39 Some researchers conclude that the RBC 
core forms due to high RBC deformability.29,31 Kumar and Graham cite hydrodynamic, 
heterogeneous collisions between blood components as a critical reason for blood cell segregation 
in flow. When relatively rigid platelets or WBCs collide with deformable RBCs, the RBCs deform, 
and the WBCs displace a farther distance. Additionally, WBCs will encounter more heterogeneous 
collisions, as they exist in a 1:100 number ratio to RBCs. The work also cites wall-induced 
migration, also known as lift, as another reason for deformable entities to congregate near the 
center of flow 30. Both rigid RBCs and deformable particles can be inserted into these theoretical 
simulations to predict their behavior. Computational work underlines the importance of 
heterogeneous collisions, i.e., impacts between rigid and deformable cells, in blood margination, 
Graham et al.30,31,34 Czaja and coworkers both experimentally and computationally investigate the 
influence RBC membrane deformability has on platelet margination.40 Interestingly, in this 
investigation, it was found that platelet margination to the vessel wall is reduced in the presence 
of rigid RBCs in blood flow.40 Additionally, in confirmation with previous work, it was found via 
cell-resolved simulations that upon heterogeneous cellular collisions, stiffer RBCS experience a 
greater displacement in comparison to their deformable counterpart.40 There are a large variety of 
theoretical models that predict hemodynamic behavior; however, most simulations oversimplify 
the complexity of blood. For example, some models disregard the blood plasma viscosity ratio; 
moreover, this parameter has been determined to either tank treading or tumbling behavior for 
RBCs 30.  There is a sizeable experimental gap in the literature in this area. Thus, there is a critical 
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need for experimental results that supplement theoretical models to understand bulk blood flow 
phenomena better and potentially optimize blood-related therapeutics.  
 
1.3. Sickle Cell Disease  
1.3.1. Understanding Sickle Cell Disease 
SCD is one of the most common and complex genetic blood disorders worldwide. 3,41,42 
SCD originates as a mutation of the gene encoding for the oxygen-binding protein hemoglobin. 
There are multiple genotypes of this hereditary blood disorder, all characterized by mutated 
hemoglobin S (Hgb S or HbS) production. 42  RBCs with a high content of HbS have a significantly 
reduced oxygen-binding capability and a high propensity to polymerize under hypoxic conditions. 
3,43 The formation of a polymer nucleus and the increased concentration of unbound oxygen inside 
the RBC then induces oxidative damage on the cellular membrane, leading to a loss in membrane 
deformability. 2 The oxidative damage to the cell membrane also makes the RBCs prone to lyse, 
resulting in anemia and the release of hemoglobin into the open bloodstream, which damages the 
vascular wall, i.e., upregulation of inflammation markers. 5,44–49 Under hypoxic conditions, the 
mutated hemoglobin can frequently polymerize to cause the trademark sickled-shape of the 
RBC.42,50 Historically, the irreversibly-sickled RBCs (i-sRBCs), i.e., having a permanent sickle 
shape, were the focus of research in SCD, leading to the understanding that these cells cause 
significant physical damage to vital organs, including the spleen, liver, and lungs, by occluding 
microvessels, and depriving the tissues of nutrients and oxygen.8,51 As such, SCD is characterized 
by highly detrimental symptoms, including pulmonary hypertension, anemia, and vaso-occlusion 
that can cause chronic organ damage. 42 These SCD symptoms are also accompanied by severe 
pain episodes known as “crisis”  that represent a significantly reduced quality of life for SCD 
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patients. 42 Chronic inflammation, vaso-occlusion, and overall negative symptoms in SCD 
originate from increased rigidity in the RBC membranes. 42,48,52 However, only a small fraction of 
i-sRBCs are present in the patient’s blood at a given time due to their high rate of lysing.53  Instead, 
the reversibly-sickled RBCs (r-sRBCs), i.e., highly rigid but not sickle-shaped, are the main 
sickled RBCs circulating in SCD, especially under stable, non-crisis conditions. Nevertheless, little 
attention has been given to how the r-sRBCs, i.e., rigid RBCs, in the bloodstream may impact the 
dynamics and functionality of other blood cells in SCD, e.g., WBCs, and the potential downstream 
contribution to disease symptoms beyond the occlusion of the microvasculature. 
The current understanding of SCD is mainly focused on the biochemical and genetic 
components of the disease. Conversely, the increased RBC membrane rigidity – separate from the 
sickled crescent-shape – is often overlooked as a significant factor in disease severity. 
Nevertheless, the presence of stiff RBCs (not altered in shape) in blood was recently shown to 
reduce the vascular wall adhesion of WBCs drastically and increase the vascular wall adhesion of 
platelet. 10,12,54 This works potentially hints at a more significant role for RBC rigidity in SCD 
patients' well-being beyond instigating vaso-occlusion. As mentioned in the previous subsections, 
bulk blood flow is dominated by many flow phenomena. Thus, any alteration in RBC 
deformability, as present in SCD, likely alters blood cell distribution in ways that contribute to the 
disease. However, RBC rigidity in SCD is often overlooked as a significant factor in exacerbating 
disease symptoms associated with the other, non-RBC, blood cells. 
The symptoms of SCD present early in life, with the most common initial symptom being 
dactylitis – inflammation of fingers or toes. As patients progressively age, continued damage to 
small vessels throughout the body leads to common symptoms such as retinal injury, kidney 
damage, neurocognitive delay, priapism, and functional asplenia.55 Late in life, it is common for 
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patients to suffer from chronic pain disorders, depression, anxiety, pulmonary hypertension, and 
stroke.55 Thus, SCD patients have a significantly decreased lifespan by 20-30 years, compared to 
healthy non-SCD individuals in industrialized countries, and by much shorter in developing 
nations.56 
 
1.3.2. Current treatments in Sickle Cell Disease 
To date, the only known curative therapy for SCD is hematopoietic stem cell 
transplantation, but outcomes depend heavily on the source of cells. Matched, related donors have 
>90% 5-year event-free survival; however, matched, unrelated donor and cord blood stem cells 
have a significantly higher mortality rate.57 Unfortunately, many patients do not have matched 
related donors and thus are not entrants for transplantation. In addition, it is often overseen that a 
large proportion of people affected with SCD are located in a developing nation or come from a 
low social-economic background.56 Thus, the aforementioned therapy is very likely to be out of 
reach for many SCD patients as it can be costly. 
Other pharmaceutical therapeutic options are aimed at decreasing disease severity by 
reducing inflammation, such as L-glutamine, or by increasing fetal hemoglobin (%HbF) with 
agents like hydroxyurea (HU). To date, these mentioned pharmaceuticals are the only US Food 
and Drug Administration-approved drugs to improve SCD complications.58  While these 
treatments prevent some symptoms; breakthrough crises are still observed in most patients.59,60 
Chronic blood transfusion is yet another option. However, it also carries significant risks, e.g., iron 
overload that is toxic to organs and alloimmunization, the process of forming antibodies against 
foreign blood products, which can lead to deadly hemolytic crisis.61 Chronic blood transfusions 
are often used for SCD patients with recurrent pain crisis or frequent acute chest syndrome.62 
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Previous studies have proposed reducing the %HbS to <30% is beneficial in moderating symptoms 
versus no transfusion.63 However, characterization of why this works is lacking.63 To our 
knowledge, no widely accepted protocols for targeting post-transfusion Hct or %S have been 
established. We hypothesize that transfusion in SCD patients directly affects blood cell mechanics, 
potentially altering WBC adhesion to the endothelium. A better understanding of how transfusion 
affects WBCs could help clinicians optimize transfusion to reduce infection rates for SCD patients 
better.  
Symptomatic treatment for pain crisis is often with opioids, but long-term use brings 
consequences, such as central sensitization syndrome and addiction risk.64 Also, there is concern 
that the recent attention to a national “opioid crisis” has raised concerns that SCD patients may 
face reduced access to opioids due to an increased reluctance by clinicians to prescribe, especially 
with the added difficulty of pain assessment in the absence of a visualizable or measurable cause.65 
During painful episodes, it is clinically typical to treat vaso-occlusive crises with intravenous fluids 
implementation.66 Potential alterations to cellular biomechanics due to changes in fluid tonicity 
are disregarded. However, Carden and coworkers have presented evidence to show that changes 
in blood tonicity, such as implementing clinical intravenous fluids, alter RBCs deformability and 
ultimately lead to changes in observed channel occlusion. 66 
 
1.3.3. Characterizing RBC Stiffness Concerning Pain crisis in Sickle Cell Disease 
Common hematological characteristics and clinical observation are the common 
determinants used to assess SCD complications in a clinical setting. However, this may not be an 
entirely reliable method for quantifying disease severity as pain is subjective and clinical 
observations may vary. Thus, using more established and consistent biomarkers for assessing 
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patients' general condition or response to medication is likely a more suitable option. To date, only 
a handful of works have focused on elucidating how RBC rigidity directly impacts disease severity 
in SCD. In two seminal publications, Ballas et al. reported that RBC stiffness is predictive for 
disease severity, where patients with more deformable RBCs, as determined by osmoscans, had a 
higher rate of crisis.67,68 However, osmoscans are a measure of RBC deformation in response to 
changes to osmolality at a fixed shear stress and may not be an accurate measure of deformability 
in SCD, i.e., RBCs are exposed to a fixed osmolality (~290 mOsm/kg) at varying shear as they 
transport through different vessels.69 Also, existing osmoscan data were mainly obtained at a shear 
stress of 30 Pa, which is larger than values encountered in vivo; yet, the characteristic of the 
osmoscan curve is significantly influenced by shear stress. Thus, recent characterizations of RBC 
rigidity employ ektacytometry to measure an elongation index (EI), i.e., changes in cell shape, in 
response to changes in shearing stresses at a fixed, physiological osmolality.70 However, these 
primarily measured the average rigidity of all RBCs in the blood sample, which can vary depending 
on the fraction of normal to sickled RBC (%S; fraction of sickled RBCs), i.e., two patients can 
register the same bulk blood rigidity but have a significantly different rigidity level in their r-
sRBCs due to variation in their %S. Understanding the degree of stiffness in reversibly sickled 
RBCs is crucial. It would allow for a more accurate characterization of the impact of RBC rigidity 
on the frequency and, more importantly, the intensity of SCD crisis, vaso-occlusion, and risk of 
infection. Alternative methods that allow for the characterization of the rigidity of sickled RBCs 
in isolation, including micropipette, AFM, optical tweezers, and membrane flickering methods, 
are limited in that they are static techniques, low throughput, labor-intensive, or require specialized 
manipulation.70–73 Recent microfluidic approaches offer high throughput but do not quantify RBC 
stiffness.72 Interestingly, microfluidic lab-on-a-chip devices have been developed to assess the 
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RBC condition of donor blood that is to be utilized for infusion therapy purposes, not specific to 
SCD.74 A better potential understanding of the scientific basis for pain in SCD can lead to better 
management, potentially reducing the frequency or need for opioid use. 
 
1.3.4. Impact of Rigid RBCs on WBC Functionality in Sickle Cell Disease  
As previously stated in a previous subsection, the unique layout of cells in the blood, RBCs 
in the core, and other cells in the CFL is, in part, due to the highly deformable RBCs experiencing 
a lift towards the center of flow while the stiffer cells are pushed to the wall, i.e., margination.28 
With such importance of deformability to cellular distribution in normal blood flow, it is likely 
that the pronounced rigidity of RBC in SCD changes cell distribution to affect their natural 
functions. Indeed, the sequestration of RBCs in the capillaries that are said to cause crisis pain is 
due to the increased margination of sickled RBCs into the CFL and hence their higher 
concentration in the capillaries.75 However, the impact of the r-sRBCs on the margination and 
function of other blood cells is less clear and underexplored. Interestingly, SCD patients are prone 
to infection that is traditionally linked to the damage to the spleen by i-sRBCs,44,76, but such 
increased rate of infection is not often observed in medical conditions where the spleen is 
deliberately removed in animals.77 It is plausible that the presence of rigid, r-sRBCs in blood alters 
WBC margination, which affects vascular adhesion and, thereby, contributes to the reported high 
infection rate in SCD. Indeed, Boggs et al. observed a diminished marginal granulocyte pool in 
SCD, i.e., the fraction of WBCs present in the tissue space,78 which they hypothesize is the cause 
of the abnormally high circulating WBC count typically reported in SCD.  
Despite the known role of WBC in the pathogenesis of SCD, there is limited work fully 
exploring the mechanism of their adhesive interactions under flow conditions with patient blood 
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or representative models of human blood. The current understanding of the adhesive behavior of 
WBCs in SCD has been generated with isolated cells and in static adhesion assays, which neglect 
the biophysical contributions of the rigid RBCs.79,80 Previously published work using SCD patient 
blood have focused on elucidating the differences in WBC adhesion molecule expression via flow 
cytometry,80 leading to the observation that WBCs are in a pre-activated state and the assumption 
of their enhanced ability to adhere to the vascular wall in comparison to cells found in the healthy 
blood. It is known that the expression of P-selectin in an inflamed endothelium significantly 
contributes to the progression of vaso-occlusive crisis in SCD.81 Recent work has utilized an in 
vitro microfluidic assay to assess the adhesive interactions between leukocytes and P-selectin in 
physiological flow conditions.82 The study mainly focused on assessing whether the drug 
candidate, Crizanlizumab, could inhibit interactions between leukocytes and P-selectin.82 The 
sparse adhesion studies with whole patient blood that exist have focused on the difference in WBC 
adhesion due to alteration in protein expression with no control for the role of RBC rigidity.83,84 
Though several analyses of WBCs adhesion in mouse models of SCD exist,84 the differences in 
RBC geometry and deformability between humans and mice,85,86 which directly impact 
margination, would prevent direct extrapolation of mice data to humans.  
 
1.4. Vascular-Targeted Therapeutics Design Considerations 
 
Particle therapeutics have received much attention for use in disease treatment due to their 
high potential for achieving localized delivery of drugs and imaging agents, and in some cases, for 
the added benefit of controlled release of therapeutics.87 The administration of therapeutic particles 
via intravenous (IV) injection is attractive due to the (1) non-invasive nature and (2) extensive 
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reach of the vascular system to target tissue throughout the body. Often, disease-specific proteins 
expressed by the endothelium – the monolayer of cells lining the lumen of most blood vessels – 
are employed for target recognition by the particle therapeutics, i.e., vascular-targeting. 
Specifically, in certain diseases, such as atherosclerosis, the endothelium produces an 
inflammatory response, 88,89, which upregulates inflammatory surface markers not found on the 
endothelium in healthy tissues and, thus, are attractive for use as targets to disease. 89 To this end, 
targeted-drug delivery systems employ the conjugation of surface moieties, such as peptides and 
antibodies, with high affinity for these differentially expressed inflammatory disease markers. In 
theory, particulate carriers fitted with the disease-specific moieties will be captured to the blood 
vessel wall expressing the targeted protein in the diseased tissue. However, to target the diseased 
vascular wall effectively, particularly in mid-to-large arterioles and postcapillary venules, particles 
must first localize, i.e., marginate, to the vessel walls. 30,90,91 Researchers have shown that particle 
margination is highly dependent on the biophysical, multicomponent nature of blood. 28,30,31,38,92–
96  
RBC deformability is known to drastically alter certain diseases of genetic origin, such as 
sickle cell disease (SCD) and hereditary spherocytosis, 3,97 and in others that developed upon a 
viral or parasitic invasion, such as human immunodeficiency virus (HIV) and malaria. 7,97 The 
RBCs in patients with Type 2 Diabetes (T2D) have also been reported to be significantly less 
deformable than healthy cells. 98 Metabolic disorders such as obesity and lifestyle habits such as 
smoking can also reduce the deformability of RBCs. 99–101 Additionally, studies have shown that 
RBC populations become stiffer, less deformable, on average in natural aging. 101,102 Since particle 
therapeutics aim to treat diseases that are most common in older age groups, such as coronary 
artery disease, understanding particle dynamics and localization functionality in the presence of 
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rigid RBCs could hold significant implications for designing particle therapeutics with high 
efficacy in diseases with altered RBCs. 103–105 
 
1.5. Dissertation Outline  
 
As mentioned in the previous subsections, the membrane deformability of RBCs can 
significantly influence blood flow dynamics and alter the functionality of other cell types in the 
blood. However, there is still a lot to uncover the underlining mechanisms of action that influence 
the alteration in blood dynamics, specifically in identifying and quantifying the true extent of 
influence RBC membrane rigidity has on said alterations. Furthermore, there is a lack of in vitro 
models that represent RBC stiffness in whole blood. The characteristic of RBC rigidity is a 
common attribute in multiple diseases. In this dissertation, we first focus on understanding the 
fundamental influence of RBC stiffness on flow dynamics and functionality of other blood cells 
as well as vascular-targeted therapeutics. Secondly, we focus on developing a more robust method 
for quantifying RBC rigidity in whole blood. Finally, we take a particular interest in investigating 
RBC rigidity in sickle cell disease and its role in influencing immune functionality and disease 
outcome.  
Chapter 1 provides a background on blood composition and a general overview of blood 
flow phenomena and methodology for quantifying RBC stiffness. In addition, a brief background 
on sickle cell disease is provided. 
Chapter 2 is a description of the experimental techniques and methodology used to collect 
data throughout the entire dissertation. 
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In Chapter 3, we explore how the degree of RBC stiffness and quantity of rigid RBCs in 
whole blood influence the ability of WBCs to adhere to an inflamed endothelium microfluidic 
model. Specifically, we identify a non-linear response in WBC adhesion reduction based on the 
fraction of rigid RBCs present in whole blood. Additionally, we identify alterations in cellular 
radial distributions in the presence of rigid RBCs. 
In Chapter 4, we further develop the methodology presented in Chapter 3. Specifically, we 
further analyze how ektacytometry measurements are impacted by both the degree of rigid RBCs 
and fraction of rigid RBCs present in a blood sample using an RBC artificial stiffening model. We 
make direct comparisons to ektacytometry measurements made on sickle cell patient blood 
samples. 
In Chapter 5, we present an interesting clinical case study. Here we observed and measured 
via ektacytometry the blood of a group of sickle cell disease patients. Interestingly, the patient 
diagnosed with the less severe variant of sickle cell disease registered the stiffest RBCs. 
Additionally, the patient of interest has an irregularly high amount of hospital admissions due to 
pain crisis.  
In Chapter 6, we further analyzed the blood of sickle cell disease patients using the 
methodology presented in Chapters 3 and 4. We develop an artificial blood model that directly 
matches the characteristics of sickle cell disease blood samples and test the ability of WBCs to 
adhere to inflammation. We find that in most cases, RBC rigidity plays a role in reducing the 
ability for WBCs to adhere to inflammation in blood flow as related to sickle cell disease. 
In Chapter 7, we investigate how blood infusion therapy in sickle cell disease alters 
immune functionality. Specifically, we probe how controlled RBC infusion in sickle cell disease 
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blood samples alters the ability of WBCs to adhere to an inflamed endothelium in blood flow. We 
find there is the potential for optimizing infusion therapy by maximizing immune cell adherence.  
In Chapter 8, we probe how the presence of rigid RBCs influences the adhesion capability 
of vascular-targeted carriers. Previous work shows that size, shape, and material characteristics of 
drug particle carriers greatly influence their targeting capability; here, we see how these effects are 
compounded by the presence of rigid RBCs in blood flow.  
Chapter 9 provides the conclusions for this dissertation and discusses the future directions 











This chapter provides a detailed list of the experimental protocols and methodology used to 
generate the experimental data presented in Chapters 3 through 8. Methodology ranging from 
human blood draw protocols to drug particle model fabrication are provided. Different 
microfluidic in vitro techniques for testing blood and drug particle adhesion capability in blood 
flow is also described.  
 
2.2. Human Study Approvals and Blood Handling 
2.2.1. Human Study Approvals for Non-SCD Blood Donors 
For the studies presented in both Chapter 3 and Chapter 8, fresh human blood is obtained 
on the day of experiments via venipuncture according to a protocol approved by the University of 
Michigan Internal Review Board (IRB-MED). Informed, written consent was obtained from all 
subjects before blood collection. Blood was obtained from healthy subjects and drawn into a 
syringe containing citric acid-sodium citrate- dextrose (ACD) as an anticoagulant and stored at 37 
ºC as described in Onyskiw et al.106 For the studies presented in both Chapter 3 and Chapter 8, 
RBCs were isolated from whole blood by adding 6% dextran to anticoagulated blood in an inverted 
syringe, which sediments the RBCs from WBCs and plasma. WBC-rich plasma was then stored at 
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37 °C until recombination with RBCs at specified Hct (% vol/vol). RBCs were washed by 
suspending in phosphate-buffered saline (PBS) (-/-) and centrifugation. For all other studies, RBCs 
were isolated strictly via series of centrifugation steps.  
 
2.2.2. Preparation of Human Non-SCD Blood for Ektacytometry Analysis 
For the studies presented in Chapters 4, 5, and 6, fresh blood was obtained from healthy, 
i.e., no SCD donors on the day of ektacytometry measurements via venipuncture. Blood was drawn 
into standard Vacutainer Lavender K2-EDTA tubes (BD). Multiple tubes were taken from healthy 
donors. For the work presented in Chapter 4, blood from healthy donors was then separated from 
WBC-rich plasma via a series of slow-speed centrifugation steps. RBCs from healthy donors were 
washed thoroughly via suspension in phosphate-buffered saline (PBS -/-) and centrifugation. 
RBCs and WBC-rich plasma were stored at 4 ºC until artificial rigidification and reconstitution, 
which was done right before ektacytometry analysis. For the work presented in Chapter 5 and 
Chapter 6, blood samples in lavender K2-EDTA tubes aimed for ektacytometry analysis are stored 
and shipped in 4 ºC cold packs overnight. 
2.2.3. Study Approvals and Preparation of Human Non-SCD Blood in SCD related Studies 
For the work presented in Chapter 6 and Chapter 7, Healthy, i.e., non-SCD donors are 
informed of the study and give written consent before blood collection. Fresh blood from healthy 
donors is drawn into standard Green Sodium Heparin Vacutainer tubes (BD). Multiple extra green 
tubes are taken from non-SCD donors. Blood from healthy donors in green sodium heparin tubes 
is then separated from WBC-rich plasma via a series of slow-speed centrifugation steps. RBCs 
from healthy donors are washed thoroughly via suspension in phosphate-buffered saline (PBS -/-) 
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and centrifugation. RBCs and WBC-rich plasma are stored at 37 ºC until artificial rigidification 
and reconstitution.  
 
2.2.4. Study Approvals and Preparation of SCD Patient Blood 
Blood draw protocols have been approved by the University of Michigan Internal Review 
Board (IRB-MED). SCD donors and legal guardians are informed of the study and give written 
consent before blood collection. Fresh blood is obtained on the day of a patient's routine clinical 
visit via venipuncture. Blood used in perfusion assays is drawn into standard Vacutainer Green 
Sodium Heparin tubes (BD) and stored at 37 ºC. In addition, three Lavender Vacutainer K2-EDTA 
tubes are taken from SCD patients for ektacytometry and hemoglobin electrophoresis analysis. 
Blood sample for ektacytometry analysis, lavender tube, was stored and shipped in 4 ºC cold packs 
overnight to Erythrocyte Diagnostics Laboratory of the Cancer and Blood Diseases Institute at the 
Cincinnati Children’s Hospital for examination the following day. All SCD patient samples are 
measured within 24 hours of blood draw. In the scenarios where patients were either not feeling 
well or had undergone multiple failed needle insertions, additional blood samples were not 
collected.  
 
2.2.5. SCD Patient Blood Analysis and Characterization 
Complete blood counts were run on a Sysmex 9100 XN automated machine.  The 
phlebotomy team collected whole blood (~3 mL) into an EDTA lavender top tube (BD).  The 
sample was then sent to the hematology lab at Michigan Medicine and run according to university 
protocol and manufacturer’s instructions. Results were verified and reported through the electronic 
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medical records at the University of Michigan. Hemoglobin evaluation was run on a Bio-Rad 
Variant II cation exchange HPLC system by high-pressure liquid chromatography (HPLC). Whole 
blood (~3 mL) was similarly collected by the phlebotomy team in an EDTA lavender top tube and 
run per protocol.  HPLC works by separating components of blood through interactions with the 
absorbent particles.  Reports typically consist of five different hemoglobin genotypes, including 
Hgb S, Hgb A1, Hgb A2, Hgb C, and Hgb F.   
 
2.2.6. Red Blood Cell Rigidification and Sample Preparation 
Washed RBCs from healthy donors were suspended in a 2% hematocrit and incubated with 
a specific concentration of Luperox tert-butyl hydroperoxide (TBHP) (Sigma-Aldrich). RBC 
deformability was analyzed using ektacytometry. For the work presented in Chapters 3, 4, and 8, 
four parent concentrations of TBHP were chosen as base RBC rigidities: 1.0, 0.9, 0.75, and 0.5 
mM TBHP. Incubation for 30 minutes induced the loss of RBC membrane flexibility. After 
adequate washing, stiffened RBCs were mixed with healthy RBCs in whole blood in increments 
of 10% rigid RBC fractions up to a total of 100% while holding the hematocrit constant at ~40%, 
unless otherwise specified. No RBC lysis was detected for the 30-minute incubation period for any 
of the TBHP concentrations evaluated. For the work presented in Chapter 6, a specified TBHP 
concentration is chosen to rigidify healthy RBCs. Stiffened RBCs are then reconstituted into whole 
blood at specified hematocrit. 
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2.2.7. Healthy Donor Red Blood Cell Rigidification and Sample Preparation 
For the work presented in Chapter 6, two different artificial blood models have been 
denoted in this study to model/mimic SCD donor blood: the Rigid Model and Non-Rigid Model. 
More specifically, fresh blood from healthy non-SCD blood donors is separated, compositionally 
altered, and reconstituted to match unique SCD donor blood characteristics. The Rigid Model uses 
reconstituted healthy donor blood to match the hematocrit, WBC count, rigid RBC fraction, and 
approximate rigidity of the rigid population. Alternatively, the Non-Rigid Model matches only the 
hematocrit and WBC count of the SCD donor blood sample, excepting the rigidity attributes. 
Washed RBCs from healthy donors are suspended in a 2% hematocrit and incubated with a specific 
concentration of TBHP to induce loss of RBC membrane flexibility. The approximate TBHP 
concentration necessary to obtain a desired rigid RBC population stiffness was calculated using 
methods highlighted by Gutierrez et al. 11 Effectively, a TBHP concentration was chosen to 
achieve a rigid RBC population stiffness like that of the rigid RBC population in a unique SCD 
patient blood sample. RBCs are incubated for 30 minutes with a specified TBHP concentration to 
induce the loss of RBC membrane flexibility. Following adequate washing, stiffened RBCs are 
mixed with healthy flexible RBCs and WBC-rich plasma into specified whole blood conditions 
matching SCD patient blood characteristics, i.e., hematocrit, rigid-to-healthy RBC fraction, and 
RBC rigidity conditions.  
 
2.2.8. Ektacytometry Deformability Measurements  
All blood samples, both healthy and SCD donors, and artificially reconstructed blood 
samples, were measured independently using a LoRRca Maxsis Ektacytometer (Mechatronics 
Instruments BV, Zwaag, The Netherlands) at the Erythrocyte Diagnostics Laboratory of the 
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Cancer and Blood Diseases Institute at the Cincinnati Children’s Hospital. SCD whole blood 
samples and reconstituted healthy donor samples were diluted ~200x in polyvinylpyrrolidone 
(MW 360,000) solution. The solution is then transferred into LoRRca automized measuring vessel. 
Measurements are taken through a range of shear stresses (Pa) up to a maximum of 60 Pa. Cell 
deformation is expressed as an elongation index calculated by Equation (1), where A represents 
the major axis and B the minor axis in deformation.  Elongation Index (EI) values are plotted 
versus shear stress (Pa) to obtain the deformability curve. 
 
2.2.9. Adhesion Ligand Density Flow Cytometry Analysis 
For the WBC adhesion ligand characterization, isolated whole blood samples were put into 
a 37 °C incubator. Subsequently, samples were stained and placed on ice for ~30 minutes as 
follows: MAC-1/CD11b, PSGL-1/CD162, LFA-1/CD11a, sLea/CLA, L-selectin/CD62L, 
(BioLegend). This step is followed by adding a 1-step Lyse/Fix solution (eBiosciences) to 
eliminate RBCs and fixate WBCs. Samples are washed twice with a FACS buffer solution (PBS -
/- +2% FBS, pH ~7.4) before flow cytometry analysis. All flow cytometry analysis was performed 
on an Attune NxT Acoustic Focusing Cytometer, and results were analyzed using FlowJo software 
(TreeStar). Neutrophil and monocyte populations were sorted using FSC/SSC. Gating was applied 
to clarify the signal of interest. Samples analyzed on the same day were compared as a fold 








2.3. Preparation of in vitro microfluidic studies 
2.3.1. Preparation of Endothelial Cell Monolayer 
Human umbilical vein endothelial cells (HUVECs) used in all assays were isolated from 
healthy umbilical cords (Mott Children’s Hospital, Ann Arbor, MI) via a collagenase perfusion 
method, as described by Onyskiw et al.106,107 Briefly, isolated HUVEC were cultured in T75 flasks 
and seeded onto 30 mm glass coverslips coated with 1% gelatin and cross-linked with 0.5% 
glutaraldehyde.108,109 Coverslips were seeded with HUVEC and incubated at 37°C and 5% CO2 
with standard media until confluent density was reached.108–110 For all studies, HUVECs were only 
used through the fourth passage. Confluent coverslips were activated with one ng/mL interleukin-
1β (IL-1β) to induce inflammation and cell adhesion molecule expression for WBC adhesion 
assays. Incubation methods between 4-hour and 24-hour inflammation time point only differed in 
duration of exposure to IL-1β media solution. Previous reports show that E-Selectin receptor 
expression on HUVECs is maximal (~20 fold increase compared to unactivated HUVEC) 4 to 8 
hours after IL-1β initial exposure. 111 
 
2.3.2. Parallel Plate Flow Chamber Laminar Blood Flow Assays 
Laminar blood flow assays were conducted as previously described in Namdee et al. to 
investigate both WBC and drug particle adhesion to inflamed HUVEC monolayer.106,112 
Coverslips with confluent monolayer were held by vacuum to the parallel plate flow chamber 
(PPFC, Glycotech, Inc.). The PPFC was fitted with a rectangular gasket (0.25 cm x 2 cm, heights: 
254 µm, 127 µm). A schematic of the PPFC configuration can be seen in Figure 2.1. Additionally, 
a microfluidic device was fabricated and employed to achieve a lower channel height of 50 µm. 
 23 
Briefly, the 50 µm channel was designed using AutoCAD software. A template was fabricated on 
silicon wafers via a soft photolithography method, as described by Namdee et al.112 
Polydimethylsiloxane (PDMS) channels were then made with the use of the silicon wafer template. 
Individual blood samples containing were perfused through the PPFC in a laminar flow profile for 
5 min at physiological WSRs of 200 s-1, 500 s-1, 1,000 s-1 by controlling the volumetric flow rate. 
The volumetric flow rate through the channel (Q) was controlled via a syringe pump (Harvard 
Apparatus), which dictates the WSR (𝛾𝑊), as shown in Equation (2), 
 
where h is the channel height (cm), w the channel width (cm), and Q the volumetric flow rate 
(mL/sec). The chamber was flushed with PBS buffer containing 1% BSA at the end of the 
experiment, and the WBCs adherent to the HUVEC monolayer was quantified using ImageJ. The 
PPFC was carefully flushed with PBS+/+ buffer (PBS, containing 1% BSA crystals, Ca2+, Mg2+ 
pH ~7.4) prior to the perfusion of the blood to clear out HUVEC surface debris and bubbles. After 
blood perfusion (5 min), PBS+/+ buffer was continuously added to the PPFC to maintain the fully 
developed flow profile and to wash out any unbound particles still in flow. Previous publications 
have shown that E-selectin expression, endothelial cell layer integrity (detachment), and flow 
profile are maintained within the experimental time frame explored in this work.113 Fluorescent 
particle adhesion to HUVEC layer was observed on a Nikon TE2000-S inverted microscope fitted 
with a Photometrics CoolSNAP EZ digital camera with a Sony CCD sensor. Particle adhesion 







length, adhesion data were collected at a constant position of ~1 cm (center) away from the channel 
entrance and exit. Entrance length estimations predict the flow profile is fully developed ~20 µm 
from the channel entry, well beyond the center of the channel where most of the data acquisition 
occurred. Both WBC and particle adhesion to the HUVEC monolayer can be represented as an 
adhesion density. However, for ease in comparison across blood donor variations, many WBC and 
particle adhesion experiments were expressed in terms of percent reduction relative to the healthy 
control of that specific donor, thus normalizing variability across blood donors. All experiments 
were quantified as the number of bound WBCs or particles/mm2 HUVEC. Particles were added to 
whole blood samples at a concentration of ~106 particles/mL, or specified concentration, of blood 
and immediately perfused over the endothelial layer in the PPFC. 
 
Figure 2.1. Illustration of Parallel Plate Flow Chamber in vitro Configuration.  
The illustration shows the basic microfluidic set-up used in PPFC assays. HUVEC are cultured onto gelatin coated glass 
coverslips and subsequently are secured to flow chamber via vacuum adhesion. The inlet reservoir contains the blood under 
experimental conditions of interest. Flow in the chamber is instigated and adjusted via syringe pump connected to the outlet 
blood reservoir. The height of the channel is adjusted via interchangeable gaskets. 
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2.3.3. Red Blood Cell Flow Distribution Studies by Confocal Microscope 
Blood samples were perfused through a ~100 µm ibidi channel similar to the PPFC setup 
as previously described by Namdee and coworkers.112 Roughly 10% of total rigid RBCs per sample 
were stained with wheat germ agglutinin (WGA-488) and incubated for 10 minutes before 
examination; a higher staining percentage of RBC would saturate the fluorescence. For the healthy 
controls, 10% of total RBCs in the sample were stained with WGA 488. Images were taken using 
confocal microscopy with a 488-nm laser at 80% power, with the photo-multiplier tube (PMT) 
voltage set at 700V, 1X gain, and 0% offset. The microscope was run in a round-trip 0.488 ms/line 
using a 2x digital zoom and a 20x water immersive objective. A total of 52 images were collected 
per trial by adjusting the focal plane 2 µm height per image.  Fluorescently-tagged RBCs were 
processed and counted using ImageJ by setting a constant threshold and the "Analyze Particle" 
function. Laser, PMT, and threshold settings were optimized for blank samples (no fluorescent 
RBCs) to contain less than 1% count of fluorescent RBC positive trials. The shutter speed was set 
to allow for visualization of individual fluorescent RBCs in the flow. The inside of the channel 
was marked with a red fluorescent protein (RFP) marker to facilitate the calibration of the starting 
height (inside-top of the channel) for the scan to begin. Results presented represent the number of 
detected fluorescent RBCs in each scanned plane, not simply the mean fluorescent intensity, and 
thus rendered RBC distribution in channel height. RBC distributions of each flow condition were 
condensed for comparison using Interquartile Range (IQR) analysis. All experiments were 
normalized to corresponding healthy control, i.e., no rigid RBCs present.  
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2.3.4. Particle Localization in Blood Flow Studies by Confocal Microscope 
Blood samples containing particles were perfused through a ~100 µm ibidi channel, similar 
to the in vitro PPFC setup, as previously described above. Images were taken of the entire height 
of the channel in increments of 2 µm using a confocal microscope with a 488-nm (to image FITC 
polystyrene particles) and 543-nm (to image rhodamine hydrogel particles) laser at 80% power. 
The microscope ran in a round-trip 0.488 ms/line using a 2x digital zoom and a 20x water 
immersive objective. Fluorescent images of particles were counted using ImageJ by setting a 
constant threshold and the "Analyze Particle" function and analyzed using the methodology 
described above.  
 
2.3.5. Sickle Cell Sample Hematocrit Alteration - Artificial Infusion Mimic 
 For the study presented in Chapter 7, individual SCD patient blood sample from green 
sodium heparin vacutainer tube is aliquoted at 1 mL volumes into 2 mL Eppendorf tubes. Using a 
simple mass balance, RBC volume plus plasma volume is equal to total volume; we derive a 
relationship that determines the RBC volume needed to raise the blood sample to a desired specific 
hematocrit. This relationship is represented as Equation (3). 
Where Radd is the volume needed to raise the blood sample to the desired hematocrit. P0 is the 
initial plasma volume, X2 is the desired hematocrit, and R0 is the initial RBC volume. Both R0 and 
P0 are determined by knowing the initial hematocrit, i.e., X0. Using RBCs obtained from healthy, 
non-SCD donors in sodium heparin, we then add controlled volumes of healthy RBCs to the SCD 
1 mL Eppendorf aliquots to raise the hematocrit to desired hematocrits. This controlled addition 
𝑅𝑎𝑑𝑑 = 𝑃0 (
1
1 − 𝑋2
− 1) − 𝑅0;  𝑚𝐿 
(3) 
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of healthy RBCs aims to mimic the simple blood infusion therapy process used to treat SCD 
patients. Once the hematocrit of a specific sample has been fixed to the desired hematocrit, it is 
ready for PPFC analysis. Of note, the total volume of the aliquots will inevitably change upon the 
addition of RBCs. Thus, only a fixed 1 mL of blood is taken from each aliquot. The total number 
of WBCs in each sample is variable. However, the concentration will be equal across all samples.  
 
2.4. Drug Particle Fabrication and Functionalization Process 
2.4.1. Deformable Hydrogel Particle Fabrication and Characterization 
Deformable hydrogel particles of 2 µm diameter were fabricated by UV-initiated 
polymerization of polyethylene (glycol) diacrylate (PEGDA), and 2-carboxyethyl acrylate (CEA) 
as described by Fish et al.114 The PEGDA, CEA, acryloxyethyl thiocarbamoyl Rhodamine B 
(Rhodamine), and lithium phenyl-2,4,6-trimethylbenzoylphosphinate photoinitiator (PI) were 
combined into methanol (MeOH) at 20% solids (80% MeOH). The MeOH-PEGDA solution was 
then emulsified into silicone oil by probe sonication and subsequently exposed to a 365 nm UV 
light for 10 minutes to initiate polymerization. All materials are obtained commercially, except the 
PI, which is synthesized internally as previously published.115,116 Hydrogel particles of a 2 µm 
diameter were obtained by a series of centrifugation and filtration steps as previously described by 
Fish et al. 114 Centrifugation at low revolution rates helps pellet particle sizes greater than ~8 µm. 
The supernatant is kept and perfused through 2 µm filter tips (Agilent Technologies). The filtrated 
suspension is then centrifuged closely to remove small particle sizes outside of the interest size 
range. The deformability of the particles can easily be controlled by modulating the hydrogel cross-
linking density. The Young’s moduli (~113 kPa) of the hydrogel particles (20% solids) closely 
matches a value reported for WBC previously.114  
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2.4.2. Ellipsoidal Shaped Particle Fabrication and Characterization 
Polystyrene (PS) rods are produced by using polyvinyl alcohol films to stretch 2 µm 
Fluoresbrite YG Carboxylate Microspheres (Polysciences, Inc). The spherical 2 µm particles were 
suspended in 100 mL aqueous solution of 7% w/v, 13,000-23,000 MW polyvinyl alcohol (PVA) 
(Sigma Aldrich). The vials were placed on a rotator for an hour to be mixed in thoroughly. The 
solution was then poured onto a single-well OmniTray (ThermoFisher) and placed on a flat shelf 
in a convection oven at 50°C overnight. The resulting films were cut into 2"x1" strips and attached 
to a single direction stretching apparatus within a convection oven that holds the strips with two 
parallel clamps – one stationary and the other moved along a pipe in one linear direction. The oven 
was preheated to 160°C before a pump pulled the moving clamp down the pipe and stretched the 
films to produce rod particles. The un-stretched ends of the films were cut off. The remaining films 
were dissolved with 30% v/v isopropanol (Sigma Aldrich). The rod particles were centrifuged and 
washed several times to remove the remaining PVA. The recovered particles were imaged using a 
Philips XL30 FEG scanning electron microscope (courtesy of the University of Michigan EMAL). 
The particle dimensions were measured using SEM images via Metamorph Software (Molecular 
Devices, LLC). The rods produced have a ratio of the major axis length to the minor axis length 
(aspect ratio) of 4 (AR4).  
 
2.4.3. Particle Conjugation with Targeting Ligands 
FluoresbriteTM YG Carboxylated polystyrene rods and spheres were conjugated with 
NeutrAvidin biotin-binding Protein (Thermo Scientific) via carbodiimide coupling chemistry as 
previously described. 112 Subsequently, avidin-coated particles were conjugated with biotinylated 
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sialyl-Lewis A (sLea)  (Glycotech, Inc.) and stored in PBS (-/-) with 1% wt BSA at 4 °C until ready 
for use in blood flow experiments. To estimate particle ligand density, particles with NeutrAvidin 
bonded on their surface are reacted with a range of Sialyl Lewis A (sLea) concentrations up to 10 
µg/mL. Particles with reacted sLea are then stained with fluorescently labeled anti-CLA 
(allophycocyanin; APC) and subsequently examined via flow cytometry (Attune; Applied 
Biosystems). The particle populations of interest are gated, and the mean fluorescent intensity 
(MFI) in the APC regime ~660 nm of each subset of particles is recorded. Using calibration beads 
(Bangs Laboratories, Inc.), we create a calibration curve to convert MFI values into molecules of 
equivalent soluble fluorochrome (MESF) values. With the MESF and surface area of a single 
particle, we can approximate the number of sLea sites on a single particle, and the ligand site 
density is determined by normalizing the sLea sites by the particle surface area. In the linear 
regime, we interpolate in between the range of concentrations tested to determine which sLea 
concentration can achieve the desired number of sites on the different types of particles used. A 




PPFC in vitro flow experiment data is an average of 10 pictures of the HUVEC layer from 
each trial, with n=3 blood donors for each data point presented. Flow distribution experiments 
were repeated with n=3 blood donors for each perfusion condition. Trials with SCD donor blood 
were performed, n=1. Trials using artificially constructed blood models were performed n=3, all 
with unique healthy blood donors for each data point presented. Particle adhesion data collected 
from the in vitro PPFC model is an average of ten pictures from each trial, with n=3 blood donors 
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for each data point presented. All data points were included in the analyses and calculations of 
means or statistical significance for all studies. Data are plotted with standard error bars and 
analyzed as indicated in figure legends. Specifically, the ten brightfield images obtained for each 
data point (n =1) were averaged, and the standard error was calculated. The average values 
obtained for each "n" are averaged over multiple donors (n = 3) and standard error obtained by 
error propagation calculations. A 2-way ANOVA integrated package on GraphPad Prism was used 
to analyze any statistical difference between rigid and healthy conditions. Asterisks indicate p 
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Modifications have been made the published document to adapt the content to this text. 
This chapter aims to probe how WBC adhesion to inflammation is impacted in the presence of 




The symptoms of many blood diseases can often be attributed to irregularities in cellular 
dynamics produced by abnormalities in blood cells, particularly RBCs. Contingent on the disease 
and its severity, RBCs can be afflicted with increased membrane rigidity as seen in malaria and 
sickle cell disease.  Despite this understanding, little experimental work has been conducted 
towards understanding the effect of RBC rigidity on cellular dynamics in physiologic blood flow. 
Though many have computationally modeled complex blood flow to postulate how RBC rigidity 
may disrupt normal hemodynamics, to date, there lacks a clear understanding of how rigid RBCs 
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affect the blood cell segregation behavior in blood flow, known as margination, and the resulting 
change in the adhesion of WBCs. In this work, we utilized an in vitro blood flow model to examine 
how different RBC rigidities and volume fractions of rigid RBCs impact cell margination and the 
downstream effect on WBC adhesion in blood flow. Healthy RBC membranes were rigidified and 
reconstituted into whole blood and then perfused over activated endothelial cells under 
physiologically relevant shear conditions. Rigid RBCs were shown to reduce WBC adhesion by 
up to 80%, contingent on the RBC rigidity and the fraction of treated RBCs present in blood flow. 
Furthermore, the RBC core was found to be slightly expanded with the presence of rigid RBCs, 
by up to ~30% in size entirely comprised of rigid RBCs. Overall, the obtained results demonstrate 
an impact of RBC rigidity on cellular dynamics and WBC adhesion, which possibly contributes to 




Blood related diseases remain common today and are difficult to manage due to their 
complex nature.1 Blood cell diseases, in particular, have proven challenging to understand and 
treat, despite decades of research, specifically those diseases involving the loss of RBC 
deformability.2 Diseases involving rigid RBCs are typically of genetic origin and have been 
studied mainly from this biological perspective, with their genetic nature limiting treatment options 
and efficacy.3 Patients inflicted with SCD, hereditary spherocytosis, iron-deficient anemia, 
pyruvate kinase deficiency, HIV, malaria, sepsis, and even natural aging have less deformable 
(rigid) RBCs than healthy patients.3,6,7,101 It is well known that rigid RBCs cause major physical 
damage when traveling through the body by occluding microvasculature, depriving tissues of 
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nutrients, and damaging the spleen, liver, and lungs walls.5,8 This damage produces further 
complications such as pulmonary hypertension, and cardiac dysfunction.4,5 However, to date, there 
is little understanding of the direct impact of RBC rigidity on the functionality of other blood cells 
and the downstream contribution to disease manifestation beyond the occlusion of 
microvasculature.9  
The ability to fully elucidate the effects of cellular rigidity and shape on hemodynamic 
blood margination can offer useful insight into the pathology of the many diseases in which RBC 
rigidity has been implicated,3,6,7,101 including in SCD that is the most described disease associated 
with altered RBC deformability. SCD is a hereditary multisystem disease,3 which affects millions 
worldwide; estimates suggest that ~100,000 Americans are affected.3 The polymerization of HbS 
produces long chains, which results in the sickling shape of the RBC, loss of membrane flexibility, 
reduced cell lifespan, and impaired blood flow to limbs.3,50 Treatments for SCD are limited and 
highly invasive, e.g., use of narcotics, blood transfusions, and bone-marrow transplants.3,117 
However, little is known about the potential direct impact of the altered RBCs on the margination 
functionality of other blood cells, particularly WBCs. Indeed, SCD patients are known to have 
compromised immune responses to infections, which is attributed mainly to splenic 
dysfunctions.45 However, it is possible that RBCs significantly alter cellular distribution in blood 
flow, and hence WBC margination, which would affect the natural immune response.  
To address the research gaps highlighted, we experimentally probe the direct effects of 
rigidified RBCs on the resulting margination of WBCs from bulk blood flow to the vessel wall via 
a PPFC and human blood flow with the presence of rigidified RBCs in this chapter. Our results 
show that rigid RBCs in flow produced varying effects contingent on the level of RBC rigidity, 
the concentration of rigid RBC, and the magnitude of the blood flow shear rate. Overall, the work 
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presented in this chapter experimentally bypasses challenges including difficulty in accurately 
modeling hemodynamics, translating computational work into realistic in vitro models, and 
obtaining blood from disease inflicted patients. Ultimately, findings gained from a comprehensive 
investigation of cellular dynamics in blood flow can lead to profound advances in the 
understanding the pathology of many diseases. 
 
3.4. Results 
3.4.1. Effect of Tert-Butyl Hydroperoxide on RBC Membrane Deformability 
 It was key to first quantitatively characterize RBC membrane rigidities to determine the 
effects on hemodynamics. To produce a range of RBC deformability, as encountered across 
diseases,118 we utilized four concentrations of TBHP to treat RBCs, 1.0 mM, 0.75 mM, 0.5 mM 
and 0.25 mM, and measured their ability to elongate under shear stress via ektacytometry, as 
described in the Materials and Methods chapter. Deformability is characterized by the change in 
axis ratio, known as EI – Equation 1. Figure 3.1.A. shows the EI curves obtained from the four 
TBHP treatments. There was no statistical difference between healthy RBCs and RBCs treated 
with 0.25 mM TBHP; therefore, we excluded 0.25 mM from the remainder of this work. 
Treatments of 0.5 mM, 0.75 mM, and 1.0 mM TBHP yielded significantly different EI curves 
versus the healthy control, translating to 2, 8 and 40 times less deformable (more rigid), 
respectively, than healthy RBCs at the highest applied shear. Furthermore, at low shear stress (≤2 
Pa), RBCs treated with 0.5 and 0.75 mM TBHP behave similarly to healthy RBCs. A WSR of 
1,000 s-1 in flow is equivalent to a shear stress of ~5 Pa, which is typically seen in vessels such as 
arterioles and capillary networks.119,120 WSRs of 500 s-1 (~ 2.5 Pa) is seen in venules, and WSRs 
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of 200 s-1 (~1 Pa) are typical in large veins.119,120  Comparing the results to previous work, the 
deformability of the RBCs treated with 0.5 mM TBHP are similar to those taken from a patient 
inflicted with sickle cell disease, while the deformability of RBCs treated with 0.75 mM TBHP 
mirrored those taken from a patient with sickle cell disease during a severe painful crisis.121 From 
brightfield images of RBCs, there is little detectable change in shape of the healthy cells (Figure 
3.1.B.) as compared to ones treated with 1.0 mM TBHP (Figure 3.1.C.). Indeed, previous works 
have shown that RBCs exposed to lower concentrations (0.5 and 1.0 mM) of TBHP exhibit 
negligible membrane protein degradation and morphological changes. 122  
 
3.4.2. Effect of Rigid RBCs on Leukocyte Adhesion as a Function of RBC Rigidity and WSR  
Once we quantitatively characterized the physical properties of the RBCs, we investigated 
how the presence of rigid RBCs in the whole blood affects leukocyte adhesion to the endothelium. 
Figure 3.1. Red Blood Cell Characterization via Ektacytometry.  
(A) Elongation indices of RBCs after treatment with 1.0, 0.75, 0.5, and 0.25 mM tert-butyl hydroperoxide and upon 
controlled applied shears. Representative image (60x) of (B) healthy (no TBHP) and (C) 1.0 mM TBHP treated RBCs 
in buffer at 2% Hct. 
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We used an in vitro PPFC model and prepared blood as described in the Materials and Methods 
chapter. RBCs were reconstituted into a whole blood sample at a hematocrit (Hct) of 40%, and the 
sample is perfused through the PPFC at different physiologically relevant WSRs (1,000 s-1, 500 s-
Figure 3.2. White blood cell binding to inflamed endothelium in vitro by Red Blood Cell Rigidity and 
Wall Shear Rate.  
Quantified WBC binding to an IL-1β inflamed endothelial layer as a function of rigid RBCs present, i.e., % 
volume rigid RBC, for the different WSRs of (A, D, G) 1,000 s-1, (B, E, H) 500 s-1, and (C, F, I) 200 s-1. All 
blood samples were reconstituted to a hematocrit of 40%. Trials plotted as reduction compared to healthy 
controls, i.e., no rigid RBCs present. Each figure represents one of three rigid RBCs treatments of 1.0 mM 
TBHP treated RBCs (most rigid), 0.75 mM TBHP treated RBCs, or 0.5 mM TBHP treated RBCs (least 
rigid). Statistical analysis of adherent density was performed using two-way ANOVA to test all WBC 
adhesion versus healthy WBC adhesion control. (*) indicates p<0.05, (**) indicates p<0.01, (***) indicates 
p<0.001, and (****) indicates p<0.0001. Error bars represent standard error. 
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1, and 200 s-1). We tested a range of RBC rigidities and percentage of rigid RBCs in blood to gain 
a general insight on the impact of these cells on hemodynamics and WBC margination. Figure 3.2. 
shows the impact of RBC rigidity on WBC adhesion relative to WBC adhesion in whole blood 
flow of a healthy control, as a function of RBC stiffness and WSR in a ~250 µm height channel. 
We chose to represent the data in this way, i.e., percent change, owing to the natural variation in 
donor WBC adhesion. Figure 3.3. shows the absolute cell adhesion density at three distinct WSRs 
– 1,000 s-1, 500 s-1, and 200 s-1 for reference. The data in Figure 3.3. also indicates WBC adhesion 
is reduced as WSRs increases in alignment with previous reports in the literature24,123,124. For all 
TBHP treatments, we observe that the addition of rigid RBCs results in WBC adhesion reduction 
across all examined WSRs. Interestingly, a linear increase in the ratio of rigid to healthy RBCs did 
not translate to a linear decrease in WBC adhesion across the different treatments. The most 
substantial reduction in WBC adhesion, ~80%, was observed for the most rigid RBCs (1.0 mM 
TBHP treatment) at the highest WSR of 1000 s-1 evaluated for the condition in which 50% of the 
RBCs were healthy, and the other 50% were rigid (Figure 3.2.A.). A visual representation of this 
high WBC adhesion knockdown to the endothelial layer is presented in Figure 3.4. A slight 
recovery in WBC adhesion is observed when the fraction of rigid RBCs present is increased to 
Figure 3.3. Donor Variation in White Blood Cell Binding.  
Quantified WBC binding to an inflamed endothelial layer after 5 mins of laminar whole blood flow as a function of healthy blood 
donor. Error bars represent standard error for each donor. WBC binding at (A) 200 s-1, (B) 500 s-1, (C) 1,000 s-1. 
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100% for the 1000 s-1 and nearly all WSRs.  As the RBC rigidity decreased from high (1.0 mM 
TBHP) to moderate (0.75 nM TBHP) to low (0.50 nM TBHP), at the 1000 s-1 shear, we see a 
decrease in the magnitude of the WBC adhesion reduction to ~60 - 70%. Moreover, the location 
of the peak adhesion shifted to between 70 and 90% rigid RBCs in blood for the moderate and low 
rigidity RBCs, respectively, compared to high rigidity where the maximum reduction was 
observed at 50%. The importance of the level of RBC rigidity on the impact of rigid RBCs on 
WBC adhesion was diminished at the intermediate WSR of 500 s-1 evaluated. The maximum 
reduction in WBC adhesion observed for the 500 s-1 assays was ~60% for all degrees of rigidity 
examined and occurred for the condition in which 50% of the RBCs were healthy, and the other 
50% were the rigid (Figure 3.2.B., 3.2.E., and 3.2.H.). Interestingly, the level of WBC adhesion 
reduction at 500 s-1 was not significantly different when compared to 1,000 s-1 despite a more 
substantial number of cells normally adherent at the former WSR, suggesting the impact of RBCs 
on WBC adhesion occurs at the point of WBC capture to the wall and not after adhesion. Of note, 
most WBC adhesion occurs in venules, which experience WSRs  close to 500 s-1. 119,125–127 At 200 
s-1, a reduction in WBC adhesion of ~45-50% was observed when 50% of the RBCs had a low 
level of rigidity. However, the reductions in WBC adhesion observed for most conditions at the 
200 s-1 WSR were not significant relative to the control (Figures 3.2.C., 3.2.F., and 3.2.I.); thus, 
no peak reduction observable for any concentration of rigid RBCs present.   
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3.4.3. Effect of Rigid RBCs on Leukocyte Adhesion as a Function of Hematocrit  
We utilized an in vitro PPFC model to examine the effect of different Hct on WBC 
adhesion to an activated endothelial monolayer. Since the amount of total whole blood per trial 
was held constant, lowering Hct required an increase in the plasma volume and decrease in total 
RBC volume. We began by reconstituting our blood samples with WBC rich plasma to Hcts of 
40%, 30%, and 20%. Afterwards, we examined healthy, i.e., no rigid RBCs present, WBC 
adhesion onto an inflamed endothelial monolayer. All three examined Hcts were reconstituted 
back-to-back with WBC rich plasma from the same donor (eliminating donor variation across 
different Hct), thus the concentration of WBCs/mL of plasma was the same for Hcts evaluated. 
Furthermore, since the volume of WBC rich plasma increased as the Hct decreased, the total 
number of WBCs in the whole blood sample increased as the Hct decreased. The WBC adhesion 
density at different Hcts at a WSR of 1,000 s-1 is shown in Figure 3.5.A. We observe that WBC 
adhesion is significantly lower at Hcts of 30% and 20% respectively, and there was no significant 
difference in WBC adhesion between Hct of 30% and 20%. Given that the channel height was 
fixed at 254 µm in this work, the decrease in the Hct from 40% to 30% likely significantly alter 
Figure 3.4. White Blood Cell Binding on Confluent Monolayer of HUVEC.  
Brightfield images of WBCs adhered to HUVEC while blood is perfused at a WSR of 1,000 s-1. (A) shows condition with 
healthy blood, i.e., no rigid RBCs present. (B) shows condition with 50% rigid RBCs treated with 1.0 mM TBHP present.   
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the RBC core and CFL dynamics, thus reducing WBC adhesion to the vessel wall. The difference 
in the size of the RBC core when the Hct decreases from 30% to 20% is likely not significant 
enough to observe a notable decrease in WBC adhesion.  
 
Subsequently, we investigated how the addition of rigid RBCs effected WBC adhesion at 
lower Hcts. We compared the WBC adhesion trends at the lower Hcts of 30% and 20% to the 
adhesion trend for the condition utilized in Figure 3.2.A., i.e., 40% Hct with 1.0 mM TBHP. We 
again compared normalized WBC adhesion data to eliminate WBC adhesion variation between 
donors and at different Hcts. Figure 3.6.A. shows the impact of RBC rigidity on WBC adhesion 
relative to WBC adhesion observed with no rigid RBCs present for low Hcts. The degree of rigidity 
and WSR were constant at 1.0 mM TBHP and 1,000 s-1, respectively.  Figure 3.6.B. compares the 
normalized (relative to 40% Hct) reductions in WBC adhesion with the 30 and 20% Hct flows.  
Figure 3.5. Blood Margination and White Blood Cell Adhesion Density at Different Hcts.  
Quantified WBC binding to an inflamed endothelial layer after 5 mins of laminar whole blood flow as a 
function of healthy blood hematocrit (Hct) at 1,000 s-1. Error bars represent standard error for each donor. 
Concentration of WBCs (~6x106 WBCs/mL of plasma) is kept the same for all conditions. (*) indicates 
p<0.05, (**) indicates p<0.01, and (n.s.) indicates no statistical difference is found. Error bars represent 
standard error. 
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For the 30% Hct case, WBC adhesion reduction was higher at most concentrations of rigid RBCs 
relative to the reduction levels observed with 40% Hct, as indicated by the ratio of WBC adhesion 
reduction at 30% to reduction at 40% Hct being greater than 1 for all concentration of rigid RBCs 
in flow. This observed enhanced reduction in WBCs at 30% Hct may be due to the higher ratio of 
WBCs-to-RBCs present in the blood sample at lower Hcts, i.e., increased probability of 
heterogeneous collision, for the conditions presented in Figure 3.6.30,31 Interestingly, for the 20% 
Hct case, a significantly smaller (p<0.01) reduction in WBC adhesion is observed as compared to 
the 40% Hct case when 50 – 70% of the RBCs present were rigid, pointing to a different RBC 
core-CFL dynamics at such a low hematocrit in a large channel. Here, since the WBC 
concentration in plasma is kept constant, an even lower Hct of 20% would imply a much higher 
Figure 3.6. White Blood Cell Binding at Low Hematocrit.  
(A) Quantified WBC binding to an IL-1β inflamed endothelial layer as a function of rigid RBCs present, i.e., % 
volume rigid RBC. All results are WBC adhesion after 5 mins of laminar whole blood flow with a constant 
TBHP treatment of 1.0 mM and WSR of 1,000 s-1. All trials plotted as reduction compared to respective healthy 
controls RBC, i.e., no rigid RBCs present, same Hct, thus eliminating donor variation in WBC adhesion levels. 
(B) Relative difference in normalized WBC binding reduction between WBCs in 30% Hct and 20% Hct as 
compared to WBC binding at 40% Hct. WBC concentration (~6x106 WBCs/mL of plasma) kept constant upon 
Hct change. Error bars represent standard error. Statistical analysis of adherent density was performed using 
two-way ANOVA to test all WBC adhesion versus healthy WBC adhesion control. (*) indicates p<0.05, (**) 
indicates p<0.01, (***) indicates p<0.001, and (****) indicates p<0.0001.  
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plasma volume and hence a higher ratio of WBCs-to-RBCs in flow, which likely translates to a 
reduced probability of mismatch collisions.  However, the rigid RBCs at the 50 – 70% 
concentration in blood may expand the core in a manner that positively benefits WBC adhesion. 
Indeed, numerous computational and theoretical models have highlighted the complex and, in 
some cases, non-linear relationship between RBCs and the CFL. 15,16,26,27,18–25 In the absence of 
the capacity to directly visualize the interactions between normal RBC, rigid RBCs and WBCs as 
was the case in our systems, such models would likely be needed to understand better the non-
linear relationship highlighted in Figure 3.6.  
 
3.4.4. Effect of Rigid RBCs on Leukocyte Adhesion as a Function of Channel Height.  
Once we understood how Hct could affect how severely rigid RBCs alter their WBC 
adhesion patterns, we then investigated different flow channel heights to see how these trends 
Figure 3.7. White Blood Cell Binding Impact by Changing Channel Height.  
Quantified WBC binding to an inflamed endothelial layer as a function of channel height. Channel heights utilized consisted of 
254 µm, 127 µm, and microchannel 50 µm. These results keep a constant wall shear rate of 1,000 s-1. All trials normalized and 
plotted in reduction as compared to respective healthy controls, i.e., no rigid RBCs present, thus eliminating donor variation in 
WBC counts. (A) 1.0 mM TBHP treated RBCs (most rigid), (B) 0.75 mM TBHP treated RBCs, (C) 0.5 mM TBHP treated RBCs 
(least rigid). Statistical analysis of adherent density was performed using two-way ANOVA to test all WBC adhesion versus healthy 
WBC adhesion control. All conditions are non-significant versus the healthy WBC control. Error bars represent standard error and 
include error propagation for multiple donors. 
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would hold in various vessels throughout the body. WBC adhesion data was collected using 
channel heights of 127 µm and 50 µm, and compared to the normalized results from the 254 µm 
channel. We utilized a setup similar to the PPFC previously described above for the 127 µm height 
and an additional PDMS microchamber for the 50 µm height. We down selected to 30% and 70% 
rigid RBCs conditions to compare to healthy RBCs in 127 µm and 50 µm channels. As discussed 
in the Discussion section of this chapter, the work by Dobbe et al. shows that sickle cell disease 
patients blood typically consists of ~30% disease inflicted (rigid) RBCs under stable conditions 
and ~70% when experiencing a severe crisis.121 All blood samples were reconstituted to a 40% 
Hct. Figure 3.7. illustrates that no significant difference in WBC adhesion patterns, i.e., normalized 
WBC adhesion, is found between channel heights in the presence of the highly rigid (1.0 mM 
TBHP-treated) RBCs. The WBC adhesion for both channels trends are nearly identical and yield 
no statistically significant difference; baseline adhesion is shown in Figure 3.8. Examination of 
Figure 3.8. White Blood Cell Binding Variation with Channel Height.  
Quantified WBC binding to an inflamed endothelial layer after 5 mins of 
laminar whole blood flow as a function of WSR with no TBHP treatment. 
All points were taken at a WSR of 1,000 s-1. Error bars represent standard 
error for each donor. 
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0.75 mM and 0.5 mM TBHP treated RBCs under the 127 µm and 50 µm channels yielded similar 
results when compared to WBC adhesion data for the 254 µm channel (Figures 3.7.B. and 3.7.C.). 
Given that no significant difference in WBC adhesion patterns is observed across all channel 
heights examined, we can speculate that disruption in WBC adhesion patterns scales in the 
different vessel sizes similar to the ones tested here.  
Figure 3.9. Confocal Images of Fluorescent Red Blood Cells in Blood Flow at Different Height Increments. 
Whole blood with fluorescently tagged with WGA-488 healthy RBCs flowing in a channel of height 100 µm at 1,000 s-1. 
The blood sample is reconstituted to a hematocrit of 40%. The direction of flow is from left to right. Images show RBC 
density at different heights within the channel while in flow. Cross-sectional image is ~164 µm by ~164 µm. 
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3.4.5. Rigid Red Blood Cell Distributions in Blood Flow.  
To better understand how these trends in WBC adhesion by percent rigid RBCs, RBC 
deformability, channel size, WSR, and hematocrit developed, we investigated the hemodynamic 
distribution of the cells types of interest under flow conditions. By leveraging confocal microscopy 
to generate Z-stack images, we investigated the distribution of rigid RBCs within a channel height. 
To determine how rigid RBC distributions are altered in blood flow, a proportion of rigidified 
RBCs were stained with wheat grain agglutinin (WGA) 488, reconstituted into whole blood at 
40% Hct, perfused through a 100 µm channel, and imaged via confocal microscopy as described 
in the Materials and Methods chapter. The generated images depicted fluorescently tagged RBCs 
at different planes of the channel height and allowed rigid RBC distributions to be compiled across 
the channel height. Figure 3.9. shows a subset of Z-stack images depicting fluorescently tagged 
RBCs in flow at different heights within the 100 µm channel under a healthy condition, i.e., no 
rigid RBCs present; a subset of healthy RBCs is fluorescently tagged. We probed whole blood 
samples containing RBCs treated with either 1.0 mM, 0.75 mM, or 0.5 mM and examined their 
distribution under flow with the confocal microscope at a WSR of 1,000 s-1.  The results are 
presented as the IQR of the rigid RBCs. Figure 3.10.A. shows the normalized IQRs, and Figures 
3.10.B., 3.10.C., and 3.10.C. show the raw distributions for the 30%, 70%, and 100% rigid RBCs 
in flow, respectively. All rigid RBC distribution IQRs were normalized to the respective healthy 
RBC control IQR from the same donor. High percentages of rigid RBCs present significantly 
(p<0.05) increase the IQR of the rigid cells, and thus the number of interactions between rigid cells 
and WBCs in the RBC-FL. The result presented in Figure 3.10.A. show changes RBC core size 
due to rigid RBC distribution do not directly explain the non-linear reduction in WBC adhesion 
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observed under different rigid RBC concentrations in the flow. We find that for flow consisting of 
100% of rigidified RBCs at the high and moderate degree of rigidity, i.e., 1.0 mM and 0.75 mM 
TBHP, the rigid RBC core is expanded by nearly 30% and 20%, respectively. Meanwhile, rigid 
RBCs do not significantly modify the RBC core size while in combination with healthy cells (30 
and 70% rigid RBCs). As shown in Figure 3.2. (A, D, G), maximum WBC adhesion reduction was 
Figure 3.10. Normalized Interquartile Ranges (IQR) of Rigid Red Blood Cell Confocal Distribution. 
Quantified rigid cell distribution, normalized and presented as IQRs in a channel of height 100 µm at 1,000 
s-1 with varying TBHP treatments and rigid RBC % vol. Statistical comparisons are to healthy IQR at unity.  
Quantified rigid red cell distributions within the channel height at three different degrees of rigidity at (B) 
30%, (C) 70%, and (D) 100% rigid RBCs present in flow. Statistical analysis of IQR magnitude was 
performed using two-way ANOVA determine the effect of the prevalence and degree of RBC rigidity. (*) 
indicates p<0.05. Error bars represent standard error and include error propagation for multiple donors. 
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observed when both soft and rigid RBCs are present in near equal amount (50% rigid RBCs for 
the 1.0 mM TBHP treated RBCs).  
3.5. Discussion 
Change in membrane rigidity can be attributed to lipid peroxidation. 122,128 Thus, this work 
decouples the changes in RBC shape and rigidity often found together in diseases to evaluate the 
impact of rigidity only. Looking at the results in the context of SCD, RBCs treated with 0.75 mM 
TBHP represent the level of rigidity observed in SCD RBCs during a severe painful crisis.  For 
these moderately rigid RBCs, the maximum negative impact on WBC adhesion (~60% reduction, 
p<0.01) was seen when 70% of the RBCs present in flow were rigid (Figure 3.2.D.) for the 1000 
s-1 WSR. Interestingly, a pervious report by Dobbe et al. suggests that roughly 70% of total RBCs 
are rigid in patients when undergoing a painful crisis in SCD, indicating that the ability of WBCs 
to marginate may be severely impacted in these patients depending on the blood flow 
characteristics of the affected vessels.121 In general, roughly 30% of the total RBCs are abnormally 
rigid, with rigidity analogous to the 0.50 mM TBHP treatment, in a patient with SCD under stable 
health, i.e., no crisis present. Here, we show that even the low presence of rigid RBCs in blood 
significantly reduced WBC adhesion (Figure 3.2.G.). Thus, the poor immune response of patients 
inflicted with SCD, or another disease relating to RBC deformability may, in part, be due to the 
physical presence of rigid RBCs altering WBC function.  
The pattern of maximum WBC reduction observed in Figure 3.2. may arise due to the 
combined effect of (1) an expanded RBC core due to stiffer RBCs being less affected by the lift 
force, and thus do not populate the core of flow as densely as normal RBCs, and (2) heterogeneous 
collisions, i.e., collisions between a rigid and a deformable cells, as described by Graham and 
coworkers. 30,31 Specifically, the mismatched resulting trajectories upon heterogeneous collisions 
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are a contributing factor for the formation of the RBC core and successful margination of the 
considerably stiffer WBCs and platelets to the vessel walls. We speculate that upon rigidification, 
RBCs also begin to marginate outside the RBC core where they more frequently collide with 
WBCs, preventing WBCs from the normal rolling and, hence, firm adhesion to endothelium. 
Overall, Figure 3.2. shows higher degrees of rigidity and higher WSRs contribute to a more 
significant reduction in WBC adhesion with rigid RBCs, which is consistent with maximum 
impact and cell displacement with collisions in blood flow. Interestingly, the negative impact of 
rigid RBCs on WBC adhesion is maximum when near equal amount healthy (soft) and rigidified 
(stiff) RBCs are present, which represents maximum occurrence of heterogonous collisions.  We 
speculate that the recovery seen when the concentration of rigid RBCs increases beyond 50 – 60% 
is attributed to the decrease in heterogeneous collisions due to the increasing presence of rigid 
RBCs and depletion of healthy RBCs. However, the 100% rigid RBCs are likely not able to tightly 
pack in the core as healthy RBCs, explaining the persistence of the reduction in WBC adhesion 
even with the elimination of soft-stiff RBC heterogeneous collisions.  
From literature, we know that the RBC core aids in pushing stiffer objects, e.g., WBCs, to 
the vessel wall where they can probe the endothelial layer.18–20 The formation of the RBC core and 
CFL is inevitable regardless of the blood Hct; However, at lower Hcts, the RBC core becomes 
thinner due to the smaller number of RBCs present since RBC tend to migrate to the center of the 
flow vessel while WBCs and platelets are pushed to the wall. 16,21 Consequently, the CFL increases 
in width if the channel size is kept constant. It is known that the RBC core supplies a cushion that 
forces WBCs towards the vessel wall, enhancing their margination. 16,21 Indeed, computational 
analysis of WBC margination under varying Hcts by Fedosov et al. 25 and Marth et al. 26 confirmed 
that WBC margination is much weaker at low concentrations of RBCs in the flow. Additionally, 
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the lower RBC concentration likely allow better motion of rigid cells to the wall and hence 
maximum disruption of WBC adhesion. These results suggest that the presence of rigid RBCs may 
be more detrimental in anemic patients, especially if WBC count is high. Lower Hcts and high 
WBC counts are typically seen in diseases such as SCD. 129 
WBCs experience a slight recovery in their adhesion as the concentration of rigid RBCs 
increased to 100% for the high WSR assays, e.g., Figure 3.2.A. We previously speculated that this 
adhesion improvement is due to the decrease in heterogeneous collisions between healthy RBCs 
and stiff RBCs as the concentration of rigid RBCs increases despite the expanded core with the 
100% rigid RBCs in the flow. Taken together, data in Figures 3.2. and 3.10. suggest a combination 
of the mismatch in RBC rigidity between the healthy (soft) RBCs and rigid (stiff) RBCs, and the 
resulting heterogeneous collision, and enlarged RBC core inhibit the ability of WBCs to marginate 




In this study, we show that the presence of rigid RBCs has a negative effect on the adhesion 
of WBCs to an inflamed human endothelium in blood flow. We utilize TBHP to artificially 
decrease RBC membrane flexibility and generate rigid RBCs simulating various hematologic 
disorders. Rigid RBCs are reconstituted into whole blood and perfused through microchannel 
model at physiologically relevant wall shear rates (WSRs). We find that higher degrees of rigidity 
in RBCs and higher WSRs produce the most significant WBC adhesion reduction. We observed a 
decrease in WBC adhesion as high as 80% when rigid RBCs are present in blood flow. 
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Interestingly, these results show that WBC adhesion reduction is maximized when a combination 
of both healthy soft RBCs and stiff RBCs are present, thus increasing rigid RBC concentration 
does not translate to worse WBC adhesion. This work offers experimental evidence that 
heterogeneous collisions (soft and stiff) between blood cells (RBC-to-RBC and RBC-to-WBC) 
hinder WBC adhesion to endothelial wall. We also show that RBC core is expanded, up to ~30%, 
when rigid RBCs are present, meaning rigid RBCs are abnormally positioned closer to the vessel 
wall. The presented results may offer insight in understanding why people with disease relating to 
RBC deformability are susceptible to infection and have a poor immune response as we observed 
a significant reduction in WBC adhesion in blood conditions analogous to blood conditions of 
RBC-diseased patients. The need for further research of the impact RBC rigidity has on 
hemodynamics is paramount towards gaining a better understanding of disease manifestation and 
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In this work, we utilized a parameterization model of ektacytometry to quantify the bulk 
rigidity of the rigid RBC population in SCD patients. Current ektacytometry techniques implement 
laser diffraction viscometry to estimate the RBC deformability in a whole blood sample. However, 
the diffraction measurement is an average of all cells present in the measured sample. By coupling 
an existing parameterization model of ektacytometry to an artificially rigid RBC model, we 
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formulated an innovative system for estimating the average rigidity of the rigid RBC population 
in SCD blood. We demonstrated that this method could more accurately determine the bulk 
stiffness of the rigid RBC populations. This information could potentially help develop the 
ektacytometry technique as a tool for assessing disease severity in SCD patients, offering novel 
insights into the disease pathology and treatment.  
 
4.3. Introduction 
The rigidity and hemoglobin (Hgb) composition of RBCs in SCD patients varies highly, 
and a high HbS content does not necessarily correlate to an increased cellular membrane stiffness. 
130 For example, there can be a scenario with a large population of HbS concentrated RBCs (%S 
fraction) with moderate to low cellular membrane stiffness or another situation with a small %S 
fraction with RBCs with high membrane stiffness. Thus, a complete understanding of the impact 
of RBC rigidity in SCD symptom presentation would require the ability to characterize this 
property in individual patient blood. Therefore, several methods have been explored to 
characterize the mechanical properties of RBCs, including micropipette aspiration, atomic force 
microscopy, microfluidic devices, and optical tweezers. However, these methods are limited since 
they require single RBC isolation and are static techniques. 73 For one, the design and fabrication 
of robust microfluidic devices can be highly labor-intensive. 71,95,131 Conversely, traditional 
ektacytometry, or laser diffractometry, is more convenient and precise than other methods and thus 
has been adopted as a promising technique for testing RBC deformability.73 Ektacytometry was 
initially developed and successfully used to screen for RBC membrane disorders such as hereditary 
spherocytosis. 132 This method in recent decades has been repurposed for the investigation of SCD. 
70  
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Ektacytometry principally works by inducing controlled shear stress on a suspension of 
RBCs in diluted blood. The resulting deformation from the applied shear stress is captured by 
shining a laser onto the sample, which creates a single diffraction pattern. The general technique 
can make three different types of measurements: (1) an Osmoscan which holds cells at constant 
shear stress while varying osmolality, (2) a deformability scan which keeps cells at a fixed 
osmolality while changing the shear stress, (3) an Oxygenscan which varies both the shear and 
oxygen gradient. 133–135 Cellular deformability, i.e., elongation, is then reported as an Elongation 
Index – a ratio of the difference between the major and minor axes in the cellular diffraction 
patterns over their sum. However, most works using ektacytometry to evaluate how RBC rigidity 
impact disease severity in SCD have focused on osmoscans, 67,68 which may not entirely recreate 
the in vivo setting. RBCs in blood flow are exposed to a relatively fixed in vivo osmolality (~290 
mOsmol/kg) and varying shear as they transport through different blood vessels. Alternatively, 
measurements that employ analysis of RBC elongation in response to changes in shearing stresses 
at a fixed osmolality may offer a better description of RBC stiffness in SCD. 70 Oxygenscans, the 
other form of shear-based analysis, are a robust method recently developed, which can measure 
the maximum RBC elongation at normal oxygen conditions and minimum RBC elongation under 
hypoxic conditions and point of sickling. 135 However, regardless of the shear-based method 
employed, ektacytometry is critically limited. It renders average deformability for all RBCs in the 
sample, 70,133,134, i.e., across both stiff and healthy RBCs. This average measurement of 
deformability may underestimate the rigidity of HbS-rich (%S fraction) or sickle RBC population 
in the blood, which could be a critical complication when it comes to assessing a patient's well-
being or treatment response. A sample with a small overall fraction of extremely rigid RBCs could 
render a similar elongation curve as a sample with a high fraction of moderately stiff RBCs. 
 54 
Previous studies have investigated how laser diffractions in ektacytometry differ based on non-
homogeneous mixtures of RBC deformability. 136 However, to date, there is no established method 
for isolating and directly characterizing the rigidity of the HbS RBC population in patient blood.  
Here, we present an approach to estimate the average rigidity of the HbS-rich (rigid) red 
cell population in SCD via a method that implements artificially rigidified RBCs mixed into whole 
blood at different rigid-to-healthy ratios. Said samples are measured via traditional shear-based 
ektacytometry deformability analysis. We then parameterize the measurements to develop a 
numerical model that predicts the rigid RBC population's bulk rigidity in SCD blood samples. This 
method can estimate the stiffness of sickled RBC populations with greater certainty, potentially 
serving as a platform for understanding disease severity in SCD patients and monitoring the 
efficacy of novel and established treatment options. 
 
4.4. Results 
4.4.1. Measurement of Artificially Rigid RBC Populations in Whole Blood Samples 
In an ektacytometry scan, a collection of EI values plotted as a function of shear stress 
renders deformability curves. Previous work has determined that the critical factor in 
characterizing alterations in cell deformability is the maximum achievable EI, i.e., EImax. 
137 
Accordingly, measurements from healthy donors registered the highest EImax values (~0.62). In 
contrast, SCD donors tended to have lower EI max values. Next, we built an artificially rigid RBC 
approach, where the RBC membrane stiffness is easily altered to test how changing the fraction of 
rigid RBCs affects the EImax of the whole blood. We artificially rigidified healthy donor RBCs via 
treatment with TBHP in varying concentrations to obtain RBCs with a range of stiffness from 
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slightly to highly rigid.  Short interactions (<60 minutes) with relatively low concentrations of 
TBHP (<3.0 mM) induces lipid peroxidation and membrane protein crosslinking in RBCs. 
Figure 4.1. Ektacytometry Analysis of Various Rigid Red Blood Cell Populations with Varying Red Blood Cell 
Membrane Stiffnesses.  
Ektacytometry curves for various rigid-to-healthy fractions ranging from 0% to 100% in increments of 10% rigid RBCs present. 
Rigid RBCs have been treated with: (A) 1.0 mM. (B) 0.9 mM. (C) 0.75 mM. (D) 0.5 mM TBHP. (E) Maximum EI recorded at 
60 Pa for each rigid fraction condition is compared to EImax of the healthy condition, these ratios are plotted as a function of 
rigid RBC fraction present. Linear regression is used to determine the slope of these rigid-to-healthy ratio trends. (F) Slopes of 
rigid-to-healthy ratio trends are plotted as a function of TBHP concentration. 
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Prolonged exposure will result in structural alteration in protein networks and eventual RBC lysis. 
138 We combined the stiffened RBCs with healthy (non-treated) RBCs in whole blood at different 
stiff-to-healthy ratios and measured the changes to the EI values. 10 The resulting deformability 
curves plotted along with the curve for the 100% healthy RBCs sample are shown in Figure 4.1. 
As expected, ektacytometry measurements yielded smaller EIs as higher fractions of rigid RBCs 
were present in the blood. Thus, the samples with 100% treated RBCs registered the lowest EImax 
for all TBHP concentrations evaluated. However, the spread between the curves became less 
pronounced with lower TBHP concentrations. Based on the 100% rigid fraction conditions, we 
observed that the highly stiff RBCs were the ones treated with 1.0 mM TBHP. The RBCs treated 
with 0.9 and 0.75 mM RBC treatments yielded intermediate stiffnesses while the 0.5 mM TBHP 
treatment yielded only slightly rigid RBCs.  
 
Figure 4.2. Blood Smear Image of SCD Patient.  
Standard blood smear image of SCD patient 10, genotype SS. Patient 10, 15-year-old male 
on hydroxyurea therapy. Patient 10 has a %S fraction of 79.3% as determined by standard 
electrophoresis analysis. Only ~7.3% of RBCs in visible smear show shape deformation 
from regular RBC discocyte shape. 
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4.4.2. Building a Predictive Algorithm for Estimating Bulk Stiffness of the Rigid RBC Population 
in Sickle Cell Disease Blood 
To understand how the spectrum of rigid RBC fractions affects EI curves and EImax, we  
parameterized the curves in Figure 4.1.A-D. The EImax recorded in every blood sample was divided 
by the average maximum EIs of healthy blood to produce a ratio of relative stiffness. Subsequently, 
we plotted these EI ratios as a function of rigid RBC fractions, as shown in Figure 4.1.E. We found 
 
Table 4.1. Sickle Cell Disease Patient General Information and Ektacytometry Maximum Elongation Index Values.  
Information includes SCD genotype, age in years, gender (male or female), current patient therapy chronic transfusions (CT) or 
Hydroxyurea (HU), %S fraction as determined by blood electrophoresis, and maximum EI measured via ektacytometry in the actual 
SCD patient blood sample. The table also includes the predicted EImax of rigid population, i.e., %S Fraction. Missing therapies 














# - years (M/F) - % - - 
1 SS 13 M CT 20.7 0.465 ~ 0.01 
2 SS 6 F CT 48.7 0.421 0.198 
3 SC 18 M HU 50.3 0.465 0.299 
4 SS 9 M CT 75.2 0.266 0.145 
5 SS 19 F CT 21.1 0.539 0.188 
6 SS 18 M CT 34.4 0.462 0.136 
7 SS 13 M HU 89.9 0.297 0.259 
8 SS 16 M CT 43.1 0.401 0.095 
9 SS 1.5 F - 89.9 0.548 0.539 
10 SS 15 M HU 79.3 0.454 0.407 
11 SC 17 M HU 47.6 0.301 ~ 0.01 
12 SS 15 M CT 55.8 0.482 0.362 
13 SS 2 F CT 37.4 0.606 0.561 
14 SS 21 F - 90.6 0.512 0.499 
15 SS 15 M HU 86.6 0.437 0.407 
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 a linear relationship between the EImax achieved and the rigid RBC fractions in a blood sample. 
As expected, the highly rigid RBCs in blood had a more substantial impact on reducing the EImax 
than intermediate and slightly rigid RBCs, as shown by the slopes of the linear trends in Figure 
4.1.E. plotted as a function of TBHP concentration in Figure 4.1.F. Parameterization of the 
relationship between the slope of rigid EI-to-healthy EI ratios versus TBHP concentration implies 
that we can interpolate between TBHP concentrations that were not experimentally tested. The 
correlations obtained by the parameterization of the EI measurements in Figure 4.1. were imported 
into a MATLAB code to construct a predictive algorithm that can estimate the TBHP 
concentration. Thus, the rigid RBC population's relative stiffness in a patient blood sample can be 
determined via two input variables: 1) EImax recorded in the standard deformability measurement 
and 2) fraction of rigid or sickle RBCs in the patient’s blood sample.  
 Given the linearity of the relationships between the stiffness and fraction of the rigid RBC 
population in a blood sample, we hypothesized that our predictive algorithm could be used in 
combination with electrophoresis and hemoglobin analysis of patient blood to map the relative 
stiffness of the rigid (HbS) RBC populations in SCD. To this end, we measured the EIs for fifteen 
unique SCD patient blood samples. Table 4.1. lists the SCD genotype, age, gender, current medical 
intervention/therapies, %S fraction, and measured maximum bulk EI for all patient blood 
evaluated. A standard blood smear image was collected for patient 10, shown in Figure 4.2. The 
maximum EI of each measured patient blood sample (measured bulk EImax in Table 4.1.) combined 
with the corresponding %S fraction is used as initial inputs to estimate the maximum stiffness, i.e., 
EImax, of the HbS only RBC population for each patient. Meaning, we match each patient’s actual 
EI curve to an EI curve generated for an artificially rigid RBC blood that matches the measured 
bulk EImax and %S (i.e., rigid RBC) fraction of the patient’s blood. The matched artificial EI curve, 
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generated with the MATLAB algorithm, can then be backtracked to estimate what TBHP 
concentration can produce a curve that matches the actual raw patient deformability curve. Hence, 
the rigid RBC population’s apparent stiffness in the patient sample can be represented as a TBHP 
Figure 4.3. Predicting the Rigidity of the Rigid Red Blood Cell Populations in Sickle Cell Disease 
Patients.  
(A) Average maximum EIs of healthy donors, actual bulk patient measured maximum EIs, and predicted 
maximum EIs of rigid population. Actual healthy and patient ektacytometry curves compared with 
predicted patient bulk ektacytometry curve and predicted curve of the rigid RBC population: (B) patient 
2. (C) patient 6. (D) patient 7. Error analysis of the predicted EIs as a function of shear was performed 
using least square difference analysis. Error bars are plotted as standard deviation of the predicted 
elongation values. Student’s t-tests are performed to determine significance between Actual Patient 
curves and Predicted Bulk Curves, no significant difference is found for any patient using an α=0.05, p-
values > 0.05. 
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concentration. That is, the rigid RBC population in the SCD patient blood has a rigidity similar to 
the rigidity of healthy RBCs that had been artificially stiffened with a specified concentration of 
TBHP. Once we knew the representative TBHP concentration for a given patient blood sample, 
we extrapolated the % rigid fraction to a 100% to predict the maximum EI for 100% rigid RBCs, 
i.e., the maximum stiffness of only the rigid population or %S fraction.   
The values of the maximum EIs of measured patient bulk blood (bulk) are plotted in Figure 
4.3.A. next to maximum EIs obtained for healthy blood samples and the predicted maximum EIs 
of only the HbS (rigid) fraction for each patient’s blood. We observed a very narrow range in 
maximum EI of healthy blood measurements, while a wide range of maximum EIs is shown for 
SCD patient bulk blood measurements. Importantly, we saw a broader distribution in the maximum 
EI values of only the HbS populations with an average lower than the average maximum EIs of 
the raw SCD patient and healthy blood. From this data, we calculated ratios that compare the 
estimated maximum EIs of the sickle population in the patient blood samples to 1) the maximum 
EI in a healthy blood sample and 2) the maximum EI of the bulk SCD patient blood sample. A 
ratio value higher than unity suggests that the maximum EI of the rigid RBC population is much 
lower than what is measured by bulk blood measurement, thus underestimating the stiffness of the 
HbS population, i.e., sickled RBC, in an SCD patient.  
Subsequently, we used the predicted maximum EI of the rigid RBC population (shown as 
“rigid” in Figure 4.3.A.) for each patient’s blood to create a deformability curve for the patient’s 

















approach previously described by Baskurt et al. 139. This simplified Skreestra-Bronkhorst model, 
Equation (4), also takes into account parameters, such as the shear stress associated with half the 
EImax (SS1/2, also estimated in our parameterization model) and the range of shear stresses (SS) 
evaluated in the ektacytometry measurement. The variable “m” was a parameterization slope that 
was simply left at a value of 1. To confirm the validity of our approach to creating HbS, i.e., rigid 
population, only elongation curve, we again utilized the Skreestra-Bronkhorst plotting model, 
Equation (4) to see if the deformability curves of the SCD patient bulk measurements can be 
replicated accurately, as well as a healthy deformability curve. We found an acceptable precision 
of the parameterization model when we compared the elongation curve derived from the actual 
measurement of a patient's bulk blood to the predicted representative curve for the patient’s blood. 
The precision is visually represented in Figure 4.3.B-D. for patients 2, 6, and 7, which shows 
combined plots of the (i) predicted HbS only RBC elongation curve alongside the (ii) predicted 
patient bulk deformability curve, (iii) actual patient bulk deformability curve, and finally, the (iv) 
a healthy deformability curve for reference. Figure 4.4. shows similar plots for all patients 
evaluated in this study. 
Interestingly, Figures 4.3.B. and 4.3.C. show drastic differences in the bulk blood’s and the 
“sickle RBC” population’s deformability curves. In some cases, the rigid population yielded a 
maximum EI that was ~2 times smaller than what a bulk measurement yielded. However, in other 
cases, as shown in Figure 4.3.D., we observed very little difference between the actual raw bulk 






Figure 4.4. Predicting the Rigidity of the Rigid Red Blood Cell Populations in Sickle Cell Disease Patients.  
Actual healthy and patient ektacytometry curves compared with predicted patient bulk ektacytometry curve and predicted curve 
of the rigid RBC population: (A) patient 1. (B) patient 3. (C) patient 4. (D) patient 5. (E) patient 8. (F) patient 9. (G) patient 10. 
(H) patient 11. (I) patient 12. (J) patient 13. (K) patient 14. (L) patient 15. Error analysis of the predicted EIs as a function of 
shear was performed using least square difference analysis. Error bars are plotted as standard deviation of the predicted elongation 
values. Student’s t-tests are performed to determine significance between Actual Patient curves and Predicted Bulk Curves, no 




One of the critical characteristics of SCD is the increased rigidity of the RBC membrane. 
42,48,52 While there is evidence of its crucial role in the evolution of symptoms in SCD, 140 RBC 
rigidity is often disregarded as a minor side-effect of SCD rather than a critical biomarker. More 
than a mere inconvenience, RBC rigidity has the potential to be utilized as an indicator of a 
patient’s condition or response to new medications or therapies. For example, Gutierrez et al. 
showed that the presence of rigid RBCs in blood flow significantly reduced white blood cells 
(WBCs)’ adhesion to an inflamed vascular wall. 10 Interestingly, the results found a non-linear 
correlation between the fraction of rigid RBCs present in whole blood flow and the level of 
reduction in  WBC adhesion across a range of RBC stiffness levels as explored in this work. 10 
Additional work by Qiu et al. investigates the impact of rigid RBCs in blood flow on the 
functionality of the endothelium in a microvasculature-on-a-chip device. 140,141 Results from this 
work showed that even in the absence of vaso-occlusion and complications relating to hemolysis, 
endothelial dysfunction and increased permeability was detectable after only mechanical 
interactions with stiffened RBCs. Although these studies have begun to unravel the critical 
associations between RBCs stiffness and the complications seen in SCD, e.g., endothelial 
dysfunction and vaso-occlusion, there is still a need for further sophisticated models for 
investigating the effect of RBC stiffness in SCD. More intricate models also offer the potential to 
be used as analytical tests for novel therapeutics and understanding patient response to medication.  
In this work, we presented an estimation method that can more precisely characterize the 
rigid RBC population’s stiffness in SCD based on the general shear-based ektacytometry 
measurement of patient blood. Originally developed as a screening tool for RBC membrane 
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disorders, 132 and repurposed for the investigation of SCD, ektacytometry has yet to reached 
widespread clinical use. While ektacytometry has been proven to be a robust method for 
investigating RBC deformability, it is not perfect. The bulk blood measurement achieved via 
Ektacytometry deformability scans can register similar EI values for two different patients with 
vastly different stiffness in the rigid RBC populations due to variation in the HbS fraction 
population. Here, we implemented artificially rigid RBCs to evaluate rigid RBC fraction’s impact 
on bulk blood stiffness. Our results showed that ektacytometry deformability measurements are 
highly influenced by the degree of RBC rigidity in the sample and the fraction of rigid RBCs 
present (Figure 4.1.A-D.). Samples containing rigid RBCs with a higher degree of stiffness showed 
the highest variability in deformability analysis upon change of the rigid fraction. These 
deformability measurements for artificially rigidified RBCs in blood allowed us to understand 
better how ektacytometry curves are altered by the amount of the stiff (i.e., sickled) RBC 
population in SCD blood. This understanding formed the base of our predictive model. Using the 
maximum EI measured and knowledge of the fraction of rigid RBCs in a mixed sample, we can 
estimate the rigid population’s stiffness in a patient’s blood. 
The rigid conditions in SCD patient blood can vary depending on the medication, age, and 
genotype. We collected fifteen unique SCD whole blood samples from a diverse pool of donors 
ranging in SCD genotype, age, gender, and current therapy (Table 4.1.).  We determined the 
fraction of HbS RBCs, i.e., what we denote as the rigid population, in the patient sample via 
electrophoresis and HPLC hemoglobin analysis. Using what we learned from the artificially 
stiffened RBCs in the blood combined with a raw ektacytometry measurement of an SCD whole 
blood sample and hemoglobin data, we estimated the stiffness of the %S fraction, i.e., the rigid 
population in an SCD patient.  
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Our results showed that the rigid population’s stiffness in an SCD patient sample is often 
underestimated (Table 4.1.). For patient 2, we see that the EImax of the stiff RBCs, 48.7%, is 3.2 
folds lower than the maximum EI given by the bulk raw measurement. Similarly, the EImax of the 
stiff RBCs was 4.4, 4.7, and 6.7 folds smaller than the bulk blood value for patients 4, 6, and 8, 
respectively. This result implies that the HbS RBCs, i.e., rigid population, in these SCD patients 
have a high degree of rigidity, which was similar to rigidity obtained for artificially rigidified 
RBCs incubated in 1.0 mM TBHP. Of note, the estimated stiffness of the rigid RBC population of 
patients 1 and 11 were predicted to be higher than the rigidity of our most stiff conditions measured 
and used to generate the numeric algorithm, i.e., RBCs treated with 1.0 mM TBHP. For these 
samples, the interpolative model cannot predict the rigid populations' max EI since it is out of 
range of our most stiff conditions measured (100% stiff fraction, 1.0 mM TBHP). Still, the max 
EI of the rigid population is many folds greater than the maximum EI in a healthy condition and 
the bulk raw standard measurement of the SCD sample. It is important to note that this analysis 
does not suggest that the maximum EI is consistently overestimated in every patient sample, but 
rather that it is a possibility. For example, for patients 9, 10, 13, 14, and 15, the maximum EI for 
the HbS RBCs was only ~1.1 times fold lower than the bulk raw measurement maximum EI. The 
estimated maximum EI of the rigid RBC population is compared to the maximum EI measured in 
the standard bulk deformability measurement, as shown in Figure 4.3.A. We observe that the 
average maximum EI for the rigid populations in the SCD patients is notably lower, ~0.32, 
compared to the standard bulk measurements, ~0.45. However, given the wide range of EIs 
constituting the averages, a statistically significant average was not calculated.   
We did not observe any specific correlation between the current therapy, i.e., chronic 
transfusion or hydroxyurea, and the rigid population’s stiffness in an SCD patient sample. 
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Hydroxyurea works by raising the levels of fetal hemoglobin in the patient’s RBCs, which 
increases the oxygen binding capability and is expected to improve deformability in SCD RBCs. 
142–144 However, one of the stiffest patient conditions we measured was that of patient 11, who was 
being treated with hydroxyurea at the time of the sample collection. One potential explanation for 
this discrepancy might be the shorter length of time the patient was on hydroxyurea medication 
than other patients on the same treatment. Also, we did not find a correlation between the stiffness 
of the rigid population and the patient genotype. Due to the availability of donors, thirteen of fifteen 
donors were genotype SS, and two donors were genotype SC. Again, one of the stiffest patient 
conditions measured was that of patient 11 with genotype SC. This observation is interesting since 
the genotype SC is typically regarded to be clinically less severe compared to genotype SS in 
regards to symptoms and occurrences of painful crises. 42,145  
For patients 2 and 6, we predicted the maximum EI of the rigid RBC populations to be 3.2 
and 4.7 folds smaller than what was recorded in the measurement of their whole blood. That is, 
the predicted ektacytometry curves are shown to be considerably different from the bulk, raw 
measurements (Figure 4.3.B. and 4.3.C.). On the contrary, we see there is not a considerable 
difference between the rigid population’s predicted curve and the actual bulk measurement in 
patient 7, with only a 1.2 times fold difference in maximum EIs, Figure 4.3.D. This visualization 
of the deformability curves shows that our predictive model can estimate the rigid population's 
stiffness in an SCD patient sample with greater precision.  
Although the method presented here can predict with greater precision the stiffness of the 
rigid RBC population in an SCD patient blood sample, it is deficient in some areas.  First, like 
traditional ektacytometry, our model cannot distinguish which RBCs have undergone irreversible 
shape change, i.e., configuration to a sickled crescent shape. Often a misunderstood disease, blood 
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from SCD affected individuals is thought to be entirely composed of sickle-shaped RBCs, i.e., 
crescent-shaped. 50 However, the reality is that irreversibly sickle-shaped RBCs (ISCs) are highly 
fragile and short-lived. 146 Therefore, the majority of HbS-rich RBCs in circulation retain their 
discocyte-shape and yet remain rigid. 146,147 An example of this is shown in Figure 4.2., wherein a 
standard blood smear of patient 10, genotype SS with a comparatively high %S fraction of 79.3%, 
only ~7.3% of RBCs in the smear show shape deformation from regular RBC discocyte shape. 
Second, others have reported that the presence of ISCs in a blood sample alters the elongation 
diffraction patterns imaged by ektacytometry. 148 That is, higher amounts of ISCs lead to more 
considerable differences in apparent bulk elongation indices, similar to results shown by Parrow 
et al. However,  these studies focused on using Osmoscan analysis. 70,148  
Thirdly, our predictive model was built using the deformability measurements of 
artificially stiffened RBCs; Thus, the degree of stiffness in this model system was uniform 
regardless of the %rigid fraction. This assumption is carried over when using the model to predict 
the stiffness of the %S fraction in an SCD patient blood sample. However, it is essential to note 
that there is likely a range of stiffnesses in a patient's %S RBC population, i.e., not all rigid RBCs 
have the same degree of rigidity. The novelty of our model is the capability to neglect the 
contribution of the healthy, i.e., HbA, RBCs in a standard ektacytometry measurement. Another 
point of interest is that the measurements performed in this study were standard deformability 
elongation analysis without any alteration in the blood's oxygen conditions. A recent development 
in ektacytometry technology is the Oxygenscan feature, 135, which determines the point of sickling 
of HbS-rich cells in a blood sample by alternating oxygen conditions. However, in terms of 
measuring a maximum elongation index at maximum shear stress, the end result is still the same 
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regardless of oxygen conditions. Given that our model is built using only information from 
maximum elongation, our approach is complementary to the Oxygenscan.  
Finally, improvements to the ektacytometry method, as demonstrated here, could increase 
its prevalence as a reliable tool for measuring RBC rigidity. This approach can also lead to the 
utilization of ektacytometry as a tool for understanding patient response to therapies. For example, 
blood transfusions are a standard treatment for SCD patients.62 A previous work has proposed that 
reducing the %S population to less than 30% is beneficial for moderating symptoms in SCD 
patients. 63 However, the reasons why this is the case remain unexplored, and it is unclear what 
role the stiffness of the %S population plays in altering symptoms. 63 The prior work by Gutierrez 
et al. showing the presence of artificially rigid RBCs in blood flow reduces WBC adhesion to 
inflamed endothelium drastically, depending on the RBC rigidity level and fraction in blood. 10 
Given the wide variability in the stiffness of HbS-rich RBCs from patient to patient demonstrated 
in Figure 4.3.A., the arbitrary prescription of reducing the %S population to less than 30% with 
transfusion may not be ideal for every patient. Specifically, some patients could have increase 
infection risk, depending on the amount and stiffness level of the HbS-rich RBCs present in the 
blood. Thus, the insight into the stiffness of the HbS-rich RBC populations offered by our 
presented method may be helpful in optimizing transfusion therapies. In another example, as 
previously mentioned, Qiu et al. show that rigid RBCs’ mechanical impact alone was sufficient to 
create endothelial injury. 140 This damage to the endothelium led to inflammation, which causes 
endothelial dysfunction in SCD, contributing to crises. 140 Given that stiffened, HBS-rich RBCs 
have a higher propensity to marginate, i.e., migrate near the blood vessel wall, 40 we anticipate 
these altered cells are likely well-positioned to cause endothelial damage regardless of their 
composition in blood. Thus, understanding the rigidity level of the HbS population can offer 
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Overall, this work presents an innovative approach for a more thorough examination of the 
ektacytometry-based assessment of RBC stiffness in SCD patients. We utilize information from 
an RBC deformability measurement combined with standard electrophoresis and hemoglobin 
analysis to build a parameterization model to predict the rigid RBC population’s bulk rigidity in a 
patient’s blood with greater precision. Although extensive future work is needed to prove 
ektacytometry as a robust clinical tool, knowledge from the presented model offers a better 
understanding of the bulk stiffness in a rigid or sickle population of a patient blood sample. This 
information could help diagnose disease severity in SCD, understand the variation of infection 





 : Red Blood Cell Stiffness Driving Patient Symptoms: A Study of Red Blood Cell 




5.1. Publication Information 
The work presented in this chapter is not yet published. This work will be submitted as a 
clinical case study article as: Mario Gutierrez, Mark Shamoun, and Omolola Eniola-Adefeso. “Red 
Blood Cell Stiffness Driving Patient Symptoms: A Study of Red Blood Cell Population Rigidity 
in Sickle Cell Patient Genotype SC Relation to Overlooked Clinical Symptoms.” 
This chapter aims to present an interesting clinical case study that suggests that red blood 
cell rigidity could play a more prominent role in sickle cell disease patient outcomes than initially 
believed. The data presented in this chapter is limited data that are unable to draw definitive 
conclusions but rather highlight an interesting clinical observation.  
 
5.2. Abstract 
Sickle cell disease is a systemic hematological disease. Various genotypes of the disease 
exist; however, the two most common include hemoglobin SS (Hgb SS) and hemoglobin SC (Hgb 
SC) disease.  Hgb SC is typically considered a less severe genotype; however, some patients with 
SC disease still have significant complications. Ektacytometry is utilized to measure red blood cell 
deformability in sickle cell patients and may help identify patients at risk for severe disease. We 
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describe a patient with genotype hemoglobin SC with a more severe phenotype, which we show 
having very rigid red blood cells via ektacytometry. The patient of interest is oddly hospitalized at 
a higher frequency, ~4x, in comparison to other SCD pediatric patients and has an irregularly high 
amount of hospital days per year, 85 days. 
5.3. Introduction  
Sickle cell disease, a hereditary multisystem illness, is one of the most prevalent blood cell 
diseases, affecting over 100,000 Americans and millions worldwide.3,52 Previous studies have 
shown many biochemical mechanisms of SCD pathology, including activation of the vascular 
endothelium, leukocytosis, oxidative stress from tissue reperfusion, and intravascular and 
extravascular hemolysis.3 The symptoms of SCD are dependent on the genotype of SCD – two of 
the most common being Hgb SS and Hgb SC. The Hgb SS is the most prevalent and severe 
genotype. At the same time, the Hgb SC is clinically accepted as milder due to fewer hemolysis 
markers and fewer associations with severe complications, including stroke, early mortality, and 
vaso-occlusive pain episodes.145 However, for both of these subtypes, the RBCs are often afflicted 
with increased membrane rigidity due to the high concentration of mutated or abnormal Hgb S 
inside the RBC. Furthermore, the mutated hemoglobin’s polymerization under hypoxic conditions 
can alter the RBC shape to an irreversibly-sickled form.  
Due to natural aging, the RBC hemoglobin density or mean corpuscular hemoglobin 
concentration (MCHC) increases moderately; however, this is severely accelerated in SCD.51,149,150 
During deoxygenation, sickle cells experience a loss of potassium that causes an ion imbalance 
and the loss of water from the cell, resulting in a higher MCHC.149,150 Past studies have reported 
that this loss of potassium from Hgb SC RBCs is higher compared to SS due to the presence of 
Hgb C.149 This unique pathophysiology of SC cells results in cells that, although they contain 
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approximately half Hgb S compared to SS cells, have a high MCHC. Interestingly, this implies 
that, depending on their hydration conditions, the SC RBCs can lose membrane deformability as 
much as, or more, SS cells. 151 However, while they have similar sickling rates to SS cells, the Hgb 
SC have a reduced capacity to irreversibly sickle – i.e., they are less likely to change shape 
permanently.150 
Unsurprisingly, the irreversibly-sickled RBCs have been a primary focus of research in 
SCD, leading to the understanding that these cells cause significant physical damage when 
traveling through the body by occluding microvasculature, depriving tissues of nutrients and 
oxygen, and damaging vital organs such as the spleen, liver, and lungs.8,152 The combination of 
vessel occlusion and tissue deprivation of oxygen results in a vaso-occlusive pain crisis 
experienced by SCD patients.  Shape alteration in RBCs is dependent on a variety of factors, 
including oxygen conditions and hemoglobin contents of individual RBCs. Under stress, Hgb S 
will spontaneously polymerize and result in RBC shape alteration.153 Although the staple crescent-
like shape is the most frequent shape deformation; it is not always guaranteed.39,153,154 However, 
alterations to the membrane flexibility are assured.39 Importantly, rigidified, non-deformed RBCs 
have a longer lifespan than RBCs that have undergone shape deformation to the sickled 
confirmation.155,156 Thus, SCD patients live more with the consequence of rigid, normal-shaped, 
i.e., discocyte, RBCs than the sickle-shaped, which may prove to be more critical in maintaining 
their general well-being. Herein, we describe a patient with Hgb SC disease with a more severe 




Our patient is an 18-year-old African American male (Patient 1) with a history of Hgb SC 
first diagnosed at age 7. His father is heterozygous for hemoglobin S, and his mother is 
heterozygous for hemoglobin C.  He has one unaffected sibling and a sister who also has Hgb SC 
(Patient 2). Over the last few years, Patient 1 has struggled significantly with vaso-occlusive crises 
(VOC) that seemed exaggerated for his genotype. In 2017, he was admitted 12 times for VOC, and 
in 2018 he had 8 admissions. In 2018, he was admitted for 85 days with an average length of stay 
of 10.6 days.  
 
In contrast, patients with Hgb SS studied (n=7) had an average of 1.3 admissions per year 
and an average length of 5.4 days per stay. During most admissions, Patient 1 was started on an 
opioid-based, patient-controlled analgesia (PCA) pump at the time of admission and often required 
additional ketamine continuous infusion or other pain modalities to help control his pain.  His care 
was managed by the acute pain service, palliative care, and pediatric hematology, and he had a 
patient-specific pain plan in place to expedite care. He was controlled at home with 
Figure 5.1. Sickle Cell Patient Red Blood Cell Deformability Analysis Via Ektacytometry.  
(A) Standard ektacytometry deformability analysis at constant osmolality (~290 mOsmol/kg) and variable shear stress. (B) 
Osmoscan ektacytometry analysis at constant shear stress (~30 Pa) and variable osmolality. 
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ibuprofen/acetaminophen and opioids.  He was also enrolled in our pain clinic with psychology 
for coping mechanisms, including music therapy, exercise, and heating pads.  His frequency of 
pain crisis and sensitivity to dehydration and weather change seemed abnormal for a patient with 
Hgb SC genotype, and thus his blood was collected for further investigation. 
We measured the deformability of blood from several SCD patients in the Erythrocyte 
Diagnostic Lab (EDL) at Cincinnati Children’s Hospital using an ektacytometer (Lorrca), which 
quantifies the elongation of RBCs as a function of shear stress at a constant physiologic osmolality 
as described in the Materials and Methods chapter. Blood samples were obtained via venipuncture 
according to a protocol approved by the University of Michigan IRB and following the declaration 
of Helsinki. Informed consent was obtained for each patient before the blood draw, and samples 
were collected into a syringe containing EDTA as the anticoagulant as described in the Materials 
and Methods chapter. Table 5.1. lists all the patients evaluated, including the SCD genotype, 
general demographics, RBC stiffness measurement, hospitalization, and pain frequency. Except 
for Patient 1, ektacytometry deformability and Osmoscan analysis were performed once for each 
patient. The ektacytometry analysis was performed three different times, each ~16 weeks apart, 
for Patient 1. All patient samples were collected during routine clinical visits, i.e., collected in a 
stable state of health. Figure 5.1. shows the deformability curve obtained for all patient blood 
evaluated with Figure 5.1.A. showing RBC elongation analysis at constant osmolality and variable 
shear stress. Figure 5.1.B. shows elongation analysis with constant shear and variable osmolality, 
i.e., osmoscan. From these curves, a maximum Elongation Index (EIMAX) can be defined as the 
maximum deformability of RBCs at high shear stress, which is accepted as a measure of the 




Table 5.1. Sickle Cell Disease Patient Demographics and Hospitalization Information.  
Table with patient information including SCD genotype, age in years, gender (male or female), maximum Elongation Index 
recorded via ektacytometry of the patient blood sample, and current patient therapy chronic transfusions (CT) or Hydroxyurea 
(HU). Missing therapies indicate the patient is not under any type of treatment at the time of the measurement. The table also 













# - years (M/F) - - - - - 
1 SC 17 M HU 0.301 8 85 N/A 
2 SC 10 F HU 0.497 8 54 N/A 
3 SC 12 F - 0.420 1 4 N/A 
4 SS 15 M HU 0.454 2 10 
Acute Chest x 1, 
AVN x1 
5 SS 21 F - 0.512 0 0 N/A 
6 SS 1.5 F - 0.548 0 0 N/A 
7 SS 16 M CT 0.401 2 7 N/A 
8 SS 13 M CT 0.465 0 0 N/A 
9 SS 18 M CT 0.462 2 9 N/A 
10 SS 19 F CT 0.539 3 12 Acute Chest x 1  
 
stiff RBCs. As with previous reports, the estimated EIMAX for healthy blood is ~0.63.
10 The EIMAX 
obtained for Patient 1 was 0.30, while the blood from other patients ranged from 0.40 to 0.55.  
We find that there is a moderate negative Pearson correlation between the EIMAX values 
measured and the number of hospital days for pain. There is a very significant difference between 
the EIMAX values measured from Patient 1 (µpat1=0.332, n=3) and the EIMAX values of the other 
nine patients (µops=0.478, n=9), yielding a p-value of 0.003 as determined by a Student's t-test 1-
tail analysis. Indeed, the mean elongation of Patient 1 blood is classified as an outlier when grouped 
into the elongations of the other nine patients. By excluding Patient 2 from this analysis, we find 
there is a very significant difference (p=0.009) for the number of hospital days for pain per 
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admission between Patient 1 and Patients 3-10. In fact, for Patients 3-10, there is an average of 4.2 
hospital days with pain for every admission, compared to the 10.6 hospital days with pain per 
admission for Patient 1. Figure 5.2. shows elongation curves for Patient 1 during different time 




Previous studies have used ektacytometry to measure rigidity as a function of changing 
osmolality at constant shear stress.157 Figure 5.1.A. shows a comparison of our deformability data 
at constant osmolality with varying shear stress and vice-versa in Figure 5.1.B. We opted to 
interpret our EIMAX with a deformability analysis based on data collected at constant osmolality 
and varied shear stress rather than with osmoscan since the former mimics the physiologic 
environment where RBCs experience changing shear stress as they flow through the various blood 
Figure 5.2. Deformability Analysis Via Ektacytometry of Focus Patient in 
Comparison to other SC Patients.  
Standard ektacytometry deformability analysis at constant osmolality (~290 
mOsmol/kg) and variable shear stress. Ektacytometry analysis of focus patient 
taken at three different time periods, compared to deformability analysis of other 
SC patients. 
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vessels at a fixed, physiologic osmolality. As shown, patient 1, which is our patient described 
above, showed the lowest EIMAX (~0.301) indicative of the presence of an ultra-rigid RBC 
population, which is interesting given his SC genotype but fits with the high VOC experienced by 
this patient. Similar to observations seen by Ballas et al., we observe from Figure 5.1.B. that the 
RBCs in the blood sample from Patient 1 are highly dehydrated, as expected to be seen in an SC 
sample.151 This dehydration is likely one of the factors driving the extreme rigidity of the RBCs in 
the patient.  
Our patient, as well as his sibling (Patient 2), were on hydroxyurea treatment in 2017 
through 2019, which is known to increase RBC deformability and a resulting higher EIMAX 
value.157 However, despite hydroxyurea treatment, our patient still had a reduced EI compared to 
other patients. In 2019, our patient was started on chronic transfusions with a partial exchange, 
given his severe phenotype, and after initiating chronic transfusions, his EIMAX increased (~0.37) 
and frequency of pain crisis subsequently decreased, as shown in Figure 5.2., Measurement 3. 
Patients 5 and 6 show similar curves to our healthy control, and neither required hospitalization 
for any complications of sickle cell disease. Patient 10 did have multiple hospitalizations; however, 
this patient did have difficulty with transportation, and although they were on chronic transfusions, 
appointments were missed.  Patient 10’s rigidity was obtained while the patient was on every 3 to 
4-week transfusions, and the missed appointments likely contributed to the hospitalizations.  
The patient’s younger sister was also analyzed (Patient 2); however, her EIMAX was higher 
and closer to other SCD patients' values. Clinically, his sister still required multiple admissions, 
but had 54 hospital days in 2018 and required significantly less intervention per stay. During many 
of her admissions, she did not require a PCA and instead could be managed on intermittent 
intravenous morphine or oral pain medications. Previous studies focusing on the psychological 
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impact of SCD and on children and their siblings suggest that little attention is given to family 
members or siblings who are not chronically ill or are healthy.158–160 These siblings often are 
subject to anxiety, feelings of rejection, and even jealousy.158–160 Given the context of this complex 
social situation, it is likely that the number of hospital days and admissions of Patient 2 are skewed 
and do not actually represent an independent patient clinical outcome. For these reasons, we opted 
to remove Patient 2 from a statistical analysis comparing the hospital days with pain per admission 
between all the patients (Patients 3-10) and Patient 1.  
Additionally, we compare Patient 1 to Patient 3, Figure 5.2. Patient 3 is also an SC genotype 
and expresses a phenotype, which is much more typically seen in SC patients. The EIMAX observed 
for Patient 3 is 0.42, closer to values observed in stable patients. In comparison, Patient 3 was 
admitted only once in 2018 for a duration of four days with pain. Certainly, Patient 3’s clinical 
stability is something regularly observed in SC patients.  
 
5.6. Conclusions 
In conclusion, our patient is observed to have abnormally highly rigid RBCs despite 
treatment and presents an abnormally high occurrence of pain for an SCD patient with what is 
regarded as a clinically less severe genotype, SC. Previous studies show SC patients tend to receive 
a late diagnosis, often not until the occurrence of a severe or fatal health complication.161 Utilizing 
RBC deformability analysis may allow for the identification of patients with a high risk for 
complications in the absence of a significant level of hemolysis or irreversible sickling. Although 
it is difficult to determine the entire and exact contribution RBC rigidity has on the development 
of VOC in our patient, it is likely a contributing factor to the variation in patient disease phenotypes 
in SCD and warrants further exploration in how one could use RBC deformability analysis for 
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 : Mechanical Impact of Rigid Red Blood Cells in Sickle Cell Disease and on 
Leukocyte Adhesion Performance 
 
 
6.1. Publication Information 
 
The work presented in this chapter is not yet published. This work will be submitted as a 
research article to Annals of Biomedical Engineering as:  Mario Gutierrez, Mark Shamoun, Tyler 
Tanski, and Omolola Eniola-Adefeso. “Mechanical Impact of Rigid Red Blood Cells in Sickle 
Cell Disease and on Leukocyte Adhesion Performance.” 
This chapter aims to probe how WBC adhesion to inflammation is impacted in the presence 
of rigid red blood cells in an in vitro model of blood flow, which has been closely tailored to match 
the blood characteristics of sickle cell disease patients. Overall, we aim to understand better the 
extent of impact red blood cell rigidity has on immune cell adhesion functionality.  
 
6.2. Abstract 
One of the significant outcomes of SCD is the alteration of RBC membrane rigidity. Although 
duly noted as a remarkable characteristic of the hematological disease, knowledge of the extent to 
which rigid RBCs influences leukocyte adhesion capability to inflammation in SCD is limited. 
Despite the known role of white blood cells in SCD pathogenesis, there is limited work fully 
exploring the mechanism of their adhesive interactions under flow conditions with patient blood 
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or representative models of human blood.  This study seeks to probe further the impact RBC 
rigidity has on immune response, specifically adhesion to inflammation, related to SCD. We 
analyze differences between SCD and healthy non-SCD blood donor leukocyte adhesion ligand 
profiles. Furthermore, we describe a series of artificially constructed blood models which match 
key characteristics of SCD patient blood, including hematocrit, total leukocyte counts, fraction of 
rigid RBCs, and average degree of stiffness in the rigid RBC population. We couple the actual 
SCD patient blood samples with our artificially constructed blood models with a microfluidic 
blood flow model to test how leukocytes adhere to inflammation in flow. We find that the presence 
of rigid RBCs in the blood flow reduces leukocyte adhesion capability to inflammation. When 
specifically focusing on the artificially constructed blood model, and the RBC rigidity factor is 
removed, we find that leukocyte adhesion to the inflamed vessel was improved. The findings from 
this study highlight the role rigid RBCs have on leukocyte adhesion tendencies in SCD. 
 
6.3. Introduction 
Sickle cell disease is a complex genetic blood disorder affecting millions across the world. 
3,42 SCD is defined by the mutation in the gene directing the production of the oxygen-binding 
protein hemoglobin. 55 Although multiple Hgb variants exist, by far, the most common one is HbS. 
Two defining qualities of HbS are its reduced capacity to bind oxygen as opposed to healthy Hgb 
and its propensity to polymerize with other HbS molecules. Individuals who have inherited HbS 
alleles from both parents suffer sickle cell anemia, the most acute type of SCD. 55,130 Red blood 
cells (RBCs), or erythrocytes, serve as the vehicle for Hgb transport across the body. 13 Under 
stressful circumstances in SCD, RBCs with high concentrations of HbS are likely to experience 
mild to severe shape alteration, resulting in the classic ‘sickle’ shape. 55 Additionally, RBCs will 
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experience a reduction in membrane flexibility and an increase in cell fragility. Outcomes include 
hemolysis, reduced gas exchange capacity, anemia, and an increased risk for a vaso-occlusive 
crisis. 5,44,55 At first, seeming like minor alterations, these changes to RBCs result in a cascade of 
detrimental outcomes that contribute to an overall reduced quality of life and high mortality rates 
in SCD patients. 55 
The higher deformability of RBCs compared to that of the other major cellular components, 
i.e., WBCs and platelets, resulting in a smaller displacement upon a heterogeneous cellular 
collision, essentially reducing the likelihood of RBC motion towards the vessel wall. 31,34 This 
higher distribution of RBCs in the center of flow is critical to maintaining hemostasis as it allows 
WBCs and platelets to interact and rapidly adhere to the wall in response to infection or vessel 
injury. Gutierrez et al. previously showed that in the presence of artificially rigidified RBCs in 
blood flow, WBC adhesion and platelet localization to an inflamed vascular wall model is reduced 
drastically. 10,40 Thus, any alteration in RBC deformability, as present in SCD, likely alters blood 
cell distribution in ways that contribute to the disease. However, RBC rigidity in SCD is often 
overlooked as a significant factor in exacerbating disease symptoms associated with the other, non-
RBC, blood cells, i.e., WBC, and is poorly investigated as a contributing factor in immune 
challenges of SCD patients. 
In SCD, the combination of i-sRBCs, WBC, and platelet adhesion to an activated 
endothelium lead to episodes of vaso-occlusive crisis. 46,55 Abnormally higher baseline WBC 
counts are associated with SCD. 53,55 Interestingly, the higher number of immune cells in this 
condition correlates with increased morbidity and mortality. 55,163,164 A higher absolute number of 
neutrophils in SCD have been correlated as a predictive biomarker for clinical complications, 
including vaso-occlusive crises and clotting issues.163 Despite an increased number of WBCs, SCD 
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patients are prone to infection that is traditionally linked to the damage to the spleen by i-sRBCs. 
44,165 However, it is plausible that rigid RBCs present in blood alters WBC margination, which 
affects vascular adhesion and, thereby, contributes to the reported high infection rate in SCD. 
Boggs et al. observed a diminished marginal granulocyte pool in SCD, i.e., the fraction of WBCs 
present in the tissue space, which they hypothesize is the cause of the abnormally high circulating 
WBC count typically reported in SCD. 78 
In this chapter, we present a series of artificially stiffened RBC blood models that have 
been tailored to match the blood conditions of actual SCD patients closely. We use these blood 
models and SCD patient blood to probe the extent to which RBC membrane rigidity is a 
contributing factor in altering WBC adhesion performance related to vascular inflammation in 
SCD. We find that when the RBC membrane rigidity factor has been removed from blood flow, 
WBC adhesion to inflammation is improved. The findings reported here present an opportunity to 
understand further the impact of the biophysical interactions of the rigid RBCs on WBC adhesion 
and the contribution to disease symptoms in SCD.  
6.4. Results 
6.4.1. SCD Patient Blood Collection and RBC Stiffness Characterization 
We begin this study with the collection of blood samples from SCD patients during routine 
visits. General information is collected from the SCD patients, including the specific SCD 
genotype, age, gender, and current therapy plan. The blood sample includes hematocrit, WBC 
count, percent hemoglobin S (HbS or %S Fraction), and ektacytometry RBC elongation analysis. 
Using the approximation method described by Gutierrez et al., the %S fraction population’s 
stiffness is estimated, and an analogous rigidity for this population is also estimated.11  This 
 84 
information can be found in Table 6.1. The majority of the SCD patients in this study are of the 
homozygous SS genotype, twelve out of fifteen. The remaining three patients express the milder  
Table 6.1. Sickle Cell Disease Patient Demographics and Blood Profile Information.  
Table with patient information including SCD genotype, age in years, gender (male or female), current patient therapy chronic 
transfusions (CT) or Hydroxyurea (HU). Missing therapies indicate the patient is not under any type of treatment at the time of the 
measurement. Blood characteristics include hematocrit, total WBC count, HbS %S Fraction, maximum Elongation Index recorded 
via ektacytometry of the patient blood sample, estimated maximum Elongation Index of %S Fraction, and analogous rigidity of 
%S Fraction represented as a concentration of tert-butyl peroxide (TBHP, mM). Incubation of healthy RBCs with TBHP induces 
loss of membrane deformability. 
 
genotype SC. Our study's patients ranged from eighteen months to twenty years of age with a 
median age of fifteen years. Eight of the patients are administered regular blood infusion therapy, 
and six patients are being treated with Hydroxyurea therapy. Patient 11, the youngest donor, was 
not on either therapy at the blood collection time. The average hematocrit across all fifteen patients 
was around 25% and an average WBC count of 12.6 million per milliliter of blood. The average 
%S Fraction across all fifteen patients was ~54%. We obtained ektacytometry elongation analysis 
for thirteen out of the fifteen SCD patients who took part in this study. Two patients opted out of 
the ektacytometry analysis. The average maximum elongation index for the thirteen patients 



















# - years (M/F) - % x10
6
 % - - mM 
1 SS 2 F CT 24.7 6.7 37.4 0.606 0.561 0.51 
2 SC 17 M HU 32.7 8.7 47.6 0.301 EImin >  1.03 
3 SS 15 M CT 20.5 14.4 55.8 0.482 0.362 0.67 
4 SS 9 M CT 17 15.3 75.2 0.266 0.145 0.86 
5 SS 19 F CT 23.6 19.9 21.1 0.539 0.188 0.82 
6 SS 18 M CT 23.1 18.9 34.4 0.462 0.136 0.87 
7 SC 18 M HU 31.1 7.8 50.3 0.465 0.299 0.73 
8 SS 6 F CT 25.8 10.5 48.7 0.421 0.198 0.81 
9 SS 13 M CT 29.3 13.4 20.7 0.465 EImin >  1.13 
10 SS 16 M CT 27.6 15.1 43.1 0.401 0.095 0.9 
11 SS 1.5 F - 25.5 7.6 89.9 0.548 0.539 0.53 
12 SS 15 M HU 21.4 18.5 79.3 0.454 0.407 0.64 
13 SS 13 M HU 19.3 17.2 89.9 0.297 0.259 0.76 
14 SS 20 F HU 24.8 9.9 68.9 - - - 
15 SC 10 F HU 32.1 5 42.4 - - - 
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6.4.2. Leukocyte Adhesion Ligand Profile Characterization of SCD Donor Blood 
To determine critical differences between a non-SCD and SCD patient WBC adhesion 
capabilities, we tested the adhesion ligand composition of both blood donor types. The five 
adhesion ligands chosen for examination were macrophage-1 antigen (MAC-1), P-selectin 
glycoprotein ligand-1 (PSGL-1), lymphocyte function-associated antigen 1 (LFA-1), sialyl lewis 
a (sLea), and L-selectin. The cell surface density of these five key adhesion ligands was examined 
via flow cytometry analysis in both neutrophils and monocytes of both non-SCD and SCD blood 
donors, Figure 6.1.A. Comparing fold differences in the density of each adhesion ligand between 
healthy non-SCD and SCD blood donors, we see that MAC-1 is overexpressed nearly 4x times in 
SCD donor neutrophils. All four other key adhesion ligands are under-expressed in SCD donors. 
Specifically, L-selectin, which is underexpressed ~3.5x less in SCD donor blood. We then take a 
closer look at the configuration in which the expressed MAC-1 is found on both healthy non-SCD 
Figure 6.1. White Blood Cell Adhesion Ligand Expression Difference Between Sickle 
Cell Patients and Healthy non-SCD Controls.  
Leukocytes of interest are neutrophils and monocytes. (A) MAC-1/CD11b, PSGL-
1/CD162, LFA-1/CD11a, sLea/CLA, L-Selectin/CD62L ligand expression fold difference 
in SCD patients compared to expression in healthy controls. (B) Difference in active MAC-
1 ligand expression in SCD patient WBCs compared to healthy control. Statistical analysis 
was performed using two-way ANOVA to test of fold change in ligand density expression 
between SCD donor and non-SCD donor WBCs. (*) indicates p<0.05, (**) indicates 
p<0.01,  (***) indicates p<0.001, and no asterisks represent no significant difference found. 
Error bars represent standard error. 
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and SCD blood donors’ neutrophils and monocytes. More specifically, we aim to find what 
percentage of the expressed MAC-1 is in an open or active configuration. We find that the active 
MAC-1 configuration is present in a much higher percentage in SCD neutrophils and monocytes 
than in non-SCD cells, Figure 6.1.B. All examined blood was processed and analyzed within two 
hours of being drawn from blood donors.  
 
6.4.3. SCD Patient Leukocyte Adhesion to Time-Varied Inflammation  
Next, we aimed to examine if WBC adhesion in SCD patients was variable with varying 
inflammation timing to an endothelium. Specifically, we wanted to see if WBC adhesion density 
to an endothelium would differ after four hours and after twenty-four hours of inducing 
inflammation via exposure to inflammatory cytokine, IL-1β. The blood of seven unique SCD 
patients was examined, all blood being perfused at three different shear rates, 1,000, 500, and 200 
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s-1, Figure 6.2. We see that for seven out of the seven patients examined, WBC adhesion density 
significantly reduced when examined at the second inflammation time point. These results 
Figure 6.2. Sickle Cell Patient White Blood Cell Adhesion Density to Inflamed Endothelium.  
Quantified WBC binding to an inflamed endothelial layer as a function of WSR and time of HUVEC exposure to inflammatory 
cytokine IL-1β, i.e., 4- or 24-hour inflammation activation. (A) Average WBC adhesion in healthy non-SCD donors. WBC 
adhesion for SCD Patient (B) 3, (C) 4, (D) 5, (E) 6, (F) 7, (G) 8, (H) 14. Statistical analysis of adherent density was performed 
using two-way ANOVA to test all WBC adhesion at 4-hour activation versus adhesion at 24 activation. (*) indicates p<0.05, 
(**) indicates p<0.01,  (***) indicates p<0.001, (****) indicates p<0.0001, and no asterisks represent no significant difference 
found. Error bars represent standard error. 
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suggested that for this study, WBC adhesion in SCD patients is maximized at 4 hours after 
inflammation to endothelium as opposed to twenty-four hours later. This pattern is something that 
is also typically observed in WBC adhesion patterns in non-SCD blood.  
 
6.4.4. SCD Patient versus Artificially Constructed Blood Model Leukocyte Adhesion 
Using the microfluidic PPFC experimental approach, we aimed to examine the adhesion 
capability of WBCs to an inflamed endothelium under different blood conditions. More 
specifically, we wanted to control the presence of rigid RBCs to observe whether RBC membrane 
stiffness in SCD is a factor influencing the adhesion WBCs in blood flow. The microfluidic 
channel height was kept constant at ~127 µm, and blood was perfused at three different shear rates, 
1,000, 500, and 200 s-1, chosen due to their relevance in venules. Three separate blood models 
were used to isolate the rigidity factor. First, we examined the actual blood taken from SCD donors, 
denoted as Actual condition. Secondly, we utilized healthy non-SCD donor blood, where we 
reconstituted this blood to match all conditions of the specified SCD donor blood, specifically the 
hematocrit, WBC count, approximate stiffness of the HbS population, and the fraction of stiff 
RBCs in the blood. This second blood model was denoted as the Rigid Model. Thirdly, we again 
used healthy non-SCD donor blood to reconstitute all SCD donor blood conditions except RBC 
stiffness, denoted as Non-Rigid Model. This modeling process is repeated for eight unique SCD 
blood donors, Figure 6.3. The WBC adhesion is examined using each unique model for all eight 
measured SCD donors. We observe that WBC adhesion tends to be higher in the blood models 
originating from healthy non-SCD donors. Furthermore, the best performer in higher WBC 
adhesion density was the Non-Rigid blood model in all eight unique cases, hinting that the absence 
of rigid RBCs in the whole blood translated to a higher WBC adhesion capability.  
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Figure 6.3. White Blood Cell Adhesion to Inflamed Endothelium in the Presence of Artificially Rigidified Red Blood Cells.  
Healthy non-SCD donor whole blood was obtained and altered through a series of centrifugation steps to match SCD patient blood 
conditions including hematocrit, WBC count, %S fraction or rigid RBC fraction, and bulk rigidity of the rigid RBC population in the 
SCD patient blood sample. RBC membrane rigidity was achieved via incubation of healthy non-SCD RBCs at appropriate concentrations 
of tert-butyl hydroperoxide that would allow to best match the bulk rigidity of the rigid population in the SCD patient blood sample. 
Inflammation of the endothelium is induced by exposure to inflammatory cytokine IL-1β for four hours prior to blood perfusion. 
Quantified WBC binding to an inflamed endothelial layer as a function of WSR for SCD Patients (A) 1, (B) 2, (C) 3, (D) 4, (E) 5, (F) 6, 
(G) 7, (H) 8. Statistical analysis of adherent density was performed using two-way ANOVA to test all WBC adhesion at 4-hour activation 
versus adhesion at 24 activation. (*) indicates p<0.05, (**) indicates p<0.01, (***) indicates p<0.001, (****) indicates p<0.0001, and no 
asterisks represent no significant difference found. Error bars represent standard error. 
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6.4.5. Leukocyte Adhesion Ligand Profile Characterization of Rigid Blood Model 
Upon observing the overexpression of MAC-1 and under-expression of L-selectin adhesion 
ligands in SCD neutrophils and monocytes, we aimed to test whether typical processing and 
handling of WBCs in healthy non-SCD donors would alter the expression of these key adhesion 
ligands. Healthy non-SCD donor neutrophils exposed to centrifugation (denoted as Neutro-Spin) 
increased their expression of MAC-1 up to 150% instead of a slight ~10% increase in neutrophils 
that were not centrifuged. Both conditions were measured approximately three hours post draw. A 
subsequent analysis was taken ~3.5 hours after the first test, ~6.5 hours after the initial blood draw. 
A slight increase in MAC-1 expression is observed at the second time point. A similar pattern is 
observed for MAC-1 expression in monocytes, Figure 6.4.A. The adhesion ligand L-selectin was 
also examined in a similar process to the one seen in Figure 6.4.A.; alternatively, the reduction or 
shedding percentage of L-selectin was tracked, Figure 6.4.B. Overall, Figure 6.4.A. and 6.4.B. 
Figure 6.4. White Blood Cell Adhesion Ligand Expression After Recomposition Process. 
Examined leukocytes ligand density percent change on neutrophils and monocytes. Time 
periods denote 1) right before running perfusion assay (~3 hours after initial blood draw) and 
2) ~3.5 hours after start of perfusion assays (~6.5 hours after initial blood draw). Spin notation 
denotes having undergone centrifugation. (A) Increase in MAC-1 ligand expression of non-
SCD donor WBCs. (B) Decrease in L-Selectin ligand expression of non-SCD donor WBCs. 
Statistical analysis was performed using two-way ANOVA to test of percent change in ligand 
density expression in non-SCD donor WBCs that have been idled vs. centrifuged. (*) indicates 
p<0.05, (**) indicates p<0.01, and no asterisks represent no significant difference found. Error 
bars represent standard error. 
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show that neutrophils and monocytes processed via centrifugation will result in the cells’ 
activation.  
6.5. Discussion 
The loss of RBC membrane deformability is a significant outcome of SCD manifestation. 
42,55 Increased RBC stiffness is linked to the frequency and severity of pain crisis and the cause of 
altered WBC adhesive interactions that lead to a high rate of infection in SCD. 46,55,78 More 
specifically, these complications are common when SCD patients are in a crisis state, which 
exhibits the formation of i-sRBCs in the blood population. 42,55 Substantial work has investigated 
in detail the systemic and cellular complications that arise in a vaso-occlusive pain crisis and 
specifically on the impact of i-sRBCs. Evidence presented by Qiu et al. suggests endothelial 
damage is a possibility only in the presence of rigid RBCs. 140,141 They investigate in a 
microvasculature-on-a-chip device how the single factor of rigid RBCs present in flow will alter 
endothelial integrity, with complications such as vaso-occlusion absent from the experimental 
setting. 140,141 However, there exists a disparity in understanding the rigid RBCs role, not i-sRBCs, 
play in influencing immune challenges in SCD patients under stable conditions. To our knowledge, 
no present work has focused on investigating the impact of RBC rigidity has on WBC adhesion 
functionality at steady, non-crisis conditions in SCD. Despite the known role of WBC in the 
pathogenesis of SCD, there is little work fully exploring the mechanism of their adhesive 
interactions under flow conditions with patient blood or representative models of human blood.46 
The current understanding of the adhesive behavior of WBCs in SCD has been generated with 
isolated cells and in static adhesion assays, which neglect the biophysical contributions of the rigid 
RBCs. 79,80  
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In this work, we present a blood flow model that probes how RBC membrane rigidity 
impacts the ability of WBCs to adhere to inflammation in a vascular wall. More specifically, we 
utilize an artificial stiffening process to alter healthy RBCs to modulate the membrane stiffness. 
Along with this capability, we alter the whole blood composition of a healthy non-SCD blood 
donor sample to match a blood sample’s characteristics from an SCD patient, e.g., hematocrit, 
WBC count, the fraction of stiff non-i-sRBCs, and degree of stiffness in the rigid RBC population. 
This study begins with the collection of SCD patient blood samples. Details from our SCD donor 
pool are shown in Table 6.1.  
Work by Benkerrou et al. using SCD patient blood has focused on elucidating the 
differences in WBC adhesion molecule expression via flow cytometry, leading to the observation 
that WBCs are in a pre-activated state and the assumption of their enhanced ability to adhere to 
the vascular wall in comparison to cells found in the healthy non-SCD blood. 80 In line with prior 
work on characterizing SCD WBC molecule expression, our results show SCD donor WBCs are 
in a pre-activated state, Figure 6.1. We specifically examine the density of five adhesion molecules 
that play a vital role in the adhesion interactions of leukocytes and inflamed endothelial cells, 
MAC-1, PSGL-1, LFA-1, sLea, and E-Selectin. We find that MAC-1 is over-expressed (~3.8x), 
and L-selectin is under-expressed (~3.5x) in SCD neutrophils and monocytes compared to those 
of healthy non-SCD donors, Figure 6.1.A. Also, we see that a higher fraction of the MAC-1 
expressed on both neutrophils and monocytes is in the active configuration. These results are not 
out of the norm and led us to hypothesize that WBCs of SCD patients are more likely to adhere to 
inflammation due to their pre-activation state.  
Subsequently, we aim to understand if there are any differences in the optimal adhesion 
patterns of WBCs between SCD patients and non-SCD donors. Specifically, we study how the 
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varied time expression of inflammation surface receptors bind WBCs in a vascular wall 
microfluidic model. Our receptors of interest are E-selectin and iCAM-1, a common leukocyte 
adhesion molecule. Previous studies have quantified the maximal expression of E-selectin and 
iCAM-1 after inducing inflammation onto HUVEC via exposure to interleukin-1β. 110,111,166,167 E-
selectin expression on HUVEC is maximized approximately four to six hours after exposure to iL-
1β and returns to basal levels after twenty-four hours. However, iCAM-1 expression is maximal 
after twenty-four to forty-eight hours of initial exposure to the inflammatory cytokine. 110,111,166,167 
Given the adhesion ligand profiles of our SCD patient pool, Figure 6.1., we wanted to test if there 
was any significant difference in the ability for WBCs to adhere to an inflamed endothelium four 
and twenty-four hours after exposure to inflammatory cytokine. We were able to examine the 
WBC adhesion with varied HUVEC inflammation time for seven of our SCD blood donors, 
Patients 3, 4, 5, 6, 7, 8, and 14, Figure 6.2. Our healthy, non-SCD blood donor control, Figure 
6.2.A., does not show any significant difference in the WBC adhesion density to endothelium after 
four and twenty-four hours after inflammation at any of the three examined shear rates, 1,000, 500, 
and 200 s-1.  
Interestingly, all seven examined SCD donors displayed a significantly reduced capacity 
to adhere WBCs to inflammation after twenty-four hours of inflammation to the vessel wall. It is 
possible that the activated profile of the SCD donor WBCs, reduced L-selectin, is the cause of the 
reduced WBC adhesion density at twenty-four hours. E-selectin plays a crucial role in the initial 
capture and weak adherence of WBCs to the vessel wall. 166,167 After twenty-four hours of initial 
inflammation, E-selectin expression is minimal. It is possible that reduced weak interactions led 
to an inability for WBCs to form tight binding between integrins and iCAM-1, despite MAC-1 
being over-expressed in WBCs of SCD patients.  
 94 
The sparse adhesion studies with whole patient blood that exist have focused on the 
difference in WBC adhesion due to alteration in protein expression with no control for the role of 
RBC rigidity. 83,84 Though several analyses of WBCs adhesion in mouse models of SCD exist, 84 
the differences in RBC geometry and deformability between humans and mice, which directly 
impact margination, would prevent direct extrapolation of mice data to humans. 86 For this reason, 
we aim to build an artificial human blood model to probe the RBC rigidity factor. Previous work 
by Gutierrez et al. utilized an artificial stiffening process to rigidify healthy non-SCD donor RBCs 
and reconstitute these rigidified RBCs into whole blood. 10 We take the blood information collected 
from our SCD patients, Table 6.1., and aim to match not only the hematocrit and WBC count but 
also the fraction of rigidified RBCs and the average stiffness of the rigid RBC population. We 
were able to do this for eight of our SCD donors, Patients 1-8. In parallel with actual SCD patient 
blood, the modeled blood is perfused through a microfluidic chamber modeling a vessel wall that 
has been inflamed to observe WBC adhesion density, Figure 6.3. When comparing the WBC 
adhesion performance of our modeled blood to that of actual SCD patient blood, variability is 
observed. Significant differences at 200 s-1 shear rates between the modeled rigid blood and SCD 
blood are found for Patients 1, 3, 5, 7, and 8. At the shear rate of 500 s-1, differences were only 
found for Patients 7 & 8, and for 1,000 s-1 shear rate, the only difference was in Patient 4. 
Interestingly, most of the significant differences in WBC adhesion density are observed between 
the actual SCD patient blood and the modeled blood that excludes rigid RBCs, i.e., the Non-Rigid 
model. All these mentioned differences occurred at the low and intermediate shear rates of 200 s-
1 and 500 s
-1. Possible causes for the differences seen in the WBC adhesion density between the 
actual SCD blood and the Rigid Model blood are possible inconsistencies in matching the RBC 
stiffness. The RBC stiffness matching method presented by Gutierrez et al. is not perfect.11 First, 
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there is a distribution of RBC stiffness within the rigid fraction of an SCD blood sample, and the 
matching model oversees this by modeling the %S fraction stiffness uniformly and not a 
distribution.  Although these assumptions might approximate and match an ektacytometry 
measurement, these differences might not perfectly translate into a blood flow model.  
In addition, a considerable shortcoming of the modeled blood is any possible 
inconsistencies in the adhesion ligand profile of the WBCs of the SCD donors and modeled blood. 
Consequently, we aimed to probe if the healthy non-SCD donor blood’s recombination process to 
match the SCD patient blood altered the adhesion ligand profile of the WBCs in any way. We find 
that the whole blood’s centrifugation pre-activated the WBCs as an increase in MAC-1 expression, 
~150% increase, and shedding of L-selectin expression, ~45% decrease, is observed in both 
neutrophils and monocytes opposed to idled blood, Figure 6.4. Interestingly, although not a perfect 
match in density magnitude, this pattern is in line with leukocytes’ activation state in SCD.   
 Overall, the results from this study are interesting when placed into the context of vaso-
occlusion in SCD. There is substantial evidence that shows the contribution of WBCs in SCD 
complications, including thrombosis and infection.76,163,164,168 It is also well documented that SCD 
patients tend to have abnormally higher total WBC counts than healthy non-SCD people.55,163,164 
The most widely accepted description of mechanisms contributing to SCD pathophysiology 
suggests contributing factors include sickled RBCs, platelets, plasma proteins, vascular wall 
conditions, blood flow conditions, and even WBCs.75,163 Previous work has shown that 
microvascular vaso-occlusion occurs most commonly in post-capillary venules.169 This is to be 
noted, given that the physiological adhesion of WBCs is most common in venules.119,125–127 
Certainly, this implies that WBC adhesion to the vascular wall is correlated to higher incidences 
of vaso-occlusion in SCD.75  
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Generally, the results presented in this study suggest that WBC adhesion efficiency is higher in 
the absence of rigid RBCs in blood flow. Comparing across all flow conditions examined in this 
study, SCD donor blood and the artificially constructed Rigid Blood Model had lower WBC 
adhesion efficiency compared to the Non-Rigid Model, i.e., no rigid RBCs present. The instinctive 
conclusion would be that rigid RBCs present in blood flow will lead to lower WBC adhesion 
densities, resulting in less risk of microvascular occlusion. However, this narrative is simplistic 
and does not encapsulate the entire complexity of factors leading up to vaso-occlusion. One 
considerable observation from this investigation was that we never observed any RBC adhesion to 
the inflamed endothelial layer for all blood conditions, neither in the SCD donor blood in the 
artificially constructed blood models. It is known that in SCD, RBC adhesion to the vascular wall 
is a significant contributor to inflammation cascades and ultimately vaso-occlusion.170 It is likely 
that this observation is due to the lack of i-sRBCs present in the artificial blood models and low 
abundance in the SCD donor blood. Considering SCD donor blood was collected from patients in 
stable condition. It is known that i-sRBCs are highly adhesive.146,147,169 It is also possible that the 
time-scale of the blood flow experiments performed in this study, there was no major endothelial 
dysfunction that would induce RBC adhesion. One major shortcoming of this study was that we 
did not explore how factors such as blood plasma and platelets contribute to WBC adhesion to 
inflammation but instead focused entirely on isolating the factor of RBC stiffness. Such factors 
could also cause further endothelial dysfunction. In the absence of considerable endothelial 
dysfunction, i.e., heme-activation, the inflammation model presented here likely more closely 
resembles a rapid inflammation occurrence in an otherwise steady-state condition. Certainly, there 
are many pieces to a complicated puzzle, and the factor of RBC rigidity is just one piece. It may 
be difficult to make any definitive conclusion regarding vaso-occlusion. However, we can 
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conclude that the presence of rigid RBCs in blood flow certainly influences WBC adhesion in a 
microfluidic vascular wall model. More specifically, WBC adhesion to inflammation, in the 




The knowledge uncovered from this work highlights the intricate impact RBC membrane 
rigidity has on reducing the capacity for WBC to properly adhere to an inflammatory challenge in 
a vessel wall model. Also, further evidence is shown that highlights the interactions between 
immune cells and RBCs in blood flow. Having a high count of WBCs does not necessarily translate 
to high adhesion to inflammation. Undoubtedly, the presence of rigid RBCs alters the ability of 
WBCs to adhere to an inflamed vessel wall. The insights gained from this study could have a 
profound impact on better understanding the pathophysiology of SCD. 171,172 This newfound 
understanding can lead to novel approaches to disease management, ultimately reducing 
infections, hospitalizations, and opiate use in the large patient population unable to receive a 
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7.1. Publication Information 
The work presented in this chapter is not yet published. This work will be submitted as a 
research article to the Journal of Biomedical Science as:  Mario Gutierrez, Mark Shamoun, Logan 
Piegols, and Omolola Eniola-Adefeso. “Alteration in Leukocyte Adhesion Patterns to 
Inflammation Upon Administration of Infusion Therapy in Sickle Cell Disease”. This work is 
largely preliminary work and substantial subsequent investigations will be performed before 
submission for publication as a journal research article.  
The goal of this chapter is to probe how WBC adhesion patterns to inflammation are altered 
with the controlled addition of healthy RBCs to SCD blood.  We mimic the infusion process by 
adding controlled volumes of non-SCD RBCs to pre-infusion SCD blood samples.  Subsequently, 
we utilize an in vitro blood flow PPFC model to quantify WBC adhesion to an inflamed endothelial 
layer. Overall, we aim to understand how infusion therapy administration influences WBC 
adhesion patterns in SCD.  
 
7.2. Abstract 
 One of the major outcomes of SCD is the increased rate of hemolysis. Among many other 
detrimental side effects, an increased hemolysis rate leads to an overall reduced capacity for     
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oxygen transport in the blood. One of the most common therapeutic options for SCD patients is 
that of blood transfusions. Understandably, the main focus of blood transfusions in SCD is to 
directly address the reduced oxygen transport capability problem and reduce the risk for vaso-
occlusive pain crisis. However, little is known about how blood infusions can alter cellular 
biophysical interactions, specifically those of immune cells. Vascular inflammation and infection 
are common in SCD, as well as high immune cell counts. Evidently, one of the common 
characteristics of SCD is an increased propensity for loss of RBC deformability. Evidence has 
shown that loss of RBC deformability can drastically impact cellular distributions in blood flow 
and the adhesion capability of immune cells. In this study, we aim to understand how immune cell 
adhesion to an inflamed in vitro vascular wall model is impacted upon the controlled addition of 
healthy non-SCD red blood cells to mimic the blood infusion process. We find that leukocyte 
adhesion density to the vascular wall is highly variable upon addition to RBCs to SCD patient 
samples. Of all the SCD infusion patients we examined, each registered a notable change in 
leukocyte adhesion patterns upon infusion. These results serve as an essential consideration when 
implementing infusion therapy, and there is a desired target for immune cell adhesion. 
 
7.3. Introduction 
 To date, the two most prevalent therapies for managing SCD are the use of 
pharmaceuticals, typically Hydroxyurea, and the use of chronic blood transfusions.174 Over the 
past decades, the popularity of chronic transfusions as an intervention method for treating SCD 
has grown in popularity. The rate of blood transfusions in children in the US has more than doubled 
over the past decade.175,176  The growing popularity of blood transfusions can be accounted for due 
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to the higher availability of quality blood supply and increased safety. Multiple studies have shown 
evidence of the efficacy of blood transfusions towards preventing stroke in young SCD patients.63  
 The current standard practice employs the use of three variations of transfusion, simple 
infusion, manual exchange infusions, and automated RBC exchange.175 One of the outcomes of all 
the transfusion interventions is lowering the HbS percentage and increasing hemoglobin A (HbA). 
One of the advantages of simple transfusions is their overall simplicity and minimal use of 
specialized equipment. However, this method offers less control over the %HbS and an increased 
risk for infusing to a hyperviscosity point and high iron accumulation. Although simple, this 
methodology is time-consuming and interventions are spaced out in short time periods. Manual 
exchange transfusions are typically implemented using an apheresis machine. In this methodology, 
there is the added step where the infusions patients' blood is also drained, phlebotomized, during 
the infusion of healthy donor blood. This added process results in less risk for reaching blood 
hyperviscosity and iron accumulation and increased control over the %HbS.175 Although not a 
widespread method due to the need for highly specialized equipment and staff, automated RBC 
exchanges offer the best control over %HbS and reduction of adverse transfusion side effects. 
When implementing blood transfusions, a general rule of thumb is to aim for ~10 g/dL hemoglobin 
in SS genotype SCD patients.175 Indeed, one of the outcomes of blood transfusion interventions is 
the reduction of %HbS or fraction of RBCs with a high propensity to have increased membrane 
rigidity. Clinically this is the desired outcome in terms of reducing blood hyperviscosity risk and 
increasing oxygen transport capability. Previous work has shown that leukocyte adhesion to 
inflammation in a vascular wall can be variable based on the fraction of rigid RBCs present in 
whole blood flow.10 Thus, there exists the need to further study how leukocyte adhesion to 
inflammation behaves under varying %HbS content upon transfusion administration.  
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 One of the unfortunate results of increased hemolysis in SCD is increased heme-activated 
inflammation in endothelial cells.170 Increased chronic inflammation often leads to vaso-occlusive 
problems and can also lead to other vascular complications. 76,170,177 Studies have shown that SCD 
patients, even when in stable clinical condition, express four critical markers of endothelial 
activation, intercellular adhesion molecule 1, vascular-cell adhesion molecule 1, E-selectin, and P-
selectin.178 Additionally, SCD patients often experience abnormal rates of infection.76 This seems 
counterintuitive given that SCD patients typically have abnormally higher immune cell 
counts.55,163,164 There is considerable clinical and theoretical evidence that show the critical role of 
RBC adhesion to inflamed vascular wall in inducing vaso-occlusive crisis.16,170,177 Interestingly, 
high absolute neutrophil count in SCD has been correlated as a predictive marker for clinical 
complications.163 The most accepted model for vaso-occlusive crisis suggests RBCs, leukocytes, 
platelets, and plasma proteins are all factors in inducing endothelial dysfunction and ultimately 
occlusion.163 However, the biophysical interplay between leukocyte adhesion to inflammation 
upon administration of infusion therapy is not fully understood. Specifically, the standard clinical 
target is the reduction of %HbS for obvious reasons. However, there is no consideration to how 
such changes may impact the adhesion of leukocytes to the vascular wall. Previous studies suggest 
the relationship between the fraction of rigid RBCs present in the blood, i.e., %HbS, and leukocyte 
adhesion to inflammation seems to be non-linear.10 Thus, it is critical to investigate how leukocyte 
adhesion to inflammation is altered upon administration of infusion therapy. Uncovering this 
information could prove valuable in understanding how to minimize or optimize leukocyte 
adhesion for clinical purposes using better-prescribed infusion therapy.  
This chapter presents a blood infusion mimic where we add healthy non-SCD RBCs to pre-
infusion SCD blood samples. We chose to closely mimic the simple blood transfusion process, 
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which entails the addition of healthy non-SCD donor RBCs to treated SCD patients. We then 
perfuse these infused samples through an inflamed vascular wall microfluidic model and quantify 
WBC adhesion. We find that WBC adhesion density is variable upon administration of blood 
infusion. Each SCD patient blood sample that underwent the mimic infusion process registered a 
unique response in WBC adhesion patterns. The findings presented in this chapter shows there is 
an evident alteration in the biophysical interactions between infused RBCs, rigid RBCs, and 
leukocytes in the infusion process. These findings suggest there is a potential for optimizing 
infusion therapy based on the desired WBC adhesion pattern to inflammation.  
 
7.4. Results 
We begin this study by collecting blood samples from SCD patients who are regularly 
treated with blood infusions. We collect blood samples before the blood transfusion.  For this 
study, we were able to collect eight unique SCD patient samples. Information including SCD donor 
genotype, age, gender, and pre-infusion blood conditions can be seen in Table 7.1. We aimed to 
collect another sample from the SCD donor’s post-infusion therapy specifically for electrophoresis 
and hematocrit analysis. Unfortunately, logistical issues with the patient's inability to stay in the 
clinic post-infusion deterred us from collecting a complete set of post-infusion samples. The post-
infusion sample information collected can be seen in Table 7.1., missing information is denoted 
with a dash in Table 7.1. In addition, to general patient information, we performed a complete 
blood count (CBC) analysis on all the eight SCD patient pre-infusion samples. Information 
including total WBC count, platelet count, mean corpuscular volume (MCV), neutrophil fraction, 
lymphocyte fraction, monocyte fraction, eosinophil fraction, and basophil fraction can be seen in 
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Table 7.2. In addition to the eight SCD patients, Table 7.2. also shows the average CBC values for 
non-SCD blood donors.  
We analyze a subset of both pre-infusion and actual post-infusion blood samples via 
ektacytometry deformability analysis. The deformability elongation curves for our patients can be 
shown in Figure 7.1. We see the deformability curves for all eight pre-infusion samples analyzed 
in Figure 7.1.A. More notably, Patient 6 registers the least deformable pre-infusion blood sample 
with a maximum elongation index value of 0.266, Figure 7.1.A. Conversely, the most deformable 
pre-infusion blood samples came from Patients 4 and 6, both registering an elongation index of 
~0.51, Figure 7.1.A. We were able to obtain the actual post-infusion samples from SCD Patients 
2, 4, and 8. We compare the ektacytometry deformability curves of the pre-infusion and post-
Figure 7.1. Deformability Analysis Via Ektacytometry of Infusion Patients.  
Standard ektacytometry deformability analysis at constant osmolality (~290 mOsmol/kg) and variable shear stress. (A) 
Ektacytometry analysis of all eight infusion patients of PRE-infusion samples. Ektacytometry measurements of PRE-infusion 
sample denoted as Measurement 1, and POST-infusion sample denoted as Measurement 2 for (B) Patient 2, (C) Patient 4, and 
(D) Patient 8. All figures include a healthy non-SCD deformability curve for reference. 
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infusion samples for SCD Patients 2, 4, and 8 shown in Figure 7.1.B., Figure 7.1.C., and Figure 
7.1.D. respectively. The pre-infusion measurement is denoted as Measurement 1, and the post-
infusion analysis is denoted as Measurement 2. In all of Figure 7.1. we implement a deformability 
curve of non-SCD blood samples denoted as Healthy. Interestingly, Patient 2 experienced the 
greatest increase in maximum elongation index value post-infusion climbing from a value of 0.422  
to 0.572, Figure 7.1.B. We do not observe a drastic change in post-infusion maximum elongation 
indices for both Patient 4 and Patient 8, Figure 7.1.C. and Figure 7.1.D. respectively. 
 
Table 7.1. Sickle Cell Disease Infusion Patient Demographics and Blood Profile Information.  
Table with SCD infusion patient information including SCD genotype, age in years, gender (male or female), pre-infusion 
hematocrit, post-infusion hematocrit, pre-infusion %HbS fraction, post-infusion %HbS fraction, pre-infusion and post-infusion 
maximum elongation indices as registered with ektacytometry deformability analysis. Missing therapies indicate the patient was 
not processed post-infusion therapy administration. 
 
We collect a surplus of pre-infusion SCD blood samples and partition them into multiple 
1 mL whole blood pre-infusion aliquots. Leveraging the PPFC model, we perfuse the raw pre-
infusion SCD blood samples at a shear rate of 500 s-1 and aim to quantify the WBC adhesion 
density of the pre-infusion condition, Figure 7.2. The endothelial layer is inflamed via exposure to 




















# - years (M/F) % % % % - - 
1 SS 16 M 31.1 34.2 31.3 24.6 0.401 - 
2 SS 21 M 24.2 - 86.6 - 0.422 0.572 
3 SS 16 M 24.6 - 34.1 - 0.482 - 
4 SS 19 F 23.9 30.5 39.8 29.2 0.513 0.539 
5 SS 22 F 32.0 - 44.7 - 0.483 - 
6 SS 9 M 24.5 - 17.6 - 0.266 - 
7 SS 13 M 33.5 - 21.3 - 0.465 - 
8 SC 11 F 29.3 - 33.8 - 0.51 0.542 
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our SCD patients from highest WBC adhesion density to lowest, with Patient 1 registering a ~1,000 
WBCs adhered/mm2 and Patient 8 with ~ 300 WBCs adhered/mm2. We average all the pre-
infusion adhesion densities, ~600 WBCs adhered/mm2, shown as the AVG bar in Figure 7.2. 
 We take surplus pre-infusion SCD blood sample aliquots and begin adding RBCs at 
controlled volumes to increase the hematocrit to the desired percentage. We take fresh, healthy 
non-SCD donor blood and isolate RBCs. We determine the volume of RBCs to add to the SCD 
pre-infusion samples using Equation 3 from Chapter 2. Once the aliquot has its hematocrit altered, 
we perfuse individual samples through the PPFC model at a shear rate of 500 s-1 and again quantify 
the WBC adhesion density onto the inflamed endothelial monolayer. We adjust the hematocrit of 
SCD blood samples up to a hematocrit of 50%. We are able to collect post-infusion samples from  
 
Table 7.2. Sickle Cell Disease Infusion Patient Complete Blood Count.  
Table with SCD infusion patient complete blood count information. Complete blood count average for healthy Non-SCD blood 
sample is shown in the last row. 
 
all eight SCD patients for perfusion studies. Following the individual perfusion of all the 
hematocrit-adjusted infusion samples, we perfuse the actual post-infusion blood sample from SCD 
patients. We quantify the WBC adhesion onto the inflamed monolayer as an adhesion density for 
Patient Total WBC PLT MCV Neutrophil Lymphocyte Monocyte Eosinophil Basophil 
# K/uL K/uL fl % % % % % 
1 15.9 370 90.1 54.9 30.6 10.9 1.8 0.5 
2 20.1 228 90.3 41.9 36.5 15.5 4.7 0.8 
3 15.8 430 89.2 41.0 12.3 4.0 3.5 0.6 
4 19.4 293 93 50.7 28.7 10.1 9.0 0.6 
5 11.7 352 89 76.7 11.6 8.8 2.1 0.4 
6 17.5 529 90.7 51.7 35.1 10.6 1.5 0.4 
7 12.80 427 91.8 51.6 22 13.6 11.5 0.7 
8 5.2 262 91.3 47.7 42 8.0 1.3 0.3 
Non-SCD  6.5 253 90 50 30 5 2.5 0.75 
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all individual patients. From here, we choose to normalize all WBC adhesion densities both in the 
actual post-infusion sample and in hematocrit adjusted infusion mimicked samples to the actual 
pre-infusion WBC adhesion density that is shown in Figure 7.2. These results are then represented 
as a percent change in WBC adhesion compared to the pre-infusion WBC adhesion for each unique 
SCD patient, Figure 7.3.   
 For Patient 1, we see a positive percent change in WBC adhesion when the hematocrit was 
adjusted to ~37%, Figure 7.3.A. Interestingly, when the hematocrit was adjusted further, a negative 
percent change in WBC adhesion is observed. This pattern is also the case for the patient actual 
post-infusion sample. For Patient 2, we see a negative percent change in WBC adhesion in the 
hematocrit adjusted samples, however, the post-infusion sample registered a WBC adhesion 
density very close to the pre-infusion sample, Figure 7.3.B. This trend was also observed for 
Patient 5 and Patient 8, Figure 7.3.E. and Figure 7.3.H., respectively. A variable pattern in WBC 
adhesion is observed for both Patients 3 and 4, Figure 7.3.C. and Figure 7.3.D. respectively. There 
Figure 7.2. White Blood Cell Adhesion Density for Sickle Cell Disease Patients.  
Quantified WBC binding to inflamed endothelial layer after 5 min of laminar whole blood flow at 
a wall shear rate of 500 s-1. The AVG bar denotes the average adhesion density of all patients. Error 
bars represent standard error for each donor. 
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was an oscillating-type trend in percent change of WBC adhesion in the hematocrit-adjusted 
samples in both these cases. Additionally, in both these patients, the actual post-infusion sample 
had a negative percent change in WBC adhesion than the pre-infusion sample.  For Patient 6, we 
observe a positive percent change in WBC adhesion in both the hematocrit adjusted samples and 
the post-infusion sample, Figure 7.3.F. More specifically, we see a ~80% increase in WBC a 
dhesion when the hematocrit is adjusted to ~35%.  For Patient 7, we observe a negative percent 
change in WBC adhesion when the hematocrit is initially adjusted to ~39%. There is a positive 
percent change in WBC adhesion observed at higher hematocrits and the post-infusion sample, 
Figure 7.3.G. Overall, Figure 7.3. shows the WBC adhesion density trends upon the artificial 
hematocrit adjustments. The artificially adjusted hematocrits aim to mimic the infusion process.  
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Figure 7.3. Quantified White Blood Cell Binding to an IL-1β Inflamed Endothelial Layer in vitro as a Function of 
Increasing Hematocrit.  
Blood samples from SCD patients is adjusted by hematocrit with the controlled addition of healthy non-SCD donor RBCs. Trials 
are plotted as a change in WBC adhesion compared to the WBC adhesion density in the PRE-infusion condition of each 
independent donor. Inflammation of the endothelium is induced by exposure to inflammatory cytokine IL-1β for four hours 
prior to blood perfusion. Quantified WBC binding to an inflamed endothelial layer at a wall shear rate of 500 s-1 for SCD Patients 
(A) 1, (B) 2, (C) 3, (D) 4, (E) 5, (F) 6, (G) 7, (H) 8. Statistical analysis of adherent density was performed using two-way 
ANOVA to test all WBC adhesion against each individual Patient PRE-infusion condition. No asterisks represent no significant 
difference found. Error bars represent standard error. 
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7.5. Discussion 
 Throughout this dissertation, we have focused on the loss of RBC membrane deformability 
and any downstream effects of this change as it relates to disease, specifically SCD. One of the 
most notable characteristics of SCD is the loss of RBC membrane deformability which ultimately 
leads to systemic issues and overall reduced quality of life in SCD patients.42,55 One notable impact 
of increased rigidity in RBCs is increased cell fragility and likelihood to lyse releasing heme into 
the bloodstream.177 As a result of increased hemolysis in SCD, higher rates of vascular 
inflammation are well documented in this disease.163,170,178,179  This ultimately results in chronic 
inflammation and increased risk for vaso-occlusion and infection.55,76,177,180 To combat this 
ailment, blood transfusions have become standard practice when treating SCD without or 
combined with a pharmaceutical treatment approach.62,174–176,181 Standard transfusion practice 
aims to increase the oxygen transport capacity of patients and reduce the risk for vaso-occlusive 
crisis, which is done by typically targeting to lower the %HbS to less than 30%.175 As the %HbS 
is lowered in the whole blood, reasonably, the fraction of RBCs with a high propensity to be highly 
rigid is reduced. Standard blood transfusion practices do not take into consideration how these 
mentioned changes happening upon infusion therapy administration can alter the immune cell 
adhesion capability to inflammation. Despite the known role of leukocyte adhesion to vascular 
wall inflammation,163,182 there is little work that explores the mechanisms of blood flow dynamics 
and leukocyte adhesion to inflammation as it relates to blood transfusion therapy.  
 This work presents a microfluidic blood flow model paired with a hematocrit adjustment 
process that mimics simple blood infusion therapy to examine how blood transfusions impact 
leukocyte adhesion in SCD. Moreover, we aim to draw attention to immune cell adhesion patterns 
upon administration of infusion therapy. Ultimately, we aim to uncover any predictive marker that 
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may help optimize blood transfusion practices to either minimize or maximize leukocyte adhesion 
to inflammation based on the desired clinical outcome. One of the primary goals of this study is to 
identify any potential blood characteristic that may determine leukocyte adhesion to inflammation 
tendencies. Specifically, we take a close look at SCD transfusion patient %HbS or %S fraction, 
ektacytometry deformability analysis, and CBC for the pre-infusion condition. Due to logistical 
issues, we could make these same analyses for the actual post-infusion samples for only a subset 
of the eight SCD patients examined in this study. We analyze the WBC adhesion density onto an 
inflamed endothelial layer in a microfluidic model for all eight patients.  
 We take a look back at the WBC adhesion density to an inflamed vascular wall of healthy 
non-SCD donor blood presented in Chapter 3, Figure 3.3.B. Although, the data from Figure 3.3. 
was obtained via blood perfusion in a ~254 µm channel; Chapter 3 also concludes that there was 
no significant difference in WBC adhesion to inflammation between ~127 µm and ~254 µm 
channel heights.10 The endothelial monolayers were prepared and inflamed using the identical 
methodology to the one presented in this chapter. The approximate average WBC adhesion density 
to inflammation at a WSR of ~500 s-1 is ~1,300 WBCs/mm2. Although the absolute WBC counts 
for the whole blood utilized in these experiments were not quantified, we make the deduction that 
they are likely to be close to the average CBC counts for healthy non-SCD blood donors, shown 
in Table 7.2., the value of the total WBC count is ~6.5 K/µL. With these assumptions made, we 
can approximate the WBC adhesion binding efficiency by dividing the WBC adhesion density by 
the total number of WBCs present in the blood sample perfused; this ratio is then multiplied by a 
scaling factor of 106. We opted to make this comparison so we can normalize across variable total 
WBC concentrations across blood samples. Using the parameters stated above, blood perfusion 
for ~5 minutes at a WSR of 500 s-1 in a channel height of 254 µm requires ~4 mL of whole blood 
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with a total WBC concentration of ~ 6.5 K/µL, if the WBC adhesion density is ~1,300 WBC/mm2, 
then the WBC binding efficiency for healthy non-SCD donors is ~50 WBCs bound/mm2/WBCs 
fed x 106. We perform a similar calculation across the eight SCD pre-infusion samples and result 
in an average WBC binding efficiency of ~40 WBCs bound/mm2/WBCs fed x 106. This 
comparison again highlights the fact that having a greater WBC concentration does not necessarily 
translate to a greater adhesion density. On average, our eight SCD donors have a total WBC count 
about 2.3x fold times larger than a healthy non-SCD blood donor.  
One major shortcoming of this investigation was forgoing leukocyte adhesion ligand 
profile characterization of our SCD donors. As shown in Chapter 6, the WBC adhesion ligand 
profiles of SCD patients differ greatly from healthy non-SCD donor WBCs, resembling a pre-
activated state with overexpression of ligand MAC-1 and under-expression of L-Selectin, Figure 
6.1. Total WBC composition did not differ greatly in our SCD infusion patients and average 
healthy non-SCD donors, Table 7.2. Roughly 50% of leukocytes present are neutrophils, 30% are 
lymphocytes, and 10% are monocytes. The remainder is made up of smaller fractions of 
eosinophils and basophils. Given these similarities in leukocyte fractional compositions, it is likely 
that the differences in WBCs density between healthy non-SCD donors and the eight pre-infusion 
SCD patients, Figure 7.2., is a result of differences in the WBC adhesion ligand profiles.  
Patient 2 is notably a compelling case, given that they registered the highest %S fraction 
in our patient pool, ~86.6%. The pre-infusion RBC deformability analysis of Patient 2 was not 
abnormal for a HbSS genotype SCD patient, registering a maximum elongation index of 0.422. 
Patient 2 was one of the patients for whom we could analyze their post-infusion blood sample with 
ektacytometry. Notably, Patient 2 recorded a maximum elongation index of 0.572, which is a 
notable improvement in whole blood deformability, Figure 7.1.B. Upon examining WBC adhesion 
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with the hematocrit adjustment, we found a negative percent change in WBC adhesion for all 
hematocrits examined. However, the actual post-infusion sample did not exhibit a WBC adhesion 
density that was notably different from the WBC adhesion density of the pre-infusion sample. We 
observe similar trends for Patient 5 and Patient 8 but cannot identify any correlation in pre-infusion 
blood characteristics that could predict these outcomes in WBC adhesion density.  
 Another notable case is that of Patient 6, who registered the lowest %S fraction, ~17.6%. 
However, Patient 6 also registered the lowest whole blood deformability amongst all SCD infusion 
patients, with a maximum elongation index of 0.266. Based on the work presented in Chapter 4, 
we can deduce that the rigid RBC population or %S fraction, in this patient has a relatively high 
degree of stiffness, given that there is a small %S fraction, but also a considerably low 
deformability elongation index. When examining the effects of hematocrit adjustment with Patient 
6, we find increasing the hematocrit using the infusion mimicking methodology that there was 
always a positive percent change in WBC adhesion density, Figure 7.3.F. This result suggests that 
for this patient, infusion therapy will likely increase WBC adhesion density.  
 Patients 1, 3, 4, and 7 all are notable cases because they exhibit an oscillating-type trend in 
percent change in WBC adhesion density upon hematocrit adjustment. Both Patient 3 and Patient 
4 recorded a typical %S fraction of 34.1% and 39.8%, respectively. Patient 1 and Patient 7 recorded 
a %S fraction of 31.1% and 33.5%, respectively. The ektacytometry whole blood elongation 
analysis did not reveal an abnormally low RBC deformability, both Patient 3 and Patient 4 
registering maximum elongation indices ~0.50, Table 7.1., and Patient 1 and Patient 7 registering 
maximum elongation indices ~0.43. 
 Variation across samples is a confounding factor that makes it challenging to identify a 
clear cause for the observations made in this infusion therapy mimicking study. There is 
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undeniable evidence that hematocrit is a major factor in determining leukocyte adhesion. This 
thesis also shows that leukocyte adhesion patterns to the vascular wall are affected by the fraction 
of rigid RBCs, or %S fraction, present in the whole blood. Unfortunately, for logistical reasons, 
we could not collect a complete detailed data set for all SCD infusion patients that include both 
pre-infusion and post-infusion hematocrit, %S fraction, and ektacytometry elongation index 
analyses. Drawing definitive conclusions from the WBC adhesion assays performed in this study 
is difficult without statistical power. Due to SCD blood donor availability and, in general, the 
nature of sample variation, we performed only one experiment per patient and hematocrit point, 
n=1. Although a difference in WBC adhesion magnitude change is observed, there is no statistical 




To our knowledge, this is the first study that directly investigates how WBC adhesion to 
inflammation is altered upon administration of blood transfusion therapy in SCD. It may be 
difficult to draw definitive conclusions from these preliminary results. However, it is evident that 
leukocyte adhesion is changed notably upon the administration of infusion therapy. Moreover, we 
observed a unique change in WBC adhesion trends for each individual SCD infusion patient 
examined in this study. This observation serves as evidence of a very patient-specific leukocyte 
adhesion response to infusion therapy. These preliminary findings highlight the need to probe 
further the biophysical interplay between rigid RBCs, leukocyte adhesion to vascular 
inflammation, and infusion therapy. Such insights could prove invaluable in providing guidelines 
for optimizing blood transfusion practices and increasing the efficacy of this prevalent therapy in 
 114 
relation to immune cell functionality and SCD pathogenesis.  Additionally, insights could aid in 




 : Vascular-Targeted Particle Efficacy in the Presence of Rigid Red Blood Cells: 
Implications for Performance in Diseased Blood 
 
 
8.1. Publication Information 
The work presented in this chapter is published as:  Mario Gutierrez, Lauro Sebastian 
Ojeda, and Omolola Eniola-Adefeso. “Vascular-targeted particle efficacy in the presence of rigid 
red blood cells: Implications for performance in diseased blood.” Biomicrofluidics 12.4 (2018): 
042217. 12 
Modifications have been made to the published document to adapt the content to this text. 
The goal of this chapter is to probe how model drug particle adhesion to inflammation is impacted 
in the presence of rigid red blood cells in an in vitro model of blood flow. 
 
8.2. Abstract 
The field of drug delivery has taken an interest in combating numerous blood and heart 
diseases via the use of injectable vascular-targeted carriers. However, vascular-targeted carrier  
technology has encountered limited efficacy due to a variety of challenges associated with the 
immense complexity of in vivo blood flow environment, including the hemodynamic interactions 
of blood cells that impact their margination and adhesion to the vascular wall. RBC physiology, 
i.e., size, shape, and deformability, drive cellular distribution in blood flow and has been shown to 
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impact VTC margination to the vessel wall significantly. RBC shape and deformability are altered 
in certain human diseases, yet little experimental work has been conducted to understand the effect 
of these alterations, specifically RBC rigidity, on VTC dynamics in physiological blood flow. In 
this work, we investigate the impact of RBCs of varying stiffness on the adhesion efficacy of 
particles of various size, modulus, and shape onto an inflamed endothelial layer in a human 
vasculature-inspired, in vitro blood flow model. The rigid RBC compositions and degrees of RBC 
stiffness evaluated are analogous to conditions in diseases such as sickle cell disease. We find that 
particles of different size, modulus, and shape yield drastically different adhesion patterns in blood 
flow in the presence of rigid RBCs when compared to 100% healthy RBCs. Specifically, up to 
50% reduction in the localization and adhesion of non-deformable 2 µm particles to the vessel wall 
was observed in the presence of rigid RBCs. Interestingly, deformable 2 µm particles showed 
enhanced vessel wall localization and adhesion, by up to 85%, depending on the rigidity of RBCs 
evaluated. Ultimately, this work experimentally clarifies the importance of considering RBC 
rigidity in the intelligent design of particle therapeutics and highlights possible implications for a 
wide range of diseases relating to RBC deformability. 
 
8.3. Introduction 
As discussed in previous chapters, blood is a highly concentrated non-Newtonian 
suspension of RBCs, WBCs, platelets, and plasma. 13 The high deformability of RBCs is a unique 
characteristic that significantly influences particle margination in blood flow. 92–95 In particular, 
the deformable RBCs are vastly susceptible to experiencing a lift force, which causes them to 
migrate away from the vessel wall and localize in the radial center of the vessel as blood flows. 
28,38,93,96 Particle-RBC collisions in the core of the vessel then promote the migration of particles 
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towards the vessel wall. 38,92 It is known that particle size is a critical factor that determines the 
margination efficacy of particle therapeutics. 109,112,183–186 In particular, work done by Charoenphol 
et al. indicates that spherical microparticles (MPs) best marginate to the vascular wall, and 
nanometer-sized VTCs exhibit less efficient margination. 108,113 Namdee et al. attribute this 
reduced margination to spherical nanoparticles (NPs) getting trapped in the RBC core. 112 Once 
out of the RBC core, the near-absolute absence of RBCs near the vessel wall, i.e., CFL, allows the 
proper binding of particles to the vessel wall. 38,92  Given the importance of RBC deformability in 
the margination of particles and hence their adhesion to the vascular, any alteration in RBC 
flexibility, as found in certain human diseases, 3,97 would undoubtedly affect particle margination 
and adhesion.   
To date, despite a vast number of computational and experimental studies that have 
examined RBC and particle margination in blood flow, there is no investigation into how changes 
in RBC deformability impact particle margination and, hence, binding efficacy. Thus, the work 
presented in this chapter experimentally probes the direct impact of rigidified RBCs on the 
adhesion dynamics of particles in blood flows via in vitro assays in a PPFC. We report that particle 
adhesion in human blood flow can be significantly reduced or improved depending on the particle 
modulus, shape, and size, where being deformable can lead to a positive impact of rigid RBCs on 
particle adhesion. We believe this proposed work is the first comprehensive, experimental 
investigation into how rigidified RBCs affect the ability of VTCs to marginate and adhere to the 
vascular wall. The knowledge presented is of importance as it can provide opportunities for 




8.4.1. Effect of Rigid RBCs on 2 µm Stiff Polystyrene Particles as a function of RBC Rigidity 
We began by examining how the presence of rigidified RBCs affects the adhesion of 2 µm 
"rigid" polystyrene MPs to an activated HUVEC layer in whole blood flow.  We tested a range of 
RBC rigidities (9x, 4x, and 2x times more rigid than healthy RBCs) and at different concentrations 
(20%, 30%, 50%, 70%, 90%, and 100%) of rigid RBCs in the blood. Polystyrene spheres were 
used as a proxy for biodegradable polymeric particle carriers. As previously described, the 2 µm 
PS spheres were functionalized with biotinylated sLea at  ~1,000 sLea site/µm2 and introduced into 
whole blood samples at a concentration of ~106 particles/mL of blood.106,113 RBCs 9x more rigid 
than healthy RBCs are presented as the highly rigid condition, ones that were 4x more rigid 
presented as moderately rigid, and RBCs 2x more rigid are labeled as slightly rigid. The EIs 
produced by the 0.75 mM and 0.5 mM TBHP treatments are of particular interest due to their 
pathological relevancy; the rigidities of RBCs in SCD patients in stable condition and SCD patients 
in crisis closely resembles the RBC rigidities generated with 0.5 mM and 0.75 mM TBHP, 
respectively.10,121 Also, it is known that patients can have different fractions (percentages) of 
rigidified RBCs present in their whole blood.10,121   
Figure 8.1. shows the impact of RBC rigidity on particle adhesion to the vessel wall as a 
function of RBC stiffness in a 127 µm height channel. The data is represented as the fraction 
reduction in particle adhesion in rigid RBC conditions relative to the adhesion of the same particles 
in a healthy condition, i.e., no rigid RBC present, to eliminate donor-to-donor variations. The raw 
adhesion density for the healthy condition represented in Figure 8.1. is shown in Figure 8.2. We 
show in Figure 8.1. that the presence of rigid RBCs in the blood flow produces a reduction in the 
adhesion of 2 µm PS MPs relative to the binding found in the healthy control regardless of the 
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RBC stiffness and percentage of rigid RBCs present. For assays with highly rigid RBCs, a 
maximum reduction (~50%, p<0.01) in the adhesion of the PS MPs occurred when 20% of the 
total RBCs present were rigidified (Figure 8.1.A.). As we increased the percentage of the rigid 
RBCs in the blood sample, there was a slight decrease in the adhesion reduction to ~25% lower 
than adhesion in the healthy control. However, the reduction in MP adhesion beyond the 30% rigid 
RBC in flow mark was not significant; i.e., PS MP adhesion in blood with highly rigid RBCs was 
not statistically different from adhesion in healthy conditions. Figure 8.1.B. shows a plot of the 
trend in 2 µm PS particle adhesion reduction for the case where moderately rigid RBCs were 
present in the blood flow. Here, we show a non-linear relationship between adhesion reduction 
and the percent of rigid RBCs present in the blood. Initially, the decrease in MP adhesion increased 
as the percentage of rigid RBCs in the blood increased up to the 50% mark, corresponding to the 
highest adhesion reduction (~52%, p<0.01). As the percentage of rigid RBCs in the blood 
increased beyond the 50%, the decrease in MP adhesion was reduced. At 100% moderately rigid 
Figure 8.1. The Adhesion of 2 µm Polystyrene Particle to Inflamed Endothelium in vitro by Red Blood Cell Rigidity.  
Quantified 2 µm polystyrene particle binding to an IL-1β inflamed endothelial layer at 106 particles/mL of whole blood as a 
function of rigid RBCs present, i.e., % volume rigid RBC, each figure utilized rigid RBCs with different degrees of rigidity (A) 
1.0 mM treated RBCs (highly rigid), (B) 0.75 mM treated RBCs (moderately rigid), and (C) 0.5 mM treated RBCs (slightly rigid). 
A WSR of 1,000 s-1 was used for all the shown conditions. Polystyrene particles are conjugated with NeutrAvidin and 
functionalized with sLea binding ligand, ~1,000 sites/µm2. All trials plotted as reduction compared to respective healthy controls, 
i.e., no rigid RBCs present, thus eliminating donor variation. Error bars represent standard error. Statistical analysis of adherent 
density was performed using two-way ANOVA to test all particle adhesion versus healthy particle adhesion control. (*) indicates 
p<0.05, (**) indicates p<0.01, and (***) indicates p<0.001. 
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RBCs present in the flow, no difference in particle adhesion was observed relative to the binding 
in the healthy condition. Interestingly, there was no particular trend in the impact of the slightly 
rigid RBCs on the adhesion of the 2 µm PS MP as the percentage of rigid RBCs is increased 
(Figure 8.1.C.). Instead, we observed the highest reduction in adhesion (~58%, p<0.001) when 
20%, 50%, and 90% of total RBCs present were slightly rigid. Conversely, there was a negligible 
reduction in MP adhesion when 30% of RBCs present are rigidified. At 70% and 100% of the 
slightly rigid RBCs present, the adhesion of the 2 µm PS MPs was reduced by ~25%, which was 
not significant from the healthy condition.  
 
8.4.2. Effect of Rigid RBCs on 2 µm Deformable Hydrogel Particles as a function of RBC 
Rigidity 
To evaluate the impact of particle deformability on the dynamics of adhesion in the 
presence of rigid RBCs, we fabricated 2 µm hydrogel (PEG-based) particles (PEG-MP) and 
Figure 8.2. Raw Particle Binding to Inflamed Endothelium in vitro.  
Quantified particle binding to an IL-1β inflamed endothelial layer at 106 particles/mL 
of whole blood at healthy conditions, i.e., no rigid RBCs are present. Blood is at 40% 
hematocrit and is perfused at a WSR of 1,000 s-1 for all the shown conditions. All 
particle types are conjugated with NeutrAvidin and functionalized with sLea binding 
ligand, ~1,000 sites/µm2. Error bars represent standard error. 
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modulated the cross-linking density to achieve particle deformability similar to the deformability 
reported for WBCs(~113 kPa, Young's Modulus).114 The PEG-MPs were conjugated with sLea at 
~1,000 sLea site/µm2, similar to polystyrene MPs. Figure 8.3.A. shows the percent difference in 
the adhesion of the 2 µm PEG-MP in the presence of the highly rigid RBCs relative to the healthy 
condition. At the lowest concentration of highly rigid RBCs, e.g., 20%, we observed a slight 
reduction in the adhesion of 2 µm PEG-MP, which represents the maximum adhesion reduction 
seen for this particle type across all rigid RBCs concentrations similar to the observation with the 
non-deformable polystyrene MPs. Interestingly, when the level of rigid RBCs present is increased, 
the reduction in hydrogel particle adhesion relative to healthy condition decreased linearly. A 
negative percent reduction in PEG-MP adhesion is present beyond 50% highly rigid RBCs in the 
blood, which translates to a raw particle adhesion that is higher than the level achieved in a healthy 
blood flow condition. Surprisingly, when 100% of the RBCs present are rigidified, we observe an 
Figure 8.3. The Adhesion of 2 µm Hydrogel Particle to Inflamed Endothelium in vitro by Red Blood Cell Rigidity.  
Quantified 2 µm hydrogel particle binding to an IL-1β inflamed endothelial layer at 106 particles/mL of whole blood as a 
function of rigid RBCs present, i.e., % volume rigid RBC, each figure utilized rigid RBCs with different degrees of rigidity 
(A) 1.0 mM treated RBCs (highly rigid), (B) 0.75 mM treated RBCs (moderately rigid), and (C) 0.5 mM treated RBCs (slightly 
rigid). A WSR of 1,000 s-1 was used for all the shown conditions. Hydrogel particles are conjugated with NeutrAvidin and 
functionalized with sLea binding ligand, ~1,000 sites/µm2. All trials plotted as reduction compared to respective healthy 
controls, i.e., no rigid RBCs present, thus eliminating donor variation. Error bars represent standard error. Statistical analysis 
of adherent density was performed using two-way ANOVA to test all particle adhesion versus healthy particle adhesion 
control. (*) indicates p<0.05, (**) indicates p<0.01, and (***) indicates p<0.001. 
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adhesion reduction of -85% (p<0.001), i.e., nearly twice the adhesion density of PEG-MPs that 
was found as compared to the healthy condition. A visual representation of the enhanced 2 µm 
PEG-MP adhesion to the endothelial layer is presented in Figure 8.4. When examining the impact 
of the moderately rigid RBCs, we observe a similar trend to the one seen for the highly rigid ones. 
At low percentages of the moderately rigid RBCs present in blood flow, a slight reduction in 
adhesion was observed for the PEG MPs relative to the healthy condition. As the percentage of 
rigid RBCs present increased, the particle adhesion improved towards similar values as obtained 
for the healthy condition.  However, unlike the highly rigid RBCs case, an enhanced PEG-MP 
adhesion relative to the healthy condition was only observed at 100% moderately rigid RBCs 
present in flow, ~-78% (p<0.001). Finally, when we examine the adhesion of the PEG-MP in the 
presence of the slightly rigid RBCs, we saw a similar oscillate-trend as was observed for 
polystyrene MPs in Figure 8.1.C. A reduction in particle adhesion occurred when 20%, 50%, and 
Figure 8.4. Hydrogel 2 µm Particle Binding on Confluent Monolayer of HUVEC.  
Fluorescent rhodamine images of hydrogel particles adhered to HUVEC while blood is perfused at 
a WSR of 1,000 s-1. (A) shows condition with healthy blood, i.e., no rigid RBCs present. (B) shows 
condition with 100% rigid RBCs treated with 1.0 mM TBHP present. 
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90% of the RBCs present were rigid. When 30%, 70%, and 100% of the RBCs present were rigid, 
no difference in 2 µm hydrogel particle adhesion was observed compared to particle adhesion in 
the healthy condition.  
 
8.4.3. Effect of Rigid RBCs on rigid 500 nm Polystyrene Particles as a function of RBC Rigidity 
Given the significant impact of rigid RBCs on adhesion patterns observed for MPs, we 
investigated the adhesion performance of rigid polystyrene NPs, which are typically proposed for 
drug delivery applications. Here, we used 500 nm-sized polystyrene particles and functionalized 
them with sLea as described with MPs. We have previously demonstrated that spherical 
nanoparticles between 100 – 500 nm show the same margination and adhesion patterns in human 
blood flow. 108,113  Again, the adhesion of the 500 nm polystyrene NPs in blood flow with rigidified 
RBCs is presented relative to adhesion in a healthy condition. Figure 8.2. shows the raw particle 
adhesion density for 500 nm polystyrene particles at a WSR of 1,000 s-1 (~900 #/mm2), which was 
lower than the adhesion observed for polystyrene MPs in line with previous works.113 As shown 
in Figure 8.5., rigidified RBCs in blood did not have any significant impact on the adhesion of PS 
NPs regardless of the level of RBC rigidity. Also, no specific particle adhesion reduction trend 
was visible when the percentage of rigid RBCs was varied. 
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8.4.4. Effect of Rigid RBCs on rigid Ellipsoidal Polystyrene Particles as a function of RBC 
Rigidity 
We also investigated the adhesion performance of non-spherical particles in whole blood 
containing rigidified RBCs due to prior interest in the use of such particles in cellular targeting 
and drug delivery. Previous reports show that non-spherical, specifically rods, particles can exhibit 
better adhesion capabilities when compared to spherical counterparts. 183,184,186–188 Here, we use 
polystyrene rod particles that were generated from heat-stretching of 2 µm spherical particles to 
an aspect ratio of 4 (AR4). Figure 8.6. shows the adhesion reduction trends for sLea-coated rods 
in the presence of rigid RBCs across the different levels of rigidity evaluated. The raw rod particle 
adhesion density in normal blood at a WSR of 1,000 s-1 is shown in Fig S1. Interestingly, negligible 
Figure 8.5. The Adhesion of 500 nm Polystyrene Particles to Inflamed Endothelium in vitro by Red Blood Cell 
Rigidity.  
Quantified 500 nm polystyrene particle binding to an IL-1β inflamed endothelial layer at 106 particles/mL of whole blood as 
a function of rigid RBCs present, i.e., % volume rigid RBC, each figure utilized rigid RBCs with different degrees of rigidity 
(A) 1.0 mM treated RBCs (highly rigid), (B) 0.75 mM treated RBCs (moderately rigid), and (C) 0.5 mM treated RBCs 
(slightly rigid. A WSR of 1,000 s-1 was used for all the shown conditions. Polystyrene particles are conjugated with 
NeutrAvidin and functionalized with sLea binding ligand, ~1,000 sites/µm2. All trials plotted as reduction compared to 
respective healthy controls, i.e., no rigid RBCs present, thus eliminating donor variation. Error bars represent standard error. 
Statistical analysis of adherent density was performed using two-way ANOVA to test all particle adhesion versus healthy 
particle adhesion control. (*) indicates p<0.05, (**) indicates p<0.01, and (***) indicates p<0.001. 
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differences in adhesion were observed for most blood flow conditions, with the exception being 
rods in blood with 100% highly rigid RBCs (Figure 8.6.A.). Here, the level of rod particle adhesion 
reduction was ~-50% (p<0.05), which translates to a 50% greater rod adhesion density compared 
to their adhesion when no rigid RBCs were present. While the rod particle exhibited negative 
reductions for other conditions with the highly rigid RBCs, these were not significant relative to 
the healthy condition. 
 
8.4.5. Effect of Targeting Ligand Density on Particle Adhesion Trends 
With the understanding that particle adhesion in flow is a function of the receptor-ligand 
kinetics, which can vary with the targeting ligand density, we evaluated the particle adhesion at a 
higher targeting ligand density and whether this increase would significantly alter the trend for the 
impact of rigid RBCs observed at the lower site density. The experimental conditions in Figure 
Figure 8.6. The Adhesion of 2 µm Volume Polystyrene Rod (AR4) Particles to an Inflamed Endothelium in vitro by 
Red Blood Cell Rigidity.  
Quantified AR4 rod polystyrene particle binding to an IL-1β inflamed endothelial layer at 106 particles/mL of whole blood 
as a function of rigid RBCs present, i.e., % volume rigid RBC, each figure utilized rigid RBCs with different degrees of 
rigidity (A) 1.0 mM treated RBCs (highly rigid), (B) 0.75 mM treated RBCs (moderately rigid), and (C) 0.5 mM treated 
RBCs (slightly rigid). A WSR of 1,000 s-1 was used for all the shown conditions. AR4 polystyrene rod particles are 
conjugated with NeutrAvidin and functionalized with sLea binding ligand, ~1,000 sites/µm2. All trials plotted as reduction 
compared to respective healthy controls, i.e., no rigid RBCs present, thus eliminating donor variation. Error bars represent 
standard error. Statistical analysis of adherent density was performed using two-way ANOVA to test all particle adhesion 
versus healthy particle adhesion control. (*) indicates p<0.05. 
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8.1.A. and Figure 8.3.A. were repeated but with MPs at three times the sLea density using the most 
rigid RBCs (1.0 mM TBHP).  
 
We focus on only the 2 µm spheres for these assays, given that minimal differences in 
adhesion were observed across all rigid RBCs for the smaller spheres and rods. The raw adhesion 
data for particles in healthy blood (0% rigid RBCs) is shown in Figure 8.7. Our results show that 
the particle adhesion reduction trends for both polystyrene and hydrogel 2 µm MPs at the higher 
density of 3,000 sites/µm2 are similar to the adhesion trends observed with particles at the lower 
site density of 1,000 sites/µm2 for all, but one of the tested conditions (Figure 8.8.). The higher 
site density only significantly alters the particle adhesion difference for the hydrogel MPs at the 
70% rigid RBCs composition, where the adhesion level at the 3,000 sites/µm2 density did not 
change with or without rigid RBCs present, contrary to the positive response observed with rigid 
RBCs at the 1000 sites/µm2. Also, the particle adhesion levels are only slightly higher with the 
3,000 sites/µm2 sLea density for the hydrogel, and not the polystyrene, MPs (Figure 8.7.), 
Figure 8.7. Raw Particle Binding to Inflamed Endothelium in vitro at Higher Adhesion Ligand Density.  
Quantified particle binding to an IL-1β inflamed endothelial layer at 106 particles/mL of whole blood at healthy 
conditions, i.e., no rigid RBCs are present. Blood is at 40% hematocrit and is perfused at a WSR of 1,000 s-1 for 
all the shown conditions. All particle types are conjugated with NeutrAvidin and functionalized with sLea binding 
ligand, ~3,000 sites/µm2. Error bars represent standard error. 
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suggesting the adhesion kinetics is in a transport-limited regime for both ligand site densities 
evaluated. 113 
 
8.4.6. Effect of Rigid RBCs on Particle Localization  
To better understand how the particle adhesion trends presented above develop in the 
presence of rigid RBCs, we investigated particle localization to the cell-free layer in whole blood 
flow. We examined the localization of 2 µm PS, 2 µm PEG-MP, and 500 nm PS particles by first 
mixing non-functionalized particles into reconstituted (~40% Hct) whole blood with varying rigid 
RBC conditions at a concentration of ~106 particles/mL of whole blood. The blood sample was 
perfused through a ~100 µm channel (no HUVEC present) at a WSR of ~1,000 s-1, and a confocal 
microscope was used to image particle density in the CFL at about 2 µm from the vessel wall. The 
CFL has been reported to range from 2-7 µm in humans depending on variables such as hematocrit, 
Figure 8.8. The Adhesion of 2 µm Particles with Different Binding Ligand Densities to Inflamed 
Endothelium in vitro by Red Blood Cell Rigidity.  
Quantified 2 µm (A) polystyrene and (B) hydrogel particle binding to an IL-1β inflamed endothelial layer at 
106 particles/mL of whole blood as a function of rigid RBCs present, i.e., % volume rigid RBC, each figure 
utilized rigid RBCs 9x more rigid than healthy RBCs, i.e., treated with 1.0 mM TBHP. A WSR of 1,000 s-1 was 
used for all the shown conditions. Polystyrene and hydrogel particles are conjugated with NeutrAvidin and 
functionalized with sLea binding ligand with either ~3,000 or ~1,000 sites/µm2. All trials plotted as reduction 
compared to respective healthy controls, i.e., no rigid RBCs present, thus eliminating donor variation. Error bars 
represent standard error. Statistical analysis of adherent density was performed using two-way ANOVA to test 
all particle adhesion between both sLea ligand densities, ~3,000 and ~1,000 sites/µm2. (*) indicates p<0.05, 
(**) indicates p<0.01. 
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vessel geometry, and flow rates. 47,189–191 Given the particle sizes examined in this study, 500 nm 
– 2 µm diameter, focusing on the plane 2 µm from the vessel wall can provide a good indicator of 
whether the particles of interest were able to exit the bulk flow and localize near the wall, i.e., a 
good indicator of successful margination.   
 
A full scan of the channel height is represented as a distribution in Figure 8.9. We 
normalized the particle localization density in all conditions where rigid RBCs were present to the 
particle localization density for the healthy condition. Figure 8.10.A. shows the raw particle 
localization density for all particles in healthy conditions. Figure 8.10.B. shows the percent change 
in localization density of 2 µm polystyrene in the presence of rigid RBCs. For most conditions 
where rigid RBCs were present, we observed a significant decrease in the localization of 2 µm PS 
particles to the CFL in the presence of the highly and moderately rigid RBCs. Conversely, Figure 
8.10.C. shows that the percent change in the localization of 2 µm PEG MPs dramatically increased 
Figure 8.9. Confocal Particle Distributions.  
Particle density distributions in a channel of height 100 µm at 1,000 s-1. Condition 
applicable for all particle types is 40% hematocrit with 100% rigid RBC volume present. 
Rigid RBCs used for all conditions are 9x more rigid than regular RBCs, i.e., treated with 
1.0 mM TBHP. Density distribution of fluorescently tagged (wheat germ agglutinin 488) 
healthy RBCs is overlaid (black curve) to compare with particle density distributions. 
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compared to localization in a healthy blood condition when a high amount of the highly and 
moderately rigid RBCs were present (70% and 100%).  
 
For the 500 nm PS particles, particle localization density significantly decreased relative 
to the healthy condition for all rigid RBC conditions (Figure 8.11.). Previous work has shown that 
nano-sized particles do not marginate to the vessel wall as efficiently as MPs, and the results shown 
in Figure 8.10.A. are in agreement. 109,112,183–186 The presence of RBC rigidity in blood seems to 
exacerbate this poor NP margination effect.  
 
 
Figure 8.10. Particle Localization to Cell Free Layer in the Presence of Rigid Red Blood Cells.  
Quantified particle localization densities 2 µm away from vessel wall in a channel of height ~100 µm at ~1,000 s-1 and ~106 
particles/mL of whole blood as a function of rigid RBCs present, i.e., % volume rigid RBC, and rigid RBCs with different degrees 
of rigidity, 1.0 mM (highly rigid), 0.75 mM (moderately rigid), and 0.5 mM treated RBCs (slightly rigid). (A) The raw particle 
localization density in a healthy control, i.e., with no rigid RBCs present. The normalized percent change in particle localization for 
varying rigid RBC conditions for the (B) 2 µm stiff polystyrene spheres and (C) 2 µm deformable hydrogel spheres. All particles 
are not functionalized with a targeting ligand. Error bars represent standard error. Statistical analysis of localization density was 
performed using two-way ANOVA to test particle localization density in rigid RBC conditions compared to healthy control, i.e., no 
rigid RBCs present. (*) indicates p<0.05 and (**) indicates p<0.01. 
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8.5. Discussion 
Several human conditions can be characterized by the loss of RBC deformability, 3,7,97–102 
with SCD being the most described, 3 but also includes HIV, T2D, and natural aging. 7,98–102 This 
presence of altered RBC membrane deformability in the blood is not without consequences; 
increased RBC membrane rigidity has been linked to pulmonary vascular resistance, crisis pain in 
SCD, and lowered cardiovascular health. 192 Gutierrez et al. recently reported that less deformable 
RBCs in blood severely reduced the adhesion of WBCs to an inflamed vessel wall in blood flow. 
10 However, to date, no experimental evidence has been put forth in the literature that evaluates 
VTC adhesion performance in a diseased (rigid RBC) blood model. The margination and adhesion 
efficacy of a polymeric drug carrier highly depend on their interaction with cellular components 
of blood; thus, it is likely that the simultaneous presence of VTCs and rigid RBCs in the 
bloodstream could significantly alter the margination and adhesion dynamics of VTCs to the 
Figure 8.11. Polystyrene 500 nm Particle Localization to Cell Free Layer in the Presence of Rigid 
Red Blood Cells.  
Quantified 500 nm polystyrene particle localization densities 2 µm away from vessel wall in a channel 
of height 100 µm at 1,000 s-1 and 106 particles/mL of whole blood as a function of rigid RBCs present, 
i.e., % volume rigid RBC, and rigid RBCs with different degrees of rigidity, 1.0 mM treated RBCs (most 
rigid), 0.75 mM treated RBCs, and 0.5 mM treated RBCs (least rigid). Particles are not functionalized 
with a targeting ligand. Error bars represent standard error. Statistical analysis of localization density was 
performed using two-way ANOVA to test particle localization density in rigid RBC conditions compared 
to healthy control, i.e., no rigid RBCs present. (*) indicates p<0.05 and (**) indicates p<0.01. 
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vascular wall. In this work, we evaluated the impact of artificially rigidified RBCs on the 
margination and adhesion of rigid polystyrene (PS) and deformable hydrogel particles, as models 
for polymeric VTCs, in vitro via human blood flow assays. We examined microparticles (MPs) 
along with nanoparticles (NPs) precisely because, under normal conditions, MPs exhibit a higher 
margination capability over NPs, as shown by previous investigators. 108,113,193 Our findings 
demonstrate that many different levels of rigidified RBCs mixed in with healthy RBCs result in a 
decrease in the margination and adhesion of these PS particles to the wall, but, in some cases, a 
dramatic increase in the margination and adhesion of deformable MPs. Overall, this work 
highlights the significance of factoring the impact of RBC rigidity into designing translatable 
particle technology into practical therapeutics. The previously noted shift towards stiffer RBCs 
with natural aging further highlights the relevance of the presented work as the bulk of the 
proposed use of VTCs are focused on the elderly, including cardiovascular diseases that continue 
to be the primary cause of mortality globally.194  
In line with the prior work with WBCs, our results show that the presence of rigid RBCs 
of varying rigidity reduces the blood flow adhesion of polystyrene microspheres by up to ~50%, 
depending on the level of RBC rigidity and the fraction composition of the rigid RBCs in the blood. 
Notably, the maximum impact of these altered RBCs is seen when they co-exist in the blood flow 
with healthy RBCs. Gutierrez et al. previously attributed the rigid RBC-induced reduction in WBC 
adhesion to heterogeneous collisions in blood flow, 10 which Graham and coworkers describe as 
the physical interaction between rigid (stiff) and deformable (soft) cells. 30,31 First, the 
heterogeneous collisions between stiff and soft RBCs lead to an expanded RBC core, i.e., rigid 
RBCs are found closer to the vessel wall (in the CFL), which occurs because the rigid RBCs 
experience a substantial displacement upon collision with the deformable RBCs. Second, the 
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increased presence of RBCs in the CFL causes an increase in heterogeneous collisions between 
RBCs and WBCs. 10 We suspect the same two-step effect of heterogeneous collisions is 
responsible for the reduced adhesion of the PS microspheres in blood flow with rigidified RBCs. 
Although a direct comparison between WBC and PS particle behavior in rigid RBC blood flow 
conditions may not be entirely relevant due to size and modulus differences, the general similarity 
of the observed trend between the two suggests a likely scenario of rigid RBCs present in the CFL 
preventing MPs from entering the CFL in large numbers. Essentially, rigid RBCs displaced to the 
wall by collisions with their softer counterparts take up spots in the CFL that otherwise would be 
occupied by MPs. Indeed, we observed a decrease in the localization of polystyrene MPs at a 2 
µm distance from the vessel wall (Figure 8.10.B.) as compared to the localization of the same 
particles in healthy blood flow. While it is possible that collisions between rigid RBCs and 
polystyrene MPs could also disrupt adhesion, the results are presented in Figure 8.8. showing 
similar levels of adhesion reduction with the presence of rigid RBCs for MP with 3x more ligand 
density suggest that altered adhesion kinetics is not a major factor in dictating the observed particle 
adhesion trends. Thus, this leads us to speculate that particle margination, or alteration in particle 
motion in the cell-free layer, plays a bigger role in influencing how particles adhere in the presence 
of rigid RBCs.  
We also probed how particle size can affect the particle adhesion trends in blood flow with 
the presence of rigid RBCs; we compared the adhesion of polystyrene MPs and NPs (2 µm and 
500 nm). We find that the adhesion reductions observed for NPs are not as significant as the 
reductions seen for MPs despite a similar adhesion trend for both particle sizes in the case where 
highly and moderately rigid RBCs were present. We speculate that the primary source of this 
different response to rigid RBCs between micro-and nanospheres is the higher propensity that MPs 
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have to marginate towards the vessel wall than NPs. With more microspheres at the cell-free layer, 
there is a greater opportunity for heterogeneous collisions with rigid RBCs and hence a more 
significant adverse effect on the final particle adhesion at the wall.  Of note, even upon 
experiencing a greater magnitude of reduction, the microsphere adhesion density is still higher 
than that for nanospheres, Figure 8.2. However, it possible that the physical size of particles itself 
also contributes to the difference in magnitude of the negative impact of rigid RBCs on 
microspheres versus nanospheres. Other things being equal, microspheres will experience a more 
significant displacement upon collision due to having a more substantial momentum, which then 
likely translates to the larger spheres needing to overcome a higher force to adhere firmly. 195 
Along this line, we find that the levels of the adhesion reductions experienced by the 2 µm PS 
microspheres evaluated here, while significantly higher than for PS NPs. Additionally, 2 µm PS 
MP adhesion reductions are generally lower than previously reported for WBCs, with an average 
diameter of 7 - 12 µm, under the same rigid RBC flow conditions. 10  
The case where RBCs were slightly rigid is interesting because an oscillate-type trend is 
observed for the adhesion of PS microspheres, but not for nanospheres. Here, RBCs are not as stiff 
as in previous conditions. However, specific percentages (20%, 50%, and 90%) of the slightly rigid 
RBCs present produced a reduction in microsphere adhesion while others had no effect (30%, 
70%, and 100%), Figure 8.1.C. This oscillate-type behavior in microsphere adhesion at different 
percentages of rigid RBCs present is also observed in the adhesion of hydrogel microspheres, 
Figure 8.3.C. Thus, this behavior seems to be particle-size-dependent. Possible variations in 
localization of slightly rigid RBCs are likely responsible for these adhesion trends, in which the 
motion of individual RBCs is not readily visualized in high shear blood flow with a physiological 
hematocrit level as evaluated here. A theoretical simulation could potentially help clarify this 
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oscillate-type trend. Theoretical models have been utilized to investigate how cellular shape and 
deformability impacts how objects behave in flow. 27,30,34,196 Some computational models have 
also examined how MPs and NPs marginate and affect drug delivery. 193 Work by Müller et al. 
simulates the margination of MPs and NPs, concluding, like many others, that MPs have a higher 
probability of localizing closer to the vessel wall compared to NPs. 193 Other interesting theoretical 
investigations have been able to modulate cellular rigidity in their simulations to investigate 
heterogeneous collisions' effect on margination. 30 Such models have served as adequate 
approximations that highlight some of the governing physics, such as lift force and heterogeneous 
collisions, that aid in giving rise to the observed blood flow phenomena. However, such 
simulations cannot fully recapitulate the complex behavior of blood flow due to limitations in 
computing power, which is often overcome by oversimplifications. To date, no theoretical 
approach has been established that investigates how increases in RBC membrane rigidity impact 
the ability of MPs and NPs to localize and ultimately bind to the vessel wall.  Thus, future work, 
experimental and computational, is still needed to understand this phenomenon further. 
Perhaps the most intriguing result from this study is the adhesion trend of the 2 µm 
deformable PEG-based hydrogel particles. Recent works in particle drug delivery have looked into 
modulating particle elasticity as a method to increase therapeutic efficacy. 114,197–201 Deformable 
particle drug carriers have become of high interest due to their capability for reduced cellular 
internalization and increased circulation time in vivo. 201,202 Previous investigations have 
developed deformable particle carriers with a wide range of sizes (22 nm -  9 µm) and modulus 
(200 Pa – 3 MPa), 114,197,203–205 with modulus tuned to resemble RBCs and even platelets in some 
cases closely. 198,199 Here, we examined deformable PEG-based MPs with a modulus similar to 
what is observed for WBCs. 114 When small percentages of highly and moderately rigid (1.0 mM 
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and 0.75 mM TBHP treated) RBCs are present, a slight reduction in hydrogel particle binding is 
observed. However, as the percentage of rigid RBCs is increased, particle adhesion to the vessel 
wall began to improve. For example, at a 100% of the highly rigid RBCs, the 2 µm hydrogel 
particle binding is enhanced by ~85%, Figure 8.3.A. We hypothesize that a combination of distinct 
phenomena, including increased heterogeneous collisions with rigid RBCs, are affecting the 
localization capability of hydrogel particles in the presence of rigid RBCs. Previous theoretical 
works suggest deformable particles do not marginate towards the vessel wall as compared to rigid 
particles. 31,206 Here, we see a substantial increase, up to 136%, in particle localization in the CFL 
for the 2 µm hydrogels with the presence of rigid RBCs, Figure 8.10.C. These results are 
counterintuitive since it would be expected that rigid particles experience greater displacement and 
thus would experience enhanced localization in the presence of rigid RBCs. Previous work has 
shown that the presence of WBCs in whole blood enhanced hydrogel MP adhesion to the vascular 
wall. 114 The presence of WBCs improves deformable MP (modulus similar to WBC modulus) 
adhesion as compared to adhesion in an RBC-plasma solution, showing that the WBCs in the CFL 
enhanced deformable MP adhesion. 114 We suspect that mismatched, i.e., heterogeneous collisions 
with rigid RBCs in addition to WBCs in the CFL promote deformable particle margination to the 
vessel wall. Still, this does not offer a complete explanation as to why having a small percentage 
of rigid RBCs in the blood produces a slight reduction in hydrogel MP adhesion. Additionally, 
although these PEG-MPs had a modulus closely resembling the modulus of WBCs, they do not 
behave like WBCs in the presence of rigid RBCs, as was reported by Gutierrez et al., suggesting 
that size is a key factor in predicting particle/cell behavior in the presence of rigid RBCs. 10 Another 
possible explanation for the differences in adhesion patterns between stiff and deformable MPs is 
the ability of deformable particles to spread onto the surface once they have adherent to the wall. 
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Unlike WBCs and deformable particles, stiff polystyrene particles do not spread on the surface 
and thus would experience a higher disruptive force from flow and potentially colliding rigid RBCs 
localized near the vessel wall. Also, although the same equivalent diameter, stiff particles would 
have a smaller contact area with the wall, which impacts adhesion strength. However, the fact that 
the impact of rigid RBCs on polystyrene microspheres did not change significantly with the 
significant increase in particle ligand density (Figure 8.8.A.) would suggest particle spreading; 
hence improved adhesion kinetics is not a significant contributor to the differences in the adhesion 
pattern between polystyrene and hydrogel microspheres.  
Particle shape has been proposed as a major factor influencing particle localization and 
binding efficacy. Previous results have shown that ellipsoidal-shaped particles exhibit enhanced 
adhesion compared to spherical counterparts. 184,186,188 In this study, we probe how particle shape 
alters adhesion in the presence of rigid RBCs. Our obtained results show that the adhesion of rigid, 
rod-shaped particles is not reduced in the presence of rigid RBCs, unlike the spherical PS particle 
types tested; thus, hinting that particle shape is a major factor in particle-RBC interactions. The 
relatively unaffected, or in some cases enhanced, adhesion of rod particles in the presence of rigid 
RBCs is likely due to rod particles having (1) a larger contact area with endothelial layer and (2) 
a streamlined shape with a small surface area exposed to shear flow.  Localization of rigid RBCs 
near the vessel wall results in increased collisions with particles in the CFL, preventing them from 
firmly adhering or even knock them off the vascular wall completely.  Having a streamlined shape 
while bound to the endothelial layer would then explain why rod particle adhesion is not as 
drastically affected by the presence of rigid RBCs. In addition to this, the typical tumbling, rolling 
dynamics, and lateral drifting velocity observed in rod particles in the flow could be enhanced by 
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heterogeneous collisions with rigid RBCs. 207 Future experimental and computational analysis is 




This work shows that the presence of rigid RBCs in whole blood can have a significant 
impact on the localization and adhesion capabilities of vascular-targeted carriers. We utilize an 
artificial rigidification method to rigidify healthy RBCs aiming to mimic various hematologic 
diseases that directly affect RBC membrane deformability. Then we reconstitute rigid RBCs, with 
varying degrees of rigidity, into whole blood at distinct fractions and perfuse through a 
microfluidic model at physiologically relevant conditions.  We aim to probe how changing particle 
deformability, size, and shape in the presence of rigid RBCs could affect particle adhesion 
capabilities. Firstly, we find that the adhesion capability of micro-sized, rigid polymeric spheres 
is highly reduced in the presence of rigid RBCs regardless of RBC degree of rigidity or rigid RBC 
concentration. Interestingly, deformable micro-sized sphere adhesion is reduced in the presence of 
small amounts of rigid RBCs. However, when a high percentage of rigid RBCs are present, the 
adhesion of deformable micro-sized particles is enhanced by up to 85%. We observe that nano-
sized particles' adhesion capability is only slightly reduced in the presence of rigid RBCs. 
Moreover, we find that ellipsoidal particle adhesion is either enhanced or not affected by the 
presence of rigid RBCs.  Overall, this work offers compelling evidence that the presence of rigid 
RBCs in whole blood can either significantly impact the localization and adhesion functionality of 
targeted drug carriers in whole blood, which can hold critical implications for a wide range of 
diseases affecting RBC deformability. The variable adhesion performance of particles observed 
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under distinct percentages of rigid RBCs and RBC stiffness suggests particle therapeutics efficacy 
can vastly vary between patients and disease severity. This unique information presented in this 
work can be highly valuable for the future development of personalized particle therapeutics with 
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9.1. Overall Dissertation Conclusions and Summary  
In this dissertation, I have elucidated some of the biophysical contributions rigid RBCs 
have on the distribution and adhesion functionality of other cells in blood flow. I investigated and 
characterized RBC rigidity as it relates to SCD. The work presented in this thesis is important 
because the findings can potentially clarify biophysical characteristics of blood disorders with 
altered RBCs deformability and aid in the design of novel treatment protocols for the clinical 
management of such diseases. Blood disorders affect about 5% of the population worldwide, with 
an estimated ~100,000 Americans affected by SCD alone. Patients diagnosed with SCD will have 
a significantly shortened lifespan with compromised quality of life beginning in childhood. Current 
treatments for SCD, including the use of powerful narcotics (e.g., opiate), bone marrow transplant, 
and chronic blood transfusions.42,52,117 Bone marrow transplant can be entirely curative but is also 
a highly invasive and costly procedure. Thus, pharmaceutical use for pain management and chronic 
transfusions remains the standard of care protocols. Unfortunately, typically patients become 
opiate-dependent as young adults. Thus, there is a dire need to develop novel therapeutic strategies 
to reduce the severe symptoms and heavy opiate use for SCD patients. The insights gained from 
this presented work can potentially have a profound impact on understanding the pathophysiology 
of SCD.171,172 This understanding can lead to novel approaches to disease management, ultimately 
reducing infections, hospitalizations, and opiate use in the large 
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patient population unable to receive marrow transplant – the only curative procedure in SCD to 
date.173 Overall, the research product from this dissertation provides a wealth of new data on 
cellular distribution and dynamics under different blood flow conditions that can be used to refine 
existing computational models for better prediction of cell dynamics in blood flows. For example, 
the stiffened RBC model presented in Chapter 3 was incorporated into a 3-Dimensional blood flow 
model to examine the margination of rigid RBCs and platelets.40 Availability of robust and optimal 
numerical methods will allow for prediction of interactions in blood flow not currently achievable 
via in vitro and in vivo assays, which would impact the understanding and treatment of all ailments 
characterized by significant rigidity in RBC membranes not only SCD, but also including 
hyperglycemia, malaria, and natural aging.171,172 Additionally, a better understanding of blood 
dynamics can be utilized to intelligently design personalized particle therapeutics for vascular use. 
In Chapter 3, we investigate the impact artificially rigidified RBCs have on WBC adhesion 
capability under physiological blood flow conditions. Our results showed that the presence of rigid 
RBCs in blood flow led to a significant reduction in WBC adhesion to an inflamed vascular wall 
model in blood flow. Importantly, we uncovered a non-linear relationship in the WBC adhesion 
reduction and the fraction of rigid RBCs present in the whole blood. We also find that rigidified 
RBCs tend to localize closer to the vessel wall than deformable healthy counterparts. These results 
and methodologies open an opportunity for improving in vitro models of blood flow, specifically 
ones that can control proportion and degree of stiffness in RBCs. 
In Chapter 4, we developed a predictive model that builds upon the ektacytometry 
technique. To build this predictive model, we rely on artificially rigidifying healthy RBCs to 
precisely control degree stiffness in RBCs, the proportion of stiff RBCs in the bulk blood sample, 
and uniformity of stiffness in the stiff RBC population. We parameterize these results and 
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extrapolate to interpret better the rigid, or HbS concentrated, RBC population in an SCD blood 
sample. We find that ektacytometry deformability measurements often underestimate the stiffness 
of rigid RBC population in a blood sample. The results presented here not only offer the 
opportunity for improvement of the ektacytometry technique but also offer a tool for building more 
precise in vitro models of rigid blood. Specifically, we can artificially construct a blood sample 
from healthy donor blood that resembles the stiffness and other key blood characteristics of an 
SCD blood sample.  
In Chapter 5, we make an interesting clinical observation when working with pediatric 
SCD patients. We observe that an SCD patient of SC genotype registered an abnormal high bulk 
blood rigidity. This observation was of interest given the patient's genotype since SC is clinically 
accepted as a milder genotype of SCD. In addition, the patient has an abnormally high rate of 
hospital admissions and was thought to be faking painful episodes. Overall, these observations hint 
at the potentially larger role RBC rigidity can have on patient outcomes.  
In Chapter 6, we build upon the in vitro blood flow model presented in Chapter 3 and the 
predictive model developed in Chapter 4 to probe further the impact of RBC rigidity in influencing 
WBC adhesion functionality in SCD. We analyze the blood profiles and general blood 
characteristics of a pool of pediatric SCD patients. Firstly, we examine the WBC adhesion to 
inflammation in a PPFC model using the SCD donor blood. Using the characterization of the SCD 
donor blood, we reconstruct separate blood models using non-SCD donor blood and match 
hematocrit, WBC count, RBC population rigidity, and rigid RBC fraction. Using the artificial 
blood models, we isolate the RBC rigidity factor and examine WBC adhesion to inflammation 
with and without RBC rigidity. We find that in most cases, the presence of rigid RBCs in blood 
flow led to a reduced capability for WBCs to adhere to inflammation. These results serve as 
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surmounting evidence of the detrimental impact rigid RBCs in blood flow have on the adhesion 
functionality of WBCs to inflammation on the vascular wall.  
In Chapter 7, we examine how WBC adhesion is altered upon administration of infusion 
therapy in SCD. We leverage an artificial model of blood infusion therapy to probe this issue. We 
take blood samples from SCD patients pre-infusion treatment and add controlled volumes of non-
SCD healthy RBCs to increase the hematocrit of the SCD blood sample. Subsequently, we perfuse 
RBC spiked blood samples through the PPFC model and examine WBC adhesion. We find that 
alterations in WBC adhesion upon infusion therapy are highly variable and unique for each 
individual SCD patient. In some cases, infusion of RBCs increases the WBC adhesion density to 
inflammation, and in other cases, the opposite is observed. Ultimately, this preliminary work 
suggests an opportunity to improve infusion therapy in SCD and potentially prescribe more 
controlled infusions based on the desired immune outcome.  
In Chapter 8, we examine how vascular-targeted carriers perform in the presence of rigid 
RBCs in blood flow. Specifically, we test a variety of particle conditions, including particle size, 
deformability, and shape. We find that the adhesion efficacy of particle carriers is highly variable 
in the presence of rigid RBCs inf blood flow in combination with particle characteristics. The 
results from this investigation offer insight into the intricate influence RBCs, specifically rigid 
RBCs, have on particle drug carriers in blood flow and open novel avenues for the intelligent 
design of vascular-targeted carriers.  
In conclusion, we demonstrate that RBC membrane rigidity is a highly influential factor in 
influencing cellular dynamics in general blood flow. Overall, the work presented in this 
dissertation characterizes RBC rigidity and elucidates the biophysical contribution of the rigid 
RBCs on the distribution and adhesion functionality of other blood cells as it relates to SCD. The 
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insights gained from this preliminary work would have a profound impact on understanding the 
pathophysiology of SCD.171,172 This understanding can lead to novel approaches to disease 
management, ultimately reducing infections, hospitalizations, and opiate use in the large patient 
population unable to receive a hematopoietic stem cell transplant.173 
 
9.2. Future Directions 
 This dissertation has further elucidated the role of RBC membrane deformability on 
cellular dynamics in blood flow and the resulting impact on the functionality of other blood cell 
types. The presented work lays the foundation for many potential future projects both of both 
experimental and computational nature. Considering the general status and need for more 
information in the research field, we highlight the impact and areas of improvement of the work 
presented in this dissertation. We feature the following major areas for improvement.   
Primarily, we focused on examining the impact rigid RBCs in blood flow had on the 
functionality of WBCs, specifically on the adhesion to inflammation capability. However, this was 
the only other major blood cell type that was examined in terms of adhesion to the vascular wall. 
Previous work by Walton et al. suggests interactions between the RBC core lead to enhanced 
platelet accumulation in vascular injury.208,209 There is considerable interest in examining the 
behavior of platelets in the presence of rigid RBCs in blood flow. Additionally, most of the work 
presented in this dissertation leveraged the robust in vitro PPFC model, which served as a paradigm 
for inflammation in a vascular wall. Although a robust model for microvasculature, there is a 
limitation in size and geometry simplification. It is inconclusive if the patterns observed in a 
microfluidic setting can be extrapolated to larger blood vessels and intricate vessel geometry.  
Work by Khoury et al. shows that the deposition of particles in a real-sized 3D carotid artery model 
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is highly influenced by vessel geometry and size.210 Further probing the impact of rigidified RBCs 
in blood flow in complex vessel geometry is a logical next step. Overall, the work presented in this 
thesis can open new opportunities for further developing in vitro models of blood flow and opening 
new avenues for better understanding SCD. Better understanding the impact a seemingly simple 
change in cellular characteristics such as increased RBC membrane rigidity can have on cellular 
functionality and ultimately downstream patient outcome in blood flow can help in the 
development of novel therapeutics or improvement of existing treatment practices.   
Some of the specific potential areas of interest for future research are listed below.  
1) Impact of RBC shape alteration on flow dynamics. This thesis focused almost 
entirely on isolating the impact of RBC membrane deformability alteration, as it is 
a common characteristic in many diseases. However, shape alteration is also a 
common cellular change in many blood disorders. It is known that  RBC shape is a 
contributing factor in the enhanced lift force experienced in flow.28 Work in the 
field has shown that spherical RBCs exhibit altered flow patterns in an artificial 
microvascular network.211 Preliminary work from the Eniola lab explored the 
alteration of RBC shape with the added factor of membrane stiffening. The shape 
of RBCs is easily altered by changing the osmolality of the solution in which they 
are suspended. However, the shape change is reversed when osmolality is returned 
to a neutral level. By coupling the osmolality change with a TBHP treatment, the 
RBCs membranes were stiffened and were less likely to return to their regular 
discocyte shape when osmolality was returned to physiological conditions.  These 
results proved helpful in making interesting whole blood reconstitutions using rigid 
spherical RBCs and regular deformable or rigid discocyte RBCs, Figure 9.1. This 
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capability can lead to the development of in vitro models, like the one presented in 
Chapter 3, that can explore the extent RBC shape alteration can have on cellular 
behavior related to hereditary diseases spherocytosis and malaria.155,212   
2) Computational modeling of RBC shape alteration on cellular dynamics. Similar to 
the previous suggestion, any conclusions drawn from the experimental exploration 
of RBC shape alteration are likely to be more robust when supplemented with a 
computational investigation. The groundwork for building 3D blood flow models 
exists already; the future work would entail making shape alterations to RBC 
geometry. 
Figure 9.1. Brightfield Images of Spherical Red Blood Cells.  
RBCs are suspended in phosphate buffer solution with 200 mM sodium salicylate to alter osmolality of solution. 1.0 mM 
TBHP solution is then added to RBC suspension to induce membrane stiffening. (A) shows rigid spherical RBCs. Stiffened 
spherical RBCs are then removed from solution and reconstituted in a neutral osmolality solution with other non-treated 
RBCs. (B) shows stiffened spherical RBCs in same solution as regular discocyte shape RBCs. 
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3) Impact of rigid RBCs in blood flow in larger complex vessel geometry. As 
previously stated in section 9.1. of this chapter, most of the work presented in this 
dissertation was accomplished in a microfluidic setting, using sub ~250 µm vessel 
sizes. It would be interesting to explore the effects of rigid RBCs in blood flow in 
a large geometry with more complex vessel geometry and flow patterns.  
4) Investigate vascular-targeted carrier performance in large vessel geometry with 
rigid RBCs present. Like the previous suggestion, it would be interesting to explore 
how particle drug carriers perform in large complex geometry. Specifically, many 
of the target diseases for particle drug carrier therapeutics are of a vascular nature, 
e.g., atherosclerosis, and complications arise in large blood vessels, e.g., carotid 
artery. Additionally, such diseases may also involve some alteration to healthy 
whole blood characteristics. Thus, it is an attractive avenue to explore particle 
carrier adhesion efficacy in large vessel geometry in the presence of disease altered 
blood.  
5) Further characterization of rigid RBC and whole blood model as SCD mimic. As 
shown in Chapter 4, we were able better to estimate the average population rigidity 
of SCD blood samples. With this capability, we paired the artificial stiffening 
model from Chapter 3 to develop an artificial blood model in Chapter 6 that 
mimicked the characteristics of SCD blood samples. This blood model focused 
almost entirely on matching the stiffness of the rigid RBC population. There is 
interest in further refining the artificial blood model for many reasons. For example, 
in a scenario where there is no accessibility to diseased blood, such as a restriction 
to SCD blood samples, normal non-diseased blood can be altered to match the 
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characteristics of diseased blood. Additionally, non-diseased blood can be altered 
to match the characteristics of other blood disorders such as hereditary 
spherocytosis and malaria. 
6) Further investigate how rigid RBCs localized in CFL impact WBC adhesion. One 
of the significant conclusions from this thesis was that indeed the presence of rigid 
RBCs in blood flow leads to the reduced capability for WBCs to adhere to 
inflammation. We deduced that one of the factors contributing to this observation 
was the reduced ability for WBCs to escape the bulk blood flow and enter the CFL. 
However, one of the shortcomings of our studies was that we analyzed our 
microscopy data in static images, i.e., we quantified our adhesion data in still 
images after a specific time of blood flow in the PPFC model. It would be 
interesting to examine the adhesion process live and quantify firm WBC adhesion 
to the inflamed endothelial layer and WBC rolling on the endothelial layer.  
7) We hypothesize that rigid RBCs localized in the CFL increase collision frequency 
with loosely adhered WBCs on the vascular wall. We hypothesize that this 
increased collision frequency leads to a reduced rate of firm WBC adhesion to 
inflammation. Future work should further characterize adhesion ligands profiles on 
WBCs used in these types of investigations. Subsequently, we would like to 
quantify firm WBC adhesion versus rolling in the presence of rigid RBCs. 
8) Building upon the previous suggestion, future work should analyze WBC adhesion 
ligand profiles of SCD donor blood and further probe WBC adhesion tendencies, 
i.e., firm adhesion versus rolling, compares to the artificial rigid RBC blood model.  
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9) Investigate the effect of SCD blood plasma on WBC adhesion patterns. The work 
presented in this dissertation primarily focused on investigating the biophysical 
effects of RBC rigidity in blood flow. However, we did not explore any 
biochemistry in the blood plasma of SCD patients as a means of explaining the 
results we observed. It is a reasonable next step to explore the plasma profile of 
SCD donor blood and test its effect on potentially inducing endothelial dysfunction 
and inflammation. Additionally, it would be of interest to see if the blood plasma 
conditions affect the adhesion ligand profile of the WBCs in the SCD patient blood 
sample. 
10) Further exploration of infusion therapy in SCD. The work presented in Chapter 7 
is very preliminary results, as we show there is a unique pattern in WBC adhesion 
density upon administration of infusion therapy for each distinctive patient sample 
we examined. It would be interesting to do a more detailed study probing the 
addition of RBCs to pre-infusion SCD blood samples. Ideally, we would like to see 
if we can target a specific WBC adhesion density. Furthermore, further 
characterizing pre-infusion SCD patient samples can translate to predict the 
outcome of infusion better as well as understand what other factors in the blood 
influence that outcome. Additionally, it would be interesting to explore the infusion 
mimicking process on SCD blood samples that do not undergo infusion therapy but 
are treated with a pharmaceutical approach to see if similar patterns in WBC 
adhesion density are observed. Overall, future work on this project should aim to 
characterize the benefit of transfusion, offering a quantitative approach, i.e., 
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standardized criteria for how patients get transfused, which can be formulated for 
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